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ABSTRACT 
Creutzfeldt -Jakob Disease (CJD) is a rare neurodegenerative disorder of the human 
central nervous system. It occurs in four main forms, defined essentially according to 
aetiology: sporadic, variant, iatrogenic and familial. All forms of the disease are 
characterised by the deposition of an abnormal cellular protein, the prion protein 
(PrPSO), within the brain. Definitive diagnosis depends on identifying this along with 
other neuropathological changes such as spongiform degeneration and astrocytic 
gliosis. 
To date variant CJD has followed a relatively stereotyped clinical course with fairly 
consistent pathological findings. However, various clinico- pathological phenotypes 
of sporadic CJD have been described. It is believed the disease phenotype is 
influenced by a number of factors including agent strain (PrP' isotype being used as 
a surrogate marker), and genotype (particularly a polymorphism at codon 129 of the 
prion protein gene). 
Data on 99 cases of sporadic CJD and 43 cases of variant CJD were analysed. The 
sporadic CJD cases were divided into 6 sub -groups, according to genotype at codon 
129 (either methionine homozygous, valine homozygous or heterozygous) and PrPfes 
isotype (either type 1 or 2A). Some trends in clinico- pathological phenotype were 
found. Notably, the methionine homozygous cases with type 1 PrP`eS isotype formed 
the majority of cases and followed a reasonably uniform disease course. The other 
groups tended to include atypical cases. These differences did not achieve statistical 
significance and there was considerable overlap amongst cases. 
14 -3 -3 protein and the use of MR imaging were analysed. The results suggest that 
these investigations may improve the diagnostic classification of sporadic CJD. 
2 
The variant CJD cases followed a relatively consistent clinico- pathological course, 
consistent with a distinct aetiology and probably a distinct strain. The data do not 
support the hypothesis that different strains of the sporadic CJD agent cause distinct 





INDEX OF TABLES 9 
INDEX OF FIGURES 12 
ABBREVIATIONS 13 
CHAPTER 
1 INTRODUCTION 15 
2 HISTORICAL PERSPECTIVE 21 
3 HUMAN SPONGIFORM ENCEPHALOPATHIES 33 
3.1 BACKGROUND 33 
3.2 SPORADIC CJD 34 
3.3 VARIANT CJD 54 
3.4 IATROGENIC CJD 61 
3.5 FAMILIAL CJD 63 
3.6 KURU 65 
4 MOLECULAR BIOLOGY OF PRION DISEASES 67 
4.1 PRION PROTEIN 67 
4.2 PrPc: STRUCTURE AND FUNCTION 68 
4.3 PrPSO: STRUCTURE AND FUNCTION 71 
4.4 CONVERSION OF PrPc TO PrPsc 74 
4.5 DETERMINANTS OF RATE OF ACCUMULATION 
OF PrPS° AND REGIONAL DISTRIBUTION 77 
5 STRAIN VARIATION 79 
5.1 SCRAPIE STRAINS 79 
5.2 INCUBATION PERIOD 80 
5.3 TITRE AND ROUTE OF INOCULUM 81 
5.4 HOST -SPECIES BARRIER 81 
5.5 MOLECULAR BASIS FOR STRAIN VARIATION 82 
4 
CHAPTER PAGE 
6 PREVIOUS STUDIES ON THE CLINICO- PATHOLOGICAL 
PHENOTYPE OF CJD 93 
6.1 INFLUENCE OF GENOTYPE 93 
6.2 INFLUENCE OF ISOTYPE AND GENOTYPE 108 
7 METHODS 118 
7.1 BACKGROUND 118 
7.2 PATIENT REFERRAL AND VISIT 119 
7.3 CLINICAL SYMPTOMS/ SIGNS 121 
7.4 INVESTIGATIONS 124 
7.5 PATHOLOGY 127 
7.6 CLASSIFICATION AND DIAGNOSIS 130 
7.7 STATISTICAL ANALYSIS 131 
8 RESULTS 132 
8.1 SPORADIC CJD: MAIN RESULTS 134 
8.2 SPORADIC CJD: INTERMEDIATE CASES 173 
8.3 SPORADIC CJD: GENOTYPE ONLY 175 
8.4 SPORADIC CJD: ISOTYPE ONLY 179 
8.5 SPORADIC CJD: GROUP B CLASSIFICATION 182 
8.6 VARIANT CJD 184 
9 DISCUSSION 196 
9.1 INTRODUCTION 196 
9.2 PROBLEMS 198 
9.3 CLINICO- PATHOLOGICAL PHENOTYPE OF SPORADIC CJD 205 
9.4 GENOTYPE AND ISOTYPE ONLY 237 
9.5 GROUP B CLASSIFICATION 243 
9.6 VARIANT CJD 246 
9.7 IS PROTEIN ISOTYPE A MARKER OF STRAIN? 254 
9.8 POSSIBLE RESEARCH IN THE FUTURE 259 
10 CONCLUSIONS 261 
5 
APPENDIX A: DESCRIPTION OF CLINICAL SYMPTOMS/ SIGNS 263 
APPENDIX B: CLASSIFICATION OF EEG 266 
APPENDIX C: DIAGNOSTIC CRITERIA FOR SPORADIC CJD 267 
APPENDIX D: DIAGNOSTIC CRITERIA FOR VARIANT CJD 270 
APPENDIX E: LABORATORY TECHNIQUES 271 
APPENDIX F: SPORADIC CJD: GROUP B DATA 274 




This thesis would not have been possible without the help and encouragement of 
a number of people all working at the NCJDSU. In particular, Dr Richard Knight 
has been a constant source of advice and support, not only as my tutor in the 
writing of this thesis, but throughout my career as a doctor. 
Professor Bob Will has also provided considerable help and advice with work on 
the thesis and throughout my time at the NCJDSU. Jan Mackenzie has patiently 
and tirelessly helped with producing data and graphs as well as countless other 
pieces of information. 
Professor James Ironside provided much of the pathological data and gave up 
time to go through slides and demonstrate pathological changes. The pathology 
staff at the NCJDSU, Margaret Le Grice, Mary Nicol and in particular Linda 
McCardle helped pull out slides and provide specimens. Suzanne Lowry also 
spent time in the laboratory with me demonstrating how protein isotyping is 
done. 
Dr Mark Head and Tristran Bunn did all the protein isotyping and spent a great 
deal of time explaining results and methodology to me. In addition Professor 
John Collinge at the Prion Unit in St Mary's Hospital, London kindly provided 
his protein isotyping data 
Dr Alison Green performed the CSF analysis of 14 -3 -3 and provided help and 
information about the protein chemistry of CSF. 
Matthew Bishop performed much of the genotype analysis and Lisa Strain and 
Kathy Estibiero performed genotype analysis before him. 
Dr Don Collie helped with obtaining MRI scans and assessed each scan. 
7 
Dawn Everington gave help and advice with statistical analysis. 
Diane Ritchie provided the pictures of pathological changes in sporadic and 
vCJD. 
The previous research registrars at the NCJDSU have all seen cases and collected 
data over the years. They are Dr Tom Esmonde, Dr Rajith De Silva, Dr Martin 
Zeidler and Dr Gillian Stewart. Special thanks to Dr Martin Zeidler who has 
provided some papers and helped me with computing problems. The current 
registrars Dr Andrea Lowman and Dr Sarah Cooper have helped me continue to 
chase scans and provide information. 
The research nurses at the unit Blaire Smith -Bathgate and Margaret Leitch have 
spent a lot of time with me travelling around the country, visiting patients and 
interviewing relatives. 
The secretarial and administrative staff at the NCJDSU provided much help over 
my time there. In particular Sandie Honeyman, Terri Lindsay, Christine 
Donaldson and Anne Mackenzie. 
Finally, thanks to all the patients and relatives who were so helpful at what was 
often a stressful and distressing time for them. 
8 
INDEX OF TABLES 
1.1 Transmissible spongiform encephalopathies 




3.1 Clinical characteristics of sporadic CJD: Symptoms at presentation 39 
3.2 Clinical characteristics of sporadic CJD: Signs during course of illness 40 
3.3 Clinical features in familial prion disease 64 
4.1 Differences between PrPc and PrPsc 72 
6.1 Amalgamation of control populations 96 
6.2 Mortality of CJD in Europe: 1993 -1995 97 
6.3 Genotype distribution 100 
6.4 Age at onset and duration of illness 102 
6.5 Clinical onset and EEG results 105 
6.6 Pathology 107 
6.7 Meta -analysis of cases with isotype and genotype data 114 
6.8 Results of investigations in study by Zerr et al. 116 
8.1 Breakdown of 151 cases 132 
8.2 Sporadic CJD: Classification of cases 135 
8.3 Sporadic CJD: Gender Distribution 135 
8.4 Sporadic CJD: Age at onset and death 136 
8.5 Sporadic CJD: Disease duration 137 
8.6 Sporadic CJD: Disease duration by subgroups 138 
8.7 Sporadic CJD: Presence of rapidly progressive dementia 140 
8.8 Sporadic CJD: Timing of dementia 140 
8.9 Sporadic CJD: Cerebellar symptoms and signs 141 
8.10 Sporadic CJD: Timing of cerebellar symptoms 142 
8.11 Sporadic CJD: Visual symptoms 143 
PAGE 
8.12 Sporadic CJD: Timing of visual symptoms 144 
8.13 Sporadic CJD: Cortical blindness 144 
8.14 Sporadic CJD: Other symptoms 145 
8.15 Sporadic CJD: Other signs 149 
8.16 Sporadic CJD: Nasogastric feeding 152 
8.17 Sporadic CJD: Akinetic mutism and NG feeding 153 
8.18 Sporadic CJD: EEG results 155 
8.19 Sporadic CJD: 14 -3 -3 and S -100b results 156 
8.20 Sporadic CJD: MRI results 158 
8.21 Sporadic CJD: Pattern of spongiform change 164 
8.22 Sporadic CJD: Pattern of immunohistochemistry 167 
8.23 Sporadic CJD: Diagnostic criteria 168 
8.24 Sporadic CJD: Intermediate cases 174 
8.25 Sporadic CJD: Genotype only: Patient statistics 175 
8.26 Sporadic CJD: Genotype only: Clinical features at onset 176 
8.27 Sporadic CJD: Genotype only: Clinical symptoms 176 
8.28 Sporadic CJD: Genotype only: Clinical signs 177 
8.29 Sporadic CJD: Genotype only: Terminal stages 177 
8.30 Sporadic CJD: Genotype only: Investigations 177 
8.31 Sporadic CJD: Genotype only: Pathology 178 
8.32 Sporadic CJD: Isotype only: Patient statistics 179 
8.33 Sporadic CJD: Isotype only: Clinical features at onset 1 80 
8.34 Sporadic CJD: Isotype only: Clinical symptoms 180 
8.35 Sporadic CJD: Isotype only: Clinical signs 180 
8.36 Sporadic CJD: Isotype only: Terminal stages 181 
8.37 Sporadic CJD: Isotype only: Investigations 181 
8.38 Sporadic CJD: Isotype only: Pathology 182 
8.42 Variant CJD: Psychiatric symptoms 186 
8.43 Variant CJD: Other symptoms 188 
8.44 Variant CJD: Other signs 190 
10 
8.45 Variant CJD: Investigations 
PAGE 
192 
9.1 Age at onset of cases 207 
9.2 Duration of illness 208 
11 
INDEX OF FIGURES PAGE 
2.1 Number of cases per year of BSE 29 
2.2 BSE exposure and incidence of vCJD by year of onset 30 
3.1 Annual mortality rate of sporadic CJD in UK: 1990 -2001 35 
3.2 Age specific incidence of sporadic CJD in UK: 1970 -1989 36 
3.3 Age specific incidence of sporadic CJD in UK: 1995 -2000 36 
3.4 A typical EEG in sporadic CJD 45 
3.5 MM of sporadic CJD showing high signal on T2- weighted imaging 
in the basal ganglia 49 
3.6 Pathology of sporadic CJD 53 
3.7 Variant and sporadic CJD: Age specific incidence at onset 54 
3.8 High signal in thalamus on T2- weighted imaging in vCJD 56 
3.9 Pathology of vCJD 57 
3.10 Deaths from vCJD per year 59 
4.1 Structure of PrP 69 
4.2 Model for tertiary structure of PrPc and PrPs` 71 
4.3 Electron micrographs of negatively stained and immunogold- labelled 
prion proteins 73 
5.1 SDS -PAGE of PrP`e5 from variant and sporadic CJD 87 
5.2 Structural variation of human PrPs related to proteinase K cleavage pattern 90 
7.1 Examples of a suggestive and typical EEG 125 
7.2 Examples of PrP isotype 1, 2A and 2B 129 
12 
LIST OF ABBREVIATIONS 
Apo E apolipoprotein E 
ASN aspartane 
BSE bovine spongiform encephalopathy 
CJD Creutzfeldt -Jakob disease 
CNS central nervous system 
CSF cerebrospinal fluid 
CT computed tomography 
C- terminal carboxy -terminal 
CWD chronic wasting disease of mule and elk 
DNA deoxyribonucleic acid 
DY drowsy 
EDTA ethylene diamine tetra -acetic acid 
EEG electroencephalogram 
ELISA enzyme linked immuno -assay 
ESR erythrocyte sedimentation rate 
FFI fatal familial insomnia 
FLAIR fluid attenuated inversion recovery 
FSE feline spongiform encephalopathy 
GP general practitioner 
GPI glycophosphatidyl inositol 
GSS Gerstmann- Sträussler -Scheinker syndrome 
H &E haematoxylin and eosin 
HGH human growth hormone 
HY hyper 
ICD international classification of diseases 
Met methionine 
MRI magnetic resonance imaging 
MRM mechanically recovered meat 
NCJDSU National CJD Surveillance Unit 
13 
NG nasogastric 
NIH National Institute of Health 
N- terminal amino -terminal 
ORF open reading frame 
PCR polymerase chain reaction 
PBS phosphate buffered saline 
Prion proteinaceous infectious particle 
PRNP human PrP gene 
PrP prion protein 
PrPc cellular form of PrP 
PrPsC abnormal pathogenic form of PrPc 
Prrs product of PrPs` after digestion with proteinase K 
PrP27 -30 product of PrP$0 after digestion with proteinase K 
SAF scrapie associated fibrils 
SDS -PAGE sodium dodecyl sulphate -polyacrylamide gel electrophoresis 
Sinc gene for scrapie incubation period 
SFI sporadic fatal insomnia 
SOD superoxide dismutase 
THE transmissible mink encephalopathy 
TSE transmissible spongiform encephalopathy 
UK United Kingdom 
Val valine 
vCJD variant Creutzfeldt -Jakob disease 
WHO World Health Organisation 
14 
CHAPTER 1: INTRODUCTION 
The Transmissible Spongiform Encephalopathies (TSEs) are a group of rare 
neurodegenerative diseases that affect animals and man. They are characterised by 
the fact that they are transmissible, and by the neuropathological hallmarks of 
spongiform change and deposition of an insoluble form of a cellular protein, the 
prion protein (PrP) in the central nervous system. The precise aetiology is unknown 
but it has been hypothesised that despite a lack of nucleic acid, PrP is the causative 
agent.' Although to date this remains unproven, it remains the most widely accepted 
theory. 
There are a variety of TSEs affecting a number of species, including scrapie in sheep 
and goats, bovine spongiform encephalopathy (BSE) in cattle, and kuru and 
Creutzfeldt -Jakob disease (CJD) in humans. (See Table 1.1) The TSEs are unique in 
that they exist in sporadic or hereditary forms, and yet may be acquired, being 
transmissible under certain circumstances; e.g. by inoculation of diseased brain 
tissue peripherally or into the central nervous system of an experimental host. There 
is no evidence of an immune response however. Despite considerable research into 
all of the TSEs many details of the mechanisms of the disease process remain 
elusive. 
The neuropathological hallmark of human TSEs is spongiform change within the 
brain and spinal cord along with variable neuronal loss and astrocytic gliosis. 
Spongiform change is not universal among the diseases and deposition of PrP and 
analysis of the human PrP gene (PRNP) on chromosome 20 are also important in 
confirmation of the diagnosis? 
Sporadic CJD is the commonest form of human prion disease, but it is still rare with 
an average worldwide incidence of approximately 1 per million population.3 To date 
no cause has been found for the disease, despite epidemiological analysis in various 
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case -control studies.4 In particular, no genetic, infectious or iatrogenic cause has 
been found. 
Table 1.1: TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES. 
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in PRNP 






Humans 1998 World wide Sporadic 
The disease occurs mainly in late middle age with a mean age at death of 65 years. It 
typically follows a very characteristic course of a rapidly progressive dementia with 
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myoclonus. Cerebellar and pyramidal signs are commonly seen, and the patient 
deteriorates quickly to a state of akinetic mutism and death. The median duration of 
illness is 4 months.5 
Routine investigation of patients with possible sporadic CJD is often surprisingly 
normal, however analysis of the electroencephalogram (EEG) reveals the presence of 
characteristic generalised periodic triphasic complexes in 60 -70% of cases.6 More 
recently, cerebrospinal fluid (CSF) analysis for the presence of 14 -3 -3 protein has 
been shown to be a sensitive and specific marker for sporadic CJD in the appropriate 
clinical context.' In addition, it has been suggested that high signal in the basal 
ganglia on magnetic resonance imaging (MRI) may also be useful in aiding 
diagnosis.8 
Atypical forms of sporadic CJD are well described although the majority of cases do 
have a fairly consistent clinical course. A small percentage of cases have a relatively 
longer duration of illness of 1-2 years or more.9 In other forms presentation is 
predominantly cerebellar: the Brownell- Oppenheimer variant,10 or with cortical 
blindness: the Heidenhain variant.11 Panencephalic and thalamic types, characterised 
by distinct neuropathological changes have also been described.5 Deposition of kuru- 
type amyloid plaques is sometimes present in cases of CJD.12 
The reason for the differences in clinico- pathological phenotype in sporadic CJD and 
the other TSEs has been the subject of speculation over the years. The disease 
process and neuropathological changes seem to be influenced by a number of factors 
within both the infectious agent and the patient or host. 
Analysis of codon 129 in human PRNP has shown that this is the site of a 
methionine/ valine polymorphism. It is known that 33% of Caucasian populations 
are methionine homozygous at this site but 71% of all cases of sporadic CJD carry 
this genotype,13 suggesting it predisposes to the development of the disease. Recent 
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evidence suggests that heterozygosity or valine homozygosity at codon 129 is 
associated with atypical forms of sporadic14 and familial disease. 15 
In addition, transmission studies of scrapie to goats have demonstrated different 
clinical features16, and in transmission studies to mice of the same genotype (hence 
apparently removing the host influence on disease phenotype) different pathological 
changes have been shown.'' It has been suggested that this is due to different strains 
of the prion agent. Recent studies of Transmissible Mink Encephalopathy (TME) 
have suggested that strain variation may be due to differences in composition or 
conformation of PrP.' 8 
Prion diseases are associated with the deposition of an insoluble form of normal 
cellular PrP (PrP°). This is termed PrPsc (from scrapie).19 A protease resistant core 
prion protein ( PrPfes) is the product of PrPsc after proteolysis. This product can be 
analysed by Western blotting. The molecular size of PrPres and the ratio of 
glycoforms present can be used to classify the PrPreS present into protein isotypes. 
Protein isotyping is currently regarded as a convenient surrogate for agent strain 
although the precise molecular basis of strain variation is uncertain. It has been 
proposed that PrP isotype therefore partially determines differences in clinico- 
pathologicaI phenotype in sporadic CJD.'4 
Different groups have identified slightly different isotypes of PrPres, 14,20 presumably 
related to differences in Western blotting technique. To date published information is 
available on a limited number of cases, but the clinical and pathological features of 
two isotypes: types 1 and 2, have been described in sporadic CJD. Type 2 has been 
subdivided into 2A and 2B and it seems that PrPres type 2A is also associated with 
atypical forms of the disease.14 Thus in sporadic CJD there are 6 possible 
combinations of PrPres isotype and codon 129 genotype (See Table 1.2) and each is 
potentially associated with a different clinico- pathological phenotype. 
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At this time only one genotype and PrPreS isotype has been seen in variant CJD 
(vCJD) but this may well change with time. These cases have followed a relatively 
consistent and distinct clinical and pathological course. In addition iatrogenic CJD 
due to human growth hormone also has relatively consistent clinical and pathological 
findings. This supports the hypothesis that a different single strain is involved. All 
cases of variant CJD have been associated with a distinct protein isotype, type 2B. 
However, both protein isotypes have been seen in iatrogenic CJD 
Table 1.2: GENOTYPE/ PROTEIN ISOTYPE COMBINATIONS 
MM / PrPres type 1 
MM / PrPreS type 2 
MV / PrPres type 1 
MV / PrPres type 2 
VV / PrPfes type 1 
VV / PrPreS type 2 
Recently, 300 cases of sporadic CJD from Europe and North America were analysed 
to look for clinical and pathological correlates within the 6 groups. Some trends were 
suggested. However, these data were amalgamated from various countries, many of 
which do not have a dedicated surveillance system. Much of the data may have been 
extracted retrospectively from case notes. In addition, the criteria for analysis of the 
EEG and MRI were not detailed and it was not clear if these were reviewed for the 
purposes of the study. 
I have analysed 99 cases of sporadic CJD referred to the National CJD Surveillance 
Unit (NCJDSU) in whom the results of genotype and isotype are available. In as 
many as possible cases the patient or their relative has been interviewed and the 
patient has been examined during life. The EEG and MRI were reviewed and 
reclassified personally where possible. It is believed that these data were as full and 
complete as possible, bearing in mind the difficulties of surveillance of a rare 
disease. The cases were allocated to the 6 groups listed above and their clinical and 
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pathological features and the results of investigations were analysed. A further 43 
cases of vCJD were reviewed and compared. 
These cases were compared to previous publications in an attempt to classify and aid 
the diagnosis of atypical cases of sporadic CJD, and to assess the influence of protein 
isotype and genotype on the clinical and pathological phenotype of this disease. 
HYPOTHESIS 
Different phenotypes of sporadic CJD are related to different isotypes of PrPTeS and 
codon 129 genotype. If PrP' is a surrogate marker of CJD, this provides evidence of 
distinct strains of CJD. 
Sporadic CJD usually follows a relatively characteristic clinical and 
pathological phenotype. 
Atypical forms of the disease are recognised. 
This is partly due to the influence of codon 129 genotype. 
It may also be due to different strains of the agent. 
Protein isotype is a possible surrogate marker of strain. 
Analysis of cases of sporadic CJD from the NCJDSU was performed looking 
for trends related to protein isotype and codon 129 genotype. 
These data were compared with variant CJD cases in which it is believed 
there is good evidence that a different single strain is involved. 
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The first of the TSEs to be described was scrapie, a neurodegenerative disease of 
sheep that was characterised by spongiform change in the brain. The earliest reports 
of the disease are from the eighteenth century when it was (and still is) endemic in 
various European countries.21 The aetiology of scrapie was unknown but in 1936 
Cuillé and Chelle reported the successful transmission of the disease by inoculating 
spinal cord of scrapie- infected sheep into the brains of healthy sheep.22 Despite the 
long incubation period following inoculation, this experiment provided evidence that 
scrapie might be an infectious disease. However, it was clear the agent responsible 
was unlike recognised microbiological vectors. 
In 1957 Gajdusek and Zigas described another condition associated with spongiform 
change.23 This disease was endemic in the Fore -speaking tribes of the eastern 
highlands of Papua New Guinea and was characterised by progressive cerebellar 
degeneration and tremor leading to death, usually in about one year. The disease was 
called "kuru" which means "trembling with fear" in the native Fore language.24 
One of the interesting features of kuru was that it affected mainly the women and 
children of the tribe, an unusual epidemiological phenomenon. 23 There is good 
evidence that ritualistic endocannibalism was practised by the local tribes. The 
women and children may have been particularly exposed to the infectious agent in 
the preparation of bodies for consumption. (Some would have been the contaminated 
brains of victims of kuru.) It seemed that Kuru was transmitted by the oral route 
and /or by inoculation through scratches and breaks in the skin or the conjunctiva by 
rubbing the eyes. The incidence of disease decreased as the practice of cannibalism 
ceased.25 
The first person to suggest a connection between scrapie and kuru was a vet in 
Cambridge named W.J. Hadlow. In 1959 he published a paper noting similarities in 
the epidemiology, clinical features and pathology of the two diseases, and suggested 
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that kuru might also be a transmissible disease.26 Seven years later Gajdusek 
successfully transmitted kuru to chimpanzees by intracerebral inoculation. The 
resultant clinical syndrome occurred after an incubation period of 18 -21 months and 
was similar to scrapie. 27 
Prior to this, in 1920, H.G. Creutzfeldt, a clinician trained in neuropathology, had 
described the case of a 22- year -old female who suffered a progressive dementia 
associated with spasticity and myoclonus.28'29 Over the next 4 years A.M. Jakob, a 
neuropathologist described five further cases of dementia associated with 
extrapyramidal and pyramidal signs and symptoms. 30,31,32,33 Jakob coined the term 
"spastic pseudosclerosis ". He noted clinical and neuropathological similarities with 
the condition described by Creutzfeldt.34 
Various aetiologies were suggested for this collection of cases, including syphilis 
and alcohol abuse. In 1922, Speilmeyer, who was the dean of neuropathology at the 
same university as Creutzfeldt, first used the term Creutzfeldt -Jakob disease (CJD).35 
This eponym, encompassing various syndromes, many with spongiform change in 
the brain, was used until the clinical and pathological criteria of CJD were redefined 
in the 1960s. 
Both Creutzfeldt and Jakob concluded they had described a neuropathological entity 
associated with many underlying disorders and that there was no unifying underlying 
disease. Jakob noted the presence of spongiform change in only one of his five 
cases.33 Indeed at that time spongiform change was believed to be an artefact from 
preparation of brain tissue.34 Subsequent analysis of the original clinical and 
pathological description by Creutzfeldt suggests that this case was not CJD. 
However re- examination of Jakobs' original neuropathological material has 
confirmed that at least two of his cases were CJD. 36 
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In 1959 it was noted that the pathology of CJD and kuru was similar.37 The 
successful transmission of CJD to chimpanzees in 1968 gave further support to a 
connection between these two diseases,38 and a body of literature continued to 
accumulate. It seemed that kuru, CJD and scrapie were related, not only by their 
pathology, but also by the fact that they were transmissible. The transmitted disease 
developed in a host months to years following inoculation but produced a similar 
clinico- pathological syndrome. It was presumed that an infectious agent was 
involved, despite the absence of an immune or inflammatory response. The most 
popular hypothesis was that this was a "slow virus ".39 
The original transmission experiments were hampered by the long incubation period 
and a low rate of successful transmissions. In 1961 Chandler successfully 
transmitted goat scrapie to mice, producing a scrapie -like illness.4o,41 This provided a 
much easier laboratory model to work with. In particular the incubation period was 
shorter. 
However, it was still not possible to transmit CJD to mice and experiments on this 
disease continued using primates as the host. Transmission studies on Alzheimer's 
disease, amyotrophic lateral sclerosis, multiple sclerosis and other subacute and 
chronic neurodegenerative diseases were attempted, as it seemed possible that they 
too were caused by a "slow virus ", but there was generally little success.42 Kuru, 
scrapie and CJD seemed to give more consistent results and these conditions became 
known as the transmissible spongiform encephalopathies (TSEs). 
Isolation of the agent proved elusive. Nevertheless, several properties were 
established: There was a long incubation period between inoculation and the first 
signs of host disease.22 The agent was highly resistant to heat,43 formalin 43, 44 and 
ionising radiation 45 It could pass through a dialysis membrane,46 suggesting it was a 
very small particle. These properties were not recognised in any viruses or known 
infective agent. 
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Studies on the serial transmission of infected brain tissue between different species 
and through successive animals of the same species were attempted and several other 
properties of the TSEs became apparent: When scrapie was transmitted from one 
animal species to another there tended to be a long incubation period and atypical 
clinical signs and neuropathology in the recipient. In transmission between animals 
of the same species the incubation period shortened and the signs and pathology 
were fixed. In addition transmission to some species was impossible. Pattison 
proposed that this was indicative of a species barrier.47 
In 1936 Gerstmann, Sträussler and Scheinker had described a family affected by a 
progressive cerebellar disease associated with dementia 48 Neuropathological 
analysis demonstrated the accumulation of atypical amyloid plaques and gliosis. 
Over the years other families with a heterogenous clinico- pathological picture were 
described. This condition became known as Gerstmann Sträussler Scheinker 
Syndrome (GSS). Latterly a family with the typical picture of GSS were noted to 
have spongiform change in the brain.49 This supported an association between GSS 
and CJD. A year later Masters et al. demonstrated the successful transmission of 
GSS to primates.50 
Cases of CJD occurring within the same family had first been reported in 1952.51 
However, a family in whom several members suffered from a degenerative clinical 
syndrome had been described in 1924 by Kirschbaum. Jakob noted similarities with 
the cases described by him, and this may be the first description of familial CJD.52 A 
review of the literature in 1979 cited 15% of cases were familial,53 however it was 
not until 1989 that an insertion mutation on chromosome 20 was linked to a family 
with CJD.54 More mutations within the same gene were identified over the next few 
years. Although two independent groups had transmitted familial CJD in 1973 
and1974, it was difficult to reconcile the notion of an infectious agent with a 
condition that was hereditary in 15% of cases. 55,56 
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Until this time, Kuru was the only human spongiform encephalopathy in which there 
was a probable identifiable exogenous source of infection, but in 1974 a 55- year -old 
woman developed CJD eighteen months after receiving a corneal graft. The graft 
donor was subsequently shown to have died of sporadic CJD.57 In 1977 two patients 
developed CJD 16 and 20 months after stereotactic electroencephalographic depth 
recordings. The same electrodes had previously been used in a patient with CJD.58 
They were sterilised with 70% alcohol and formaldehyde vapour. The prion agent 
has subsequently been shown to be resistant to this process. Indeed one electrode 
successfully transmitted disease when implanted in the cortex of a chimpanzee.59 
Other case reports followed of probable iatrogenic transmission of CJD following 
neurosurgery,60 cadaveric dura mater graft transplantation,6' and in recipients of 
pituitary- derived human growth hormone,62,63,64 and human pituitary 
gonadotrophin.65 Reports of case -to case transmission of CJD continued to be 
unusual but there was concern as the number of reports of CJD in recipients of 
human growth hormone increased.66 
In these cases there was an identifiable source of infection. However, surveillance of 
CJD in many countries had established an incidence of approximately 1 case per 
million and despite some reports of geographical clustering,67 no consistent risk 
factor was found for the majority of CJD cases.68 About 85% appeared to occur 
sporadically.3 
Clearly the transmissible agent was unlike any recognised vector of infection: It was 
associated with diseases occurring in acquired, sporadic or hereditary forms; There 
was an absence of inflammatory changes in the brain and cerebrospinal fluid, unlike 
any other infectious disease; There was a long incubation period and the majority of 
cases had no obvious common exposure to other infected individuals, through diet or 
by geography, with only rare reports of clustering in the human diseases. (Epidemics 
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of scrapie within herds of sheep were described in Europe throughout the late 
eighteenth and nineteenth century.69) 
These were unusual epidemiological properties for any infectious agent and it was 
hard to conceive of a route of person -to- person spread of the disease. As protein 
biochemistry techniques improved other properties of this highly resistant agent 
became evident. It was about the same size as a small RNA virus70 with an apparent 
molecular mass of 100 000 kDa.71 It seemed to be concentrated in the cell membrane 
of brain tissue.72 No virus could be seen under an electron microscope, and the lack 
of an immune response seemed odd. In addition immune -suppressed mice developed 
scrapie in the same way as normal mice.73 
Some of the information about the properties of the scrapie agent came from 
transmission studies, in which it was shown that different isolates of scrapie 
produced different reproducible clinical phenotypes when passaged into the same 
species. This was first demonstrated in goats in which two separate clinical 
syndromes, termed "nervous" and " scratching ", were consistently found following 
intracerebral inoculation.16 As well as clinical syndromes, differences in incubation 
period74 and neuropathological lesion profile were also found.17 This appeared to 
suggest there were different strains of the agent. 
Over several years it was shown that the agent was inactivated by proteases but not 
by lipases, glycosidases and, most importantly, nucleases.75 This implied that the 
agent was devoid of nucleic acid, a hypothesis that had been explored in 1967 by 
Alper.76 An infectious agent that carried strain dependent properties, but apparently 
contained no DNA, contradicted all genetic principles. 
In 1982 Prusiner reawakened the controversial theory that the agent consisted of 
only protein. He demonstrated that scrapie infectivity was associated with a protein 
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that was partially resistant to proteolytic degradation and had a molecular mass of 
27 -30 kDa.19 He called the agent a prion (from "proteinaceous infectious agent ").' 
The protein was isolated and termed PrP, (for prion protein). Further analysis 
suggested that PrP was a structural component of the prion rather than a product of 
infection with a prion disease.77 PrP was identified in the brains of patients with CJD 
and seemed to be concentrated in the amyloid plaques.78 PrP antigens were also 
demonstrated in normal brain tissue in addition to CJD -affected brain, suggesting it 
was derived from host proteins.79 Prusiner, extending a theory originally proposed by 
Griffith in 1967,80 suggested that the scrapie agent was an abnormal isoform of a 
host protein, and might be self -replicating.' 
The gene encoding PrP was identified8i and soon located on the short arm of 
chromosome 20.79 Human PrP was fully sequenced and shown to consist of 253 
amino acids.82 It was already known that familial CJD and GSS were inherited in an 
autosomal dominant pattern and in 1989 a 144- base -pair insertion was identified on 
PRNP.54 Not long after, a missense mutation at codon 102 of PRNP was identified 
and linked to GSS.83 Further support for the central role of PrP was provided when 
an analogous mutation in transgenic mice produced spontaneous neurodegeneration. 
This suggested that an abnormality within the structure of the protein caused 
spongiform degeneration, rather than a genetic mutation predisposing to infection 
from an unidentified agent.84 
This hypothesis has become the most widely accepted. Further evidence has 
demonstrated that PrP is a ubiquitous protein.85 Prusiners' group have shown that in 
disease the protein changes structure, increasing the insoluble ß- pleated sheet 
content. This may set off a self -replicating chain reaction.86 He hypothesised that in 
hereditary disease an underlying mutation predisposes to this change. In acquired 
disease the introduction of exogenous abnormal PrP provides a template for host PrP 
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to undergo change and in sporadic disease a random stochastic event or a somatic 
PRNP mutation causes change to occur.' 
There has been some resistance to this hypothesis however. The exact nature of the 
agent and in particular the absence of DNA remains controversial.87 Other 
hypotheses have been suggested, such as the virino hypothesis, in which the agent 
consists mainly of nucleic acid and uses host protein in replication.88 
Over the years other diseases in animals have been included in the family of TSEs: 
TME has been recognised on mink farms since 1947. The clinical features and 
neuropathology are similar to the other TSEs but the source of TME remains 
unresolved. Scrapie has never been successfully transmitted to mink by the oral 
route. BSE has been transmitted both orally and intracerebrally but the clinical signs 
and pathology are distinct from recognised TME.89 No other potential source has 
been identified. 
Chronic Wasting Disease (CWD) is a naturally occurring spongiform disease. It has 
only been reported in deer and elk from Colorado and Wyoming, and has mostly 
occurred in animals in captivity although there are reports of the disease in free - 
living animals.90 The first case occurred in 1967 but the disease was not reported in 
the literature until many years later.91 The clinical signs and neuropathology are akin 
to other TSEs. Like scrapie, the mechanism of transmission of the disease remains an 
enigma and attempts at eradication have failed.90 
Interest in prion diseases escalated in the 1980s with the emergence of BSE. In 1986 
two cases of a spongiform encephalopathy were identified in cattle in the ÚK.92 
Retrospective analysis suggested the first case occurred in 1985.93 The disease 
reached epidemic proportions in the early 1990s by which time measures, such as the 
banning of ruminant -derived protein in animal feed in the UK, had been introduced 
to eradicate the disease. Up to 30 June 2001 there have been over 178,000 cases of 
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BSE in the ÚK.94 There are now only a few cases each month in comparison to the 
epidemic of the early 1990s. (See Figure 2.1.) 
It was suggested that the disease derived from exposure of cattle to a scrapie -like 
agent. The most likely source was cattle feedstuffs containing ruminant -derived 
protein beginning in 1981/82. About that time changes in rendering processes 
reduced the temperature and shortened the timing of preparation of animal material. 
In addition fewer hydrocarbons for fat extraction were used.95 There is compelling 
epidemiological evidence for this theory but the exact mechanism will probably 
never be established definitively. 
Figure 2.1: NUMBER OF CASES PER YEAR OF BSE 
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It has also been suggested, most recently in the summation of the BSE Inquiry, that 
the disease was the result of a chance stochastic mutation in cattle PrP. Abnormal 
PrP was then propagated through the recycling of cattle in ruminant feed.96 If the 
latter theory is correct then BSE might continue to occur long after the expected 
projections, which are based on current figures and assume that cases of BSE did not 
occur unnoticed before the epidemic. 
Figure 2.2: BSE EXPOSURE AND INCIDENCE OF vCJD BY YEAR OF ONSET 
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Despite the evidence that scrapie did not transmit to humans there were fears that if 
scrapie had now passed to cattle then BSE might in turn pose a threat to the public. 
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In 1986 a captive nyala developed a spongiform encephalopathy.97 A number of 
cases of TSE in a variety of captive wild ruminant species including gemsbok, 
Arabian oryx, greater kudu, eland and scimitar -horned oryx followed. A case of TSE 
was reported in a domestic cat in 1990, Feline Spongiform Encephalopathy (FSE).98 
The temporal relationship to the BSE crisis all pointed to a common origin of 
infection with BSE. In addition, BSE was successfully transmitted to mice in 1988, 
indicating it was another transmissible disease. 99 
In 1996 ten unusual cases of CJD were described in the UK.100 This disease had a 
different clinical profile to sporadic CJD, having a longer duration of illness and a 
prolonged psychiatric onset. In addition the disease affected younger individuals. 
The disease was named new variant CJD (vCJD) and the temporal relationship to 
BSE fuelled concerns that BSE might have transmitted to humans. (See Figure 2.2.) 
Subsequent evidence from transmission studies has given support to the causal 
relationship between BSE and vCJD: 
1. Intracerebral inoculation of BSE contaminated material to macaques produced 
clinical, molecular and neuropathological disease characteristics similar to 
vCJD.101 
2. The prion protein has two sites for potential sugar attachment, thus it may be 
unglycosylated, monoglycosylated, or diglycosylated. The glycoform ratio 
appears to vary between different types of disease. The glycoform ratio of vCJD 
and BSE are similar but different from sporadic CJD.20,102 
3. Transmission studies to mice have shown that BSE and vCJD have very similar 
incubation periods and neuropathological lesion profiles. The same pattern is 
seen with FSE and experimentally induced BSE in sheep and goats. Notably, the 
profile is distinct from sporadic CJD and other spongiform 
encephalopathies.103,104 
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To 16/12/02 there have been 129 confirmed and probable cases of variant CJD in the 
UK anda further 6 cases in Frances °5'1 °6 and one each in the Republic of Ireland, 
Italy, Canada and USA.107 It is not clear how many people will develop the disease. 
Predictions are hindered by insufficient information about the dose required to cause 
disease, the number of people exposed, the susceptibility of those exposed and the 
likely incubation period. In addition all cases to date have been homozygous for 
methionine at codon 129 and it is not known if cases will emerge in valine 
homozygotes and heterozygotes. 
The number of cases was originally estimated to be increasing at a rate of 33% per 
year since 1994 when the disease was first reported.108 However, more recent 
estimates have shown the rate to be approximately 16% and it has even been 
suggested the epidemic may have reached a peak. (NCJDSU website). Based on 
mathematical modelling of these figures and an average incubation period of 20 
years a prediction of an upper limit of about 136,000 cases has been made.109 
However, these figures are based on many unknown parameters and recent models 
have given predictions ranging from an optimistic 20511° to a more pessimistic "few 
thousand ".111 
This chapter covers the following topics: 
Description of the recognition of a group of diseases with a common 
pathogenesis known as the TSEs. 
Development of the "protein only hypothesis ". 
Emergence of BSE and related conditions. 
Description of vCJD and predictions about the future number of cases. 
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3.1: BACKGROUND 
Despite its rarity, CJD has become a well- recognised disease in recent years due to 
extensive media attention. Historically various syndromes have been described in the 
medical literature which in retrospect may well be sporadic CJD. A number of 
aetiologies for the condition have been proposed during that time. 
In 1954 Nevin and Jones published a description of two cases of a rapidly fatal 
illness occurring in late adult life associated with myoclonus and recurrent sharp - 
wave discharges on EEG. Spongiform changes were found in the brain at autopsy.12 
They remarked on similarities between their two cases and-five others described in 
the literature and suggested a vascular aetiology, distinct from hypertension. 
Although they included three cases described by Heidenhain, they noted he 
differentiated his three cases from "Jakob -Creutzfeldt's syndrome ". 
Nevin et al. reviewed 23 cases in 1960. He described the various onsets of a subacute 
encephalopathy, including progressive visual failure and a cerebellar onset. He noted 
that mutism was common and myoclonus was often present. The disease progressed 
steadily with dementia and paralysis. He commented on the great variation in the 
course and duration of the disease. The EEG showed progressive slowing with the 
appearance of sharp wave complexes.113 
In 1967 Nevin went on to comment on the diversity of conditions given the blanket - 
term Creutzfeldt -Jakob disease and proposed the use of the term "syndrome ". Noting 
the original descriptions by Creutzfeldt and Jakob, he proposed that this syndrome 
was distinct from subacute spongiform encephalopathy.52 However, following the 
successful transmission of sporadic CJD in 1968, 38 serial transmission experiments 
had also been successful,114 inducing spongiform change in the experimental 
anima1.115 Transmission experiments were used to show that subacute spongiform 
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encephalopathy and CJD were the same disease.55 Spongiform change, neuronal loss 
and gliosis were subsequently identified as the pathological hallmarks of CJD and 
the TSEs.116 
3.2: SPORADIC CJD 
Although it is rare, the clinical and pathological features of sporadic CJD are well 
described. Systematic epidemiological studies have been undertaken in various 
countries,68,117,118,119,120 and European collaborative surveillance has been in place 
since 1993, giving scope for a rare disease to be studied in greater detail. 
The eponymous title sporadic Creutzfeldt- Jakob disease is now used to describe a 
rapidly progressive dementia associated with neurological decline including 
typically myoclonus, cerebellar and pyramidal signs leading to a state of akinetic 
mutism and death, usually within 4 months. The EEG characteristically shows 
generalised periodic triphasic complexes. Confirmation of the diagnosis is dependent 
on the neuropathological triad of spongiform change, neuronal loss and gliosis.121 
A: EPIDEMIOLOGY 
The incidence of CJD approximates to 1 case per million. Sporadic CJD accounts for 
about 85% of all human spongiform encephalopathies.122 Because the disease is of 
short duration, incidence and mortality rate are inter -changeable. In 1999 -2000 
mortality rates from sporadic CJD in England, Scotland, Wales and Northern Ireland 
were, respectively, 0.63, 0.86, 1.00 and 0.46 /million /year.123 These rates were 
comparable to those observed in Europe and elsewhere in the world. Regional 
variation in the observed mortality rate occurs but to date the variation has not 
achieved statistical significance when adjusted for sex and age, and no evidence of 
space -time clustering has been identified.123 (See Figure 3.1) 
The reported mortality rate may be influenced by a number of factors including the 
number of cases in which necropsy is performed.122 The average number of cases per 
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annum of sporadic CJD has been consistently higher since 1990. This is believed to 
be because of increased case ascertainment since the BSE crisis although it is not 
possible to exclude an underlying rise in actual incidence of the disease. A similar 
phenomenon has been observed in other European countries.123 In addition there has 
been an increase in the number of young cases, and atypical cases 
reported.117'122'123 
°124 Retrospective reviews of deaths in England from 1979 -96 found 
no new cases of likely sporadic or variant CJD, suggesting that this increase in 
young cases is likely to be genuine and cases are not being missed.'25,126 
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The increased mortality rate has been noted in all age groups but the greatest 
increase has been in the over 75 -age group. 
123 The disease becomes more common 
with age, age specific incidence rate peaking in the 70 -79 years age group.123 This 
has changed from earlier studies which had suggested a peak mortality in the 60- 
64127 and 65 -69 age group.128 The reason is believed to be improved case- 
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ascertainment but may be due to a cohort effect. It may be that autopsy rates have 
also increased in the elderly. (See Figures 3.2 and 3.3) 
Figure 3.2: AGE SPECIFIC INCIDENCE OF SPORADIC CJD IN UK: 1970 -89 
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During the period 1990 to date in the UK the median age at onset is 65 years (range 
15 -94) and age at death is 66 years (range 20 -95). The median duration of illness is 4 
months (range 1 -74). Most studies have shown an over -all excess of female cases 
(male /female ratio 1:1.4, not corrected for age 122) 
The cause of sporadic CJD is unknown. Geographical clusters have been described 
over the years.67 An apparent cluster in Libyan Jews was originally suggested to be 
due to the local consumption of sheep's eyeballs.'29 Latterly, a mutation at codon 
200, resulting in the substitution of Lysine for Glutamine was identified, showing 
that the increased incidence was due to familial CJD.130 Epidemiological analysis 
has not identified a consistent geographical or temporal cluster.4 
In addition, previous surgery,53 previous upper respiratory tract infection,131 diet,132 
family history of dementia,133' 134 occupation128 and even stress135 have been 
proposed as potential risk factors for sporadic CJD over the years. In particular, 
exposure to scrapie, dietary or otherwise, seemed less likely to be a risk factor when 
in 1979 it was shown that there was no relation between the worldwide distribution 
of scrapie and of sporadic CJD.53 Case -control studies have failed to identify a 
common and consistent environmental risk factor for the development of the disease 
and the cause of sporadic CJD remains unknown.4'136 
It is not known if sporadic CJD is the result of a chance stochastic mutation within 
the prion protein gene or an as yet unidentified external source of infection. Clearly 
if the former hypothesis is correct then the chances of a spontaneous mutation 
occurring increase with age and in theory the age -related incidence data should not 
show exponential growth but should be directly proportional to age. 
It is possible that there are a variety of underlying causes of sporadic CJD. Some 
cases may be due to a stochastic mutation and others may be due to a number of 
different acquired causes that a case -control study might not be able to establish or 
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exclude. The increasing incidence with age may be explained by an increasing 
susceptibility to an unidentified exogenous factor. 
B: CLINICAL FEATURES 
Classically, sporadic CJD is described as a rapidly progressive dementia associated 
with multifocal neurological dysfunction and myoclonus. The patient deteriorates 
rapidly to a state of akinetic mutism and death within a period of months.55 
A prodrome has been noted in about one third of cases.5 °137 Symptoms such as 
depression, disturbances of sleeping and eating patterns and weight loss, usually 
beginning a few weeks before the onset of neurological dysfunction have been 
described. A similar frequency of symptoms has been seen in controls and their 
presence may not always be attributable to CJD.3 
In one study the onset was abrupt in about 5 %, suggesting a diagnosis of stroke,138 
but progressive neurological signs and symptoms ensued, suggesting an alternative 
diagnosis. In a further study an abrupt onset of focal symptoms or signs was noted in 
20% of cases but other features at onset made the diagnosis of stroke unlikely.5 
The presenting symptoms of sporadic CJD are usually of cognitive decline or ataxia. 
Rare presentations are well recognised however, including an onset with visual 
symptoms, progressing to cortical blindness, usually associated with visual 
hallucinations: the Heidenhain variant. This term was coined by Meyer et al. who 
described a case of CJD associated with cortical blindness and pronounced occipital 
pathology. 139 They attributed the original description to Heidenhain, who in 1929 
had described 3 cases of rapidly progressive dementia charaterised by visual failure 
leading to cortical blindness in the early stages of the disease.l 1 The Heidenhain 
variant of sporadic CJD encompasses cases who present with visual failure before or 
with dementia. 
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A pure cerebellar presentation has also been described, known as the Brownell - 
Oppenheimer variant.10 Brownell and Oppenheimer described 10 cases with an onset 
of ataxia before going on to develop dementia and other features of CJD.10 A later 
review of cases presenting with ataxia, including the 10 described by Brownell and 
Oppenheimer, gave an average duration of illness of 8 months (range 2 -18), slightly 
longer than might be expected. Most of the cases were noted to have a typical EEG 
but other case reports of this variant have emphasised the EEG is not always 
diagnostic.140 Pathologically, the cerebellum was particularly affected and two cases 
had Kuru plaques. Further analysis suggested that 10% of cases of CJD presented 
with a pure cerebellar syndrome.141 
Table 3.1: CLINICAL CHARACTERISTICS OF SPORADIC CJD: SYMPTOMS 
AT PRESENTATION 
England & Wales 
1970 -1979 137 
(n =124) % 
France 
1968 -1977 127 
(n =124) % 
USA 
1963 -1993 121 
(n =232) % 
Dementia 21 29 48 
Ataxia 19 29 33 
Behavioural Disturbance 18 30 29 
Dizziness 11 8 13 
Visual 9 17 19 
Involuntary Movements 5 1 2 
Dysphasia 5 N/A 4 
Sensory 4 2 N/A 
Headache 3 10 N/A 
It has been suggested that the presence of cerebellar or visual disturbance early in the 
clinical picture may point towards a diagnosis of CJD rather than another dementia 
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such as Alzheimer's disease.142 Other cases may have a particularly focal onset with, 
for example, progressive aphasia.143 
The frequency of the most common symptoms and signs at presentation, which were 
determined in various large epidemiological studies, are listed in Table 3.1 The 
French and UK studies include a small number of familial cases. It is not possible to 
separate these cases from the data as a whole. 
Table 3.2: CLINICAL CHARACTERISTICS OF SPORADIC CJD: SIGNS 
DURING COURSE OF ILLNESS 
England & Wales 
1970 -1979 137 
(n =124) % 
France 
1968 -1977 127 
(n =124) % 
USA 
1963 -1993 121 
(n =144) % 
Dementia 100 100 100 
Myoclonus 82 84 78 
Pyramidal 79 44 62 
Dysphasia 62 N/A N/A 
Cerebellar 42 56 71 
Akinetic Mutism 39 N/A N/A 
Primitive Reflexes 30 N/A N/A 
Cortical Blindness 13 N/A N/A 
Extrapyramidal 3 60 56 
Lower Motor Neurone 3 12 12 
Seizures 9 9 19 
The disease follows a relentless course. The presence of various symptoms and signs 
and the timing of them can vary from patient to patient. Dementia develops in all and 
myoclonus is present in over 80 %.5 Pyramidal and cerebellar signs are common. 
Most cases deteriorate to develop primitive reflexes, paratonic rigidity and 
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dysphasia. A proportion develop cortical blindness. The terminal stage is often of 
akinetic mutism. Seizures are unusual, reported in 10 %. (See Table 3.2) 
75 % -80% of cases of sporadic CJD have been reported to have a characteristic 
periodic EEG.5,137 The typical clinical features of the disease, together with the EEG 
have been used to establish diagnostic criteria for sporadic CJD.5,53 These have been 
altered slightly over the years, more recently to include CSF analysis of 14 -3 -3 
protein, but have proved remarkably consistent and reliable for the majority of 
cases.144 Recently, high signal in the basal ganglia on T2- weighted Magnetic 
Resonance Imaging (MRI) has been reported in 79% of sporadic CJD cases.8 This 
investigation may also prove to be useful in aiding diagnosis. 
C: ATYPICAL CASES 
Although the majority of sporadic CJD cases follow a relatively characteristic 
course, atypical cases are well described. Early epidemiological studies used 
differing clinical and pathological criteria to sub -classify the disease. An early 
review of 38 cases attempted to rationalise previous classifications and used duration 
of illness as well as clinical and pathological criteria to generate three sub -types of 
CJD.131 It was noted that cases with a longer duration of illness (1 -2 years) were on 
average 10 years younger than the more acute groups. A typical EEG was regarded 
as a feature of cases of short duration. 
One of the hallmarks of sporadic CJD is the short duration of illness and so cases of 
long duration have attracted added attention. The number of cases with a prolonged 
duration varies in several studies from 5 %5 to 24% in Japan where a higher 
prevalence of panencephalopathic cases occurs.l45 Brown et al. reported that no 
particular "form" of illness could be correlated with the variables of age at onset or 
duration of illness. He found that the youngest patients tended to have the longest 
illness,' although Masters et al. did not find such an association.50 
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Brown et al. reported their findings in 33 cases with long duration CJD, i.e. an illness 
of 2 years or more,9 amounting to 9% of cases of CJD seen by this group. (Although 
these were a selected group of cases and this figure is higher than would be expected 
when studying cases of sporadic CJD as a whole.) A number of patients had a family 
history of CJD and, with the benefit of genetic analysis, might now have an 
identifiable mutation. Otherwise, the cases tended to be younger. There was a lower 
frequency of myoclonus, but no other significant clinical differences from classical 
sporadic CJD. Less than half of the cases had a periodic EEG, suggesting this 
investigation is less helpful when the disease is of long duration, potentially making 
diagnosis more difficult. However, it is possible that the EEG was not repeated in 
these cases because CJD was not considered a likely a diagnosis. 
Young cases of sporadic CJD have attracted attention in the medical literature 
because the disease occurs typically in the elderly or late middle age. A case of a 19- 
year -old girl was reported in 1985. The course of the disease was typical for sporadic 
CJD and duration of illness was 4 months. An EEG showed 1 -2 cycle per second 
pseudoperiodic sharp wave spike activity. 146 At that time only one other case of 
sporadic CJD had been reported in the literature in an adolescent.147 Other cases in 
young people had occurred in familial and iatrogenic disease.53,58 Another case had 
been reported in a 26- year -old woman,148 and three cases have been reported in 
Poland of disease duration 3 to 10 months. The EEG was not typical in any of the 
cases but all three had changes of spongiform encephalopathy at autopsy.149 
Several reports of CJD in young people in the UK were subsequently shown to be 
cases of vCJD. 150,151,152 Since its description in the UK in 1996 there have been over 
100 cases of vCJD. A young person with features of CJD in the UK may be 
suspected of having variant rather than sporadic CJD, because, in this age group 
vCJD is relatively more frequent. (Although there are of course other important 
differences between the conditions.) However cases of sporadic CJD still occur in 
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young people, and the most common diagnosis in the differential of vCJD is 
sporadic CJD.153 
It has already been suggested that the clinical presentation of CJD is important. 
Isolated case reports have commented on various patients with atypical 
presentations, including alien hand occurring as the presenting sign,154'155 Wernicke- 
Korsakoff syndrome156 and acute psychosis.157 
Sensory symptoms in sporadic CJD are unusual. Various reviews have reported 
sensory symptoms in 3 %119 to 6 %120,121 at onset. Some of the cases described by 
Brownell and Oppenheimer were also noted to have vague sensory symptoms at the 
onset.10 A further 11 %121 to 16 %119 developed sensory symptoms at some stage 
during the illness. In the study by Lundberg et al. the sensory symptoms included 
paraesthesias, itching or pain and were more common in younger patients.119 
Peripheral neuropathy has been described in sporadic CJD.158 
Many of the original reports of sporadic CJD included an amyotrophic variant i.e. 
dementia with motor neurone disease.137 These cases are no longer classified as 
prion diseases because transmission studies have been unsuccessful.159 Indeed, some 
of these early reports may not in retrospect have been sporadic CJD and it is now 
widely accepted that motor neurone disease can be associated with a severe dementia 
in some cases.160 Lower motor neurone signs are rare, noted in 6% of the NIH 
series,121 but amyotrophy can occasionally be a prominent feature of prion disease.161 
Other variants of sporadic CJD include the thalamic variant. The first case was 
probably described in 1939.162 Since then other cases of a thalamic variant of 
sporadic CJD have been reported.163'164 Recently, the phenotype has been described 
as sporadic fatal insomnia (i.e. fatal familial insomnia with no recognised PRNP 
mutation).165 The clinico- pathological phenotype is characterised by dysautonomia, 
dementia and ataxia. Sleep disturbances are common. Cases tend to be of longer 
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duration and do not have a typical EEG. At autopsy there is invariably thalamic and 
olivary neuronal loss and astrogliosis. 
There are also many reports of a panencephalopathic variant in the literature. These 
cases are usually of long duration with a disproportionately large involvement of 
spongiosis, neuronal loss and gliosis in the white matter of the cortex and 
brainstem.166'167 The panencephalopathic variant has been reported frequently in 
Japan, and it has been stated that as many as 38% of Japanese cases are.of this 
type 168 
D: INVESTIGATIONS 
A definite diagnosis of CJD depends on neuropathological findings. However, brain 
biopsy is usually undesirable in life and a diagnosis of suspected CJD is often 
reached by exclusion; most investigations, including Computed Tomography (CT) 
imaging of the head and routine CSF analysis are usually normal or negative, thus 
excluding structural disease or other conditions such as cerebrovascular or 
inflammatory disease. There are no specific diagnostic blood tests but underlying 
toxic or metabolic problems can be excluded. Liver function tests have been reported 
as abnormal in 40% of cases,137 but this may reflect the general condition of the 
patient or be due to other factors such as drug treatments. Other biochemical and 
haematological parameters are usually normal. 
i): ELECTROENCEPHALOGRAM (EEG) 
The EEG has been the mainstay in the clinical diagnosis of sporadic CJD until 
recently. Nevin and Jones first described periodic complexes in association with 
spongiform encephalopathies in 1954.112 A classical EEG in sporadic CJD is 
reported to show slowing of background rhythm with stereotyped periodic 
complexes which are often asymmetrical. (See Figure 3.4) Serial EEG recordings 
have recorded the presence of typical periodic sharp -wave complexes in 75% to 94% 
of cases, often developing as the disease progresses.137'169 The EEG has been found 
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to be typical in about two thirds of cases at the NCJDSU. Until recently the EEG was 
the single criterion that differentiated probable from possible cases in the agreed 
diagnostic criteria. 
Figure 3.4: A TYPICAL EEG IN SPORADIC CJD 
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The absence of periodic complexes was felt to be evidence against a diagnosis of 
CJD.10 However, more recently, a negative EEG has been shown to have a negative 
predictive value of only 30 %.171 Part of the difficulty is that there have been few 
attempts to devise objective criteria for a "typical" EEG in sporadic CJD and there 
are numerous case reports in the medical literature of conditions in which a "CJD - 
like" EEG has been recorded. Some of these causes, such as metabolic disorders, can 
be distinguished on medical grounds. Others, such as Alzheimer's disease can 
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occasionally give rise to confusion, despite stricter evaluation of the EEG.144 (The 
criteria used in this study are set out in chapter 7: Methods.) 
In addition, the EEG may become "typical" only as the disease progresses and repeat 
EEG recordings are not always undertaken. It is possible that the EEG is less likely 
to be repeated if the first record is not suggestive of CJD and the diagnosis is not 
considered, i.e. the case is atypical from the outset. There are not many other 
conditions in which serial EEG recordings are helpful. Thus, there may be an under- 
reporting of typical EEGs in atypical cases of sporadic CJD. 
Two recent studies have reported a sensitivity of 66% and 75% and specificity of 
74% and 86% respectively. 171'172 Steinhoffs' study defined periodic sharp wave 
complexes as "being mono- or multi -phasic, occurring in a strictly periodic fashion 
at an interval between 500 and 2000 milliseconds ". However it also included 
lateralised and localised complexes that would not be included as typical in this 
study. This may account for the higher sensitivity and specificity seen in his study. 
The final stages of the disease are characterised by generalised attenuation of the 
EEG.169 A normal EEG does not absolutely exclude a diagnosis of sporadic CJD, but 
is very unusual; however, there are reports of a normal EEG even in the terminal 
stages of the disease.173 
ii): CSF ANALYSIS 
Routine analysis of CSF is usually normal in sporadic CJD. It is generally accepted 
that inflammatory cells are not seen in the CSF but a moderately elevated protein, (a 
rather non -specific result), occurs in some cases. ' 74 Three series report that CSF 
pleocytosis was never seen.121'175'176 
A few case reports have commented on a raised CSF white cell count and protein. In 
one study 23% (13/57) of cases had an abnormal CSF. Of these, the protein was 
raised all 13 cases (52 -150 mg /dl), and 6 cases (11 %) had a pleocytosis (10 to 
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303 /mm3). No further details are given.120 This is a Japanese study and it is well 
recognised that the clinical features and pathology of CJD in Japan are rather 
different from that seen in Caucasians. There are little, if any, data given on the 
clinical features of other cases with abnormal CSF in the literature, e.g. in most cases 
it is not clear if a raised protein is associated with a raised red cell count or if serial 
LPs were performed. 
As a general rule, abnormal CSF results, in particular a pleocytosis, should make one 
consider an alternative diagnosis to CJD. Oligoclonal bands in CSF but not in serum 
have also been reported but are not commonly seen.177 
In recent years, analysis of various brain -specific proteins has become a useful and 
reliable tool in the diagnosis of CJD. These are normal brain proteins that may be 
released into the CSF in disease states. Hence, they are not specifically related to the 
underlying disease mechanism of CJD or to PrP. 
Initially four abnormal proteins were identified by 2- dimensional gel 
electrophoresis.178 Two of these proteins were found pre -mortem in the CSF of two 
cases of CJD in whom brain biopsy had been unhelpful.179 A simpler assay for a 
protein whose amino acid sequence matched these 2 proteins was subsequently 
developed. This protein was named 14 -3 -3.18° Initial evaluation of the 14 -3 -3 
immunoassay by the German surveillance system has reported a sensitivity of 94% 
and specificity of 93.3 %.7 
As might be expected, the specificity of this test has fallen as it has become more 
widely used. False positives have been reported in hypoxic brain damage, 
meningoencephalitis, metastatic brain disease, Alzheimer's disease, fronto -temporal 
dementia, stroke, herpes simplex encephalitis, Rett's syndrome, subarachnoid 
haemorrhage, paraneoplastic syndrome and acute transverse myelitis.7,176,1so,1s1,1az,1s3, 
Some of these cases would not meet WHO criteria for "possible" CJD however, and 
47 
CHAPTER 3 HUMAN SPONGIFORM ENCPHALOPATHIES 
it is arguable whether or not 14 -3 -3 was an appropriate investigation in the 
context.184 False negative results have also occurred.183,185 
A more recent analysis has re- evaluated the sensitivity and specificity of 14 -3 -3 
analysis to be 94% and 84% respectively. The specificity of CSF analysis was 
greater than that of the EEG (74 %).171 Based on these results either a positive 14 -3 -3 
or typical EEG are now used in the diagnostic criteria for sporadic CJD, (sensitivity 
97 %, specificity 65 %) 
14 -3 -3 protein is the most specific of the brain -specific proteins in the diagnosis of 
sporadic CJD. However, other proteins have also been detected in the CSF and may 
be used: S -100, a product of astrocytic breakdown has been detected at significantly 
raised concentration.186 Sensitivity and specificity has been found to be 84.2% and 
90.6% respectively at a cut -off level of 8 ng /mL. 187 S -100 can also be detected in 
serum and it has been suggested there is potential for serum analysis of this 
protein.188 
In addition neurone -specific enolase (NSE) has been detected and has a reported 
sensitivity of 80% and specificity of 92% at a cut -off level of 35 ng /mL.1ß9 Tau - 
protein can be detected by ELISA in the CSF of CJD patients at a higher level than 
other dementias, including Alzheimer's disease, and may also be a useful 
discriminator.190 
iii): CEREBRAL IMAGING 
The cerebral CT imaging in CJD is usually normal, even in advanced disease, with 
severe dementia, cerebellar ataxia, cortical blindness and myoclonus. There are case 
reports of atrophy but no other abnormality.191 
The advent of MRI did not initially provide more information other than isolated 
case reports: Serial imaging noted the development of cerebral atrophy and non- 
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specific white matter changes in 2 cases.192 Severe cerebellar atrophy on MRI has 
been reported in a case of panencephalopathic CJD of 17 months duration.193 
Another panencephalopathic case was noted to show periventricular 
hyperintensity.194 T2- weighted, Fluid Attenuated Inversion Recovery (FLAIR) and 
diffusion- weighted MRI have been reported to show high signal intensity changes 
throughout the cerebral cortex in sporadic CJD.'95,196'197,198 
A review of MRIs in 1992 reported scattered high signal in 4 of 12 cases (33 %). 2 
cases (17 %), of duration 6 and 10 months, showed mild to moderate atrophy. 5 
(42 %) cases were normal and 1 had movement artefact.199 
Figure 3.5: MRI OF SPORADIC CJD SHOWING HIGH SIGNAL ON 
T2- WEIGHTED IMAGING IN THE BASAL GANGLIA 
Milton et al. reported high signal in the basal ganglia in a case with pronounced 
extrapyramidal features in 1991.200 There have been other reports of high signal in 
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the striatum and thalamus on T2- weighted images, some linking MRI changes to 
areas of more pronounced status spongiosis and gliosis in these areas. 201, 202, 203,204, 
205, 206 These changes have also been noted on T- weighted, FLAIR and diffusion - 
weighted images.207,208 
The presence of high signal in the putamen and basal ganglia on T2- weighted 
imaging was evaluated by the German surveillance system in 29 cases of sporadic 
CJD. The abnormality was found in 79% of cases.8 (See Figure 3.5) Further 
evaluation of these cases reported a sensitivity of 67% and specificity of 93% for 
sporadic CJD.209 An Italian review of 31 cases found the changes in 100% of their 
cases.210 It has been suggested that the MRI changes should also be used in the 
diagnostic criteria for sporadic CJD.209 These early results suggest it may yet prove 
to be useful in aiding the diagnosis of this disease, however, the use of MRI in 
sporadic CJD needs further evaluation. 
Correlation of the MRI changes with the clinical picture has been examined in an 
isolated review. 10 of 15 cases with extrapyramidal involvement in the illness had 
basal ganglia changes on MRI. It was noted that patients without basal ganglia 
changes hád a longer duration of illness.211 
D: DIAGNOSTIC CRITERIA 
Masters et al. devised criteria for the diagnosis of CJD in 1979.53 These have been 
somewhat modified and current criteria use the presence of 14 -3 -3 protein in 
addition or instead of a typical EEG to aid the diagnosis. (See Chapter 7: Methods) 
To be considered a possible case of sporadic CJD, there should be a rapidly 
progressive dementia of less than 2 years duration. In addition there should be 2 of 
the following clinical signs: myoclonus, pyramidal, cerebellar and extrapyramidal 
signs, cortical blindness and akinetic mutism. 
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To be considered a "probable" case, either the EEG should be positive or 14 -3 -3 
protein should be positive and the disease should be of less than 2 years duration. 
Currently a diagnosis of possible CJD carries about a 50% chance of being correct. 
However, a probable diagnosis is approximately 95% specific.212 
F: PATHOLOGY 
The definitive diagnosis of CJD rests on the neuropathological examination of 
central nervous system (CNS) tissue. This is usually done at autopsy although 
cerebral biopsy is sometimes done during life. The classical changes of spongiform 
change, usually accompanied by neuronal loss and gliosis, are the main diagnostic 
features. More recently techniques for PrP staining have been developed and 
improved, aiding diagnosis. The neuropathological diagnostic criteria have been 
published in a consensus document.213 
Macroscopically the brain often appears normal although there may be focal or 
generalised cortical atrophy.213 The presence of spongiform change, neuronal loss 
and astrocytosis is highly variable. Severe cortical damage may be characterised by 
the lack of any specific feature and is termed "status spongiosis ". Spongiform 
change is usually distributed in varying severity in the grey matter, sometimes 
confined only to a few focal areas. (See Figure 3.6a) 
The degree of gliosis increases as the disease progresses and spongiform change 
becomes less obvious.116 However, an analysis of 50 cases with pronounced 
pathological cerebellar changes found no correlation with more marked clinical 
cerebellar symptoms and signs. Nor was there a relationship between the degree of 
cerebellar atrophy and the duration of disease.214 
Amyloid kuru plaques are seen in 10 -15% of sporadic CJD cases. The typical kuru 
plaque consists of a central eosinophilic disc with radiating amyloid fibrils and often 
a pale halo. They do not always require immunostaining for identification and are 
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normally present in the cerebellum, particularly the granular layer.215 (See Figure 
3.6c) In some cases the plaques have been noted in association with a cerebellar 
onset.216 There are reports in the medical literature of atypical cases of CJD 
associated with kuru plaques217 and a review of case reports in 1988 suggested that 
the plaques tend to be associated with a younger age at onset and a longer duration 
of illness.216 However, 5% of Browns NIH series121 had kuru -type plaques and their 
presence bore no relation to the duration of illness. 
The panencephalopathic variant may also show spongiform changes in the white 
matter.213 These cases seem to be of two types depending on the presence or absence 
of kuru -type plaques, those with plaques being of longer duration.167 
The identification of PrP either by western blotting or by immunocytochemistry aids 
diagnosis. As it is not possible to distinguish between normal and disease -associated 
PrP, pre- treatment with proteinase K is required prior to western blot.20 Various 
treatments including autoclaving at 121 °C, immersion in 96% formic acid and then 
4M guanidine thiocyanate are required prior to immunocytochemistry for PrP.215 
PrP may be distributed in three patterns, often overlapping: plaque, diffuse synaptic 
and patchy/ perivacuolar. The PrP deposits tend to be more finely distributed in the 
cortex (See Figure 3.6b) however in the cerebellar cortex the distribution is more 
prominent, particularly in the granular layer.213 (See Figure 3.6d) 
PrP has been found in the muscle of a patient with inclusion body myositis (although 
there was no evidence of CJD or prion disease).218 The significance of this is 
unclear. It is interesting that transgenic mice expressing a high degree of PrP were 
found to have a necrotising myopathy with accumulation of the transgene PrP within 
the muscle fibres.219 
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Figure 3.6: PATHOLOGICAL CHANGES IN SPORADIC CJD 
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a) Spongiform change (x20) 
b) PrP deposition in the cerebral cortex (x20) 
c) Kuru plaque within the cerebellum (x40) 
d) PrP deposition in the cerebellum- sporadic (x20) 
PrP immunolabelling with KG9 
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3.3: VARIANT CJD 
The clinico- pathological phenotype of vCJD has remained fairly constant since it 
was first described in 1996.100 The disease is relatively distinct from sporadic CJD, 
both in the clinical and pathological features, (although there are also similarities 
between the two conditions). It tends to affect younger individuals and has a longer 
duration of illness. 
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To date there have been 129 cases of definite or probable vCJD within the UK. A 
further 6 cases have occurred in France and 1 each in Ireland, Italy, Canada and USA 
102,103.104 The male to female ratio is 1.1:1. The median age at onset is 26 years 
(range 12 -74), and at death is 28 years (range 14 -74). One of the distinguishing 
features of variant from sporadic CJD is that it tends to affect younger individuals. 
(See Figure 3.7) However, recently a case has been reported in a 74- year -old man.22° 
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The clinical and pathological features of the disease were similar to other cases of 
vCJD however this case is 20 years older than any other identified case of vCJD. 
There was no unusual identifiable exposure to the BSE agent. Clearly a case of vCJD 
within this age group has important epidemiological implications. 
Typically, the disease onset is characterised by early psychiatric symptoms, in 
particular depression, anxiety and withdrawal. These symptoms are often present for 
many months prior to developing other neurological signs. More frank psychotic 
symptoms have been present in a minority of cases.221, 222 Sensory symptoms are a 
prominent feature in about a third of cases from the onset and developed at some 
stage in nearly two- thirds of cases. These are often non -specific including limb pain, 
dysaesthesia and numbness or tingling.223 After a median period of 6 months patients 
go on to develop ataxia and cognitive impairment. Involuntary movements, often 
dystonic or choreiform in nature, are usually present.163 Patients deteriorate to a state 
of akinetic mutism and death, similar to the terminal stages of sporadic CJD. 
Diagnosis of vCJD was initially difficult. The EEG is non -specifically abnormal in 
most cases; none have shown the typical periodic complexes of sporadic CJD.224 
Routine CSF analysis is normal in most cases and 14 -3 -3 protein is positive in about 
50% of cases. In combination with a raised level of tau protein this test may be more 
sensitive but as CSF tau is relatively non -specific there is still no reliable CSF test in 
the diagnosis of vCJD.22' 
As with sporadic CJD, routine CT scanning is unhelpful. However, MRI scanning in 
vCJD has proved to be very useful. Many of the cases have exhibited high signal on 
T2 or proton density weighted imaging in the pulvinar area of the thalamus. These 
changes can be asymmetrical and are present bilaterally. High signal changes are 
also seen in the medial thalamus and periaqueductal grey matter. 
226 (See Figure 3.8) 
Of the 101 available scans at the NCJDSU the pulvinar sign has been present in 92% 
of cases of vCJD. FLAIR MRI may be the best way of visualising these findings.227 
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Figure 3.8: HIGH SIGNAL IN THALAMUS ON T2- WEIGHTED IMAGING IN 
vCJD 
The clinical features together with a positive scan have been used to develop 
diagnostic criteria for vCJD. (See Appendix D) These have been validated and the 
diagnosis of probable vCJD has a sensitivity of 92% and specificity of 100% to date. 
(Personal communication, NCJDSU) 
Prion protein has also been identified in the lymphatic tissue of the appendix and 
tonsils in cases of vCJD, distinguishing the condition from other forms of CJD.228,229 
Because of these findings, tonsil biopsy has been suggested as a useful diagnostic 
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Figure 3.9: PATHOLOGICAL CHANGES IN VARIANT CJD 
a) Florid plaque within cerebral cortex (x40) 
b) PrP deposition within the cerebral cortex (x40) 
PrP immunolabelling with KG9 
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too1.230 This is an invasive procedure and in the presence of a positive MR! scan is 
probably not necessary.231 However, in the case of a negative MRI scan, the 
identification of PrP in a tonsil biopsy would also make a case with the appropriate 
clinical setting "probable vCJD ". 
Confirmation of diagnosis still rests upon neuropathology. Spongiform change, in 
the absence of plaques, is focally distributed throughout the cerebral cortex, 
particularly in the occipital and inferior frontal regions. Extensive spongiform 
change is seen in the caudate nucleus and putamen. Marked astrocytosis and 
neuronal loss is present in the posterior thalamic nucleus and midbrain. PrP is 
deposited in the form of florid plaques, particularly in the cerebral and cerebellar 
cortex.232 These plaques are distinct from the kuru -type plaques seen in sporadic 
CJD. (See Figure 3.9a) PrP staining is widespread throughout the brain, seen 
particularly in the occipital cortex and cerebellar cortex. (See Figure 3.9b) 
There are a number of unknown variables that may influence the future number of 
cases of vCJD. These include the number of people who have been exposed to 
infectious material, the susceptibility of individuals, the dose of infectious material 
required to develop disease and the incubation period between exposure and first 
signs of disease. 233 As stated previously, estimates of the predicted number of cases 
vary considerably and recent analyses have suggested from 205 to a " few thousand" 
cases are possible.11°'111 The number of cases of vCJD continues to increase. 
Analyses of short-term trends currently indicate an approximate doubling in the 
number of cases of vCJD in the UK every 3 years.108 However, despite early 
concerns of an increase in the number of deaths from the condition, an exponential 
rise in case has not been seen to date.234 (See Figure 3.10) 
In addition there have been concerns that cases of vCJD could have been missed, 
either because an individual has died and the disease has been unrecognised, or 
because cases have died from other causes prior to a diagnosis of vCJD being made. 
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Look back studies of case records and neuropathological material have failed to 
identify missed cases of vCJD.'25,126 
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A further cause for concern is the possibility of secondary transmission of vCJD, 
either by blood products or contaminated surgical instruments. It is conceivable that 
apparently healthy individuals are silently incubating the BSE agent and pose a 
potential risk of secondary spread of vCJD. The magnitude of this risk remains 
unknown. Look back studies of sporadic CJD have not identified any cases that 
could be attributed to the administration of blood or blood products,235 however, 
transmission of CJD has been demonstrated using intracerebral inoculation of blood 
or buffy coat in experimental rodent models. 236 
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Of course the risk from vCJD may be different from that of sporadic CID. 
Theoretically it could be higher because PrP is found in tonsillar tissue in vCJD237 
and it has been shown that the buffy coat probably has the highest degree of 
infectivity.236 Laboratory models have shown that at least 5 to 7 times the amount of 
infectious agent would be required to transmit disease by the intravenous rather than 
the intracerebral route, and that there is probably little significant plasma infectivity 
before the onset of symptomatic disease.238 In addition, retrospective study of prion- 
protein accumulation in tonsil and appendix tissues from surgically resected samples 
from the (presumed) healthy UK population did not identify PrP in any of over 3000 
cases.239 
Never the less, measures have been taken within the UK to reduce the chance of 
potential secondary transmission. These include universal leucocyte depletion of 
blood products, limiting the use of fractionated plasma products and donor selection, 
deferring donors who have a family history of CJD and those who have a history of 
corneal or dura mater grafting, neurosurgical intervention or human pituitary- derived 
hormone exposure. 
It is assumed, although unproven, that vCJD transmitted to humans through the oral 
route. The likely source of infection would be tissue high in BSE infectivity; i.e. 
brain, spinal cord, dorsal root ganglia and retina. This would not normally be 
consumed, but bovine vertebral column has been used in the production of 
mechanically recovered meat (MRM) in New Zealand and it is not unreasonable to 
assume that similar practices were used in the ÚK.240 It is believed that MRM was 
used in the production of various foods such as beef burgers, pies and sausages. 
Recently a potential cluster of cases has been described in the Leicestershire area.123 
Analysis of butchering practice in this area suggested that unusual methods were 
used that may have exposed individuals to meat contaminated with brain material. 
However these data are not yet published.241 (Indeed, it is not yet established if the 
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butchering methods used were peculiar to the Leicester area only.) Other reports 
have suggested clustering close to rendering plants. 242 However analysis has shown 
the distribution of these cases to be due to chance. 243 
A geographical variation of cases of vCJD has been demonstrated however; the 
disease has occurred more frequently in the North of the UK compared to the South. 
The reason for this is not clear. Regional variation in diet has been suggested as a 
cause but it has not to date been possible to determine whether or not this is the 
case.244 
Recently, treatment of CJD has been suggested based on studies of acridine and 
phenothiazine derivatives. These substances were shown to partially inhibit the 
formation of PrPsc in vitro.245'246 Despite initial enthusiastic press reports of 
substantial clinical improvement in one case of vCJD747, it remains to be seen if 
these products will prove to be effective in a clinical setting. 
3.4: IATROGENIC CJD 
Human prion disease can also be acquired through a variety of external routes. The 
first instance of possible iatrogenic transmission was in the recipient of a corneal 
graft in 1974 who developed CJD. The donor had also died from CJD.57 Three years 
later, it was suggested that infection by contaminated stereotactic intracerebral EEG 
needles caused two further cases of CJD.58 In retrospect it is possible that three of 
the cases described by Nevin and Jones may have been transmitted by neurosurgical 
instruments.60 Epidemiological studies have reported increased rates of head surgery 
in cases of sporadic CJD over the years,53' 248 possibly related to cross -contamination 
by neurosurgical instruments. However, review of case -control studies has not found 
a consistent risk factor, including previous surgery.4 
More recently iatrogenic transmission by contaminated human growth hormone 
64 
and dura mater grafts have been described.249 The latter have mostly occurred in 
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Japan. Recently published figures counted 139 growth hormone cases (more than 
half occurring in France), and 114 dura mater cases.250 Four recipients of human 
pituitary gonadotrophin have developed CJD in Australia.65 
The clinical features of human pituitary growth hormone (HGH) related CJD are 
relatively distinct from sporadic CJD. In some cases there is a prodrome of sleep 
disturbance and personality change. The majority present with a progressive 
cerebellar syndrome and in many, dementia is not a prominent feature, at least until 
late in the disease.`'' Disease duration tends to be longer than in sporadic CJD, in 34 
HGH recipients in France the median duration was 17 +/- 9 months.252 It has also 
been reported that dura -mater cases usually have a cerebellar presentation, 
irrespective of the site of the graft.250 In iatrogenic CJD due to central inoculation the 
clinical features are similar to classical CJD. The clinical picture is dominated by a 
dementing illness.59 
Periodic complexes typical of sporadic CJD were seen in only 2/34 (6 %) of a French 
review.252 It has been suggested that a typical EEG occurs more frequently thàn 
this.250 A positive 14 -3 -3 protein result has been reported in 100% of cases in a 
recent French study of HGH cases, however the result is often negative in the first 
months of illness and becomes positive some months into the disease progression.2" 
Some cases have been reported to show MRI changes in the putamen.250 
The pathology of iatrogenic CJD is similar to sporadic disease, exhibiting the triad of 
spongiform change, astrocytosis and neuronal loss. The distribution varies from case 
to case. There is prominent cerebellar involvement in HGH cases, with marked 
cerebellar atrophy, extensive neuronal loss, widespread spongiform change and PrP 
plaque formation.254 
62 
CHAPTER 3 HUMAN SPONGIFORM ENCPHALOPATHIES 
There is a diffuse pattern of staining of PrP in the granular layer of the cerebellum on 
immunocytochemistry.2 However, atypical cases associated with plaque -like deposits 
have been described.255 
3.5: FAMILIAL CJD 
Prion diseases are inherited in 5 -15% of cases.256 There are now 22 mutations 
identified in PRNP that are associated with disease. These include 13 point 
mutations, a stop codon mutation at codon 145, and 8 insertion mutations (consisting 
of 1,2 and 4 -9 repeats of 24 base pairs located between codons 51 and 91).257 
Deletions and polymorphisms are also recognised, although these are not necessarily 
associated with disease. The best known is the codon 129 polymorphism but 6 other 
polymorphisms, some silent, have been described.257 There is also a silent deletion of 
one 24 -base pair repeat found in 1 -2.5% of the population.258 
The diseases are classified as Gerstmann -Sträussler -Scheinker disease (GSS), 
associated with a point mutation at codon 102 of PRNP, fatal familial insomnia 
(FFI), associated with a D178N mutation encoupled with methionine at codon 129 
on the mutated allele, and familial CJD with which several mutations of PRNP are 
recognised. (See Table 3.3) 
The pattern of inheritance is invariably autosomal dominant. The degree of 
penetrance of most of the mutations is not known although it is generally believed to 
be high. However, the codon 200 mutation has been shown to have incomplete 
penetrance and elderly unaffected carriers have been identified.259' 26° Some of the 
disease mutations show a trend towards anticipation.261' 262 
In general, compared to sporadic disease, the age at onset is often younger and the 
disease duration often longer in familial CJD. 263 The clinical syndromes are variable 
but the codon 200 mutation is characteristically reported to show a disease 
phenotype similar to sporadic CJD.6'264 There is also variation in clinical 
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presentation both within and between families;265 pedigrees of GSS have been 
identified in which some family members present with the GSS phenotype and 
others with a phenotype similar to sporadic CJD.266 
Diagnosis of familial CJD rests on identifying the genetic mutation on PRNP within 
an appropriate clinical setting. The EEG often does not show periodic sharp 
waves,767 indeed these changes have only been described in a single case of GSS,268 
although the EEG may be positive in up to 75% of codon 200 mutations.257 14 -3 -3 
analysis may be helpful in about 50% of cases.6 In general cases with a disease 
phenotype similar to sporadic CJD are more likely to have a typical EEG or positive 
14 -3 -3 protein. Oligoclonal bands have been reported in a case of FFI.269 There is 
very little information on the use of MRI. In some cases imaging has shown a degree 
of atrophy and non -specific white matter changes.27 °,271 
Table 3.3: CLINICAL FEATURES IN FAMILIAL PRION DISEASE 6 
MUTATION CLINICAL FEATURES 






Similar to sporadic CJD 
Codon 102* (GSS) 
Codon 117 
Codon198 (Indiana kindred) 
Codon 212 
Codon 217 
Slowly progressive ataxia, pyramidal signs 
and dementia. 
Some cases similar to sporadic CJD 
Codon 178 (methionine at codon 129) 
(FFI) 
Dysautonomia, insomnia, progressive 
dementia 
Codon 105 Progressive spastic paraparesis, dementia 
Insert mutations* Variable- features of sporadic CJD or GSS 
Codon 145 Slowly progressive dementia 
Codon 183 Personality change, dementia, parkinsonism 
* Atypical phenotypes described 
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As with all human prion diseases, confirmation of the diagnosis rests on 
neuropathological examination. Familial CJD can only be diagnosed if the 
characteristic pathology is present along with a recognised mutation of PRNP in an 
appropriate clinical setting. A wide variation in the degree of spongiform change has 
been reported and there are case reports of a recognised mutation of PRNP, in 
association with dementia, but with no characteristic pathological abnormalities.272 
Cases of FFI have also been reported with no spongiform change where the 
pathology is predominantly of thalamic gliosis.273 
GSS is characterised by the presence of multi- centric amyloid plaques in the brain. 
particularly the cerebellum. Spongiform change is also present in the CNS and 
neurofibrillary tangles are present within the cerebral cortex in the codon 198 
mutation. The pathology is again characteristically variable.254 
3.6: KURU 
The clinical features of kuru are well described, although it is now almost extinct, 
and as far as we know affected only one defined population. Study of the condition 
has provided the most extensive knowledge of an acquired prion disease. In most 
cases the duration of illness was 3 -6 months and rarely over a year.24 In some of the 
later cases an average duration of illness of 16 months was found 274 and cases of a 
duration up to 2 years have been noted.24 The age at onset varied from 5 years to 
over 60.275 The disease occurred more commonly in females.24 
Most of the cases of kuru followed a fairly uniform clinical course. 25, 274 The clinical 
features were of a progressive ataxia and tremor of the trunk, head and limbs. The 
tremor was exaggerated during voluntary motor activity or fatigue and settled at rest. 
Pyramidal tract signs and sensory symptoms were generally not a feature in the 
original description. However in later descriptions extensor plantar responses were 
noted in some patients. In some cases, the disease was preceded by a history of joint 
pains. 24 
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Dementia did not appear to be an early feature but it did appear after some months, 
often with inappropriate euphoria. In other cases a prominent frowning was noted 
and hallucinations and aggression have been seen. The patients deteriorated to a state 
of immobility and were often left to die at this stage. Mutism, rigidity and 
choreoathetoid movements often developed and a convergent strabismus was noted 
in nearly all patients.24 
The results of blood and CSF testing were normal although, the Erythrocyte 
Sedimentation Rate (ESR) was raised in some cases.24 Autopsy findings were of a 
widespread neuronal degeneration, affecting particularly the cerebellum and 
extrapyramidal system. Spongiform change was present in a variable distribution in 
the cerebral cortex, basal ganglia, thalamus and cerebellum.254 The most striking 
abnormality was the presence of amyloid plaques, occurring in about 70% of cases, 
particularly in the cerebellum.37 
This chapter covers the following topics: 
Discussion of the possible aetiology and the epidemiology of sporadic CJD. 
Review of the typical clinical and pathological features and investigation of 
sporadic CJD. 
Review of atypical cases of sporadic CJD. 
Review of the clinical and pathological features and investigation of variant 
CJD. 
Review of the clinical and pathological features and investigation of 
iatrogenic and familial CJD and of kuru. 
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4.1: PRION PROTEIN 
Although there is still debate over the nature of the causative agent in prion 
diseases,276 understanding of the underlying molecular biology, biochemistry and 
disease mechanisms has improved. 
PrP is a ubiquitous protein, present in leukocytes, heart, skeletal muscle, lung, 
intestine, spleen and other organs.85 It is concentrated particularly in the central 
nervous system, especially in neurones.277 The normal cellular form of PrP is usually 
termed PrPc. Prion diseases are associated with the deposition of an abnormal form 
of PrPc,278 often termed PrPs` (from scrapie). Whilst PrPc is rapidly digested by 
proteinase K, PrPs` is largely protease- resistant. Only the amino -terminus (N- 
terminus) is cleaved to yield a protein of 27 -30 kDa,77 which may be denoted as 
Pr's or PrP27 -3 °. PrPc and PrPs` have the same primary structure but differ in 
several other respects, in particular the tertiary structure: PrPc is predominantly 
composed of a -helix and PrPs` has a high f3- pleated sheet content.86 
In order to understand the pathogenesis of prion diseases it is important to 
understand the mechanism of PrPs` production from PrPc. There has been an 
increased understanding of the structure and cell biology of both forms of PrP over 
the years, and there is now a greater knowledge of some of the aspects of this 
transformation. 
Of greatest importance to the pathogenesis of prion diseases is the fact that 
transgenic mice which are devoid of PRNP (PrP °'0) are resistant to scrapie. 279 It is 
also known that normal PrPc must be expressed in a cell for the toxic effects of PrPs` 
to take effect.280 Whether the neurodegeneration seen in prion diseases is related to 
the toxic effects of PrPs` or the loss of PrPc, or indeed a combination of both is not 
known. 
67 
CHAPTER 4 MOLECULAR BIOLOGY OF PRION DISEASES 
Several experimental approaches are used: 
structural analysis of PrP isoforms by spectroscopy 
transgenic mice carrying modified or ablated PrP genes 
in vitro reconstitution of PrPs` from PrP peptides and purified proteins 
cell culture. metabolic labelling and subcellular fractionation of PrP 
4.2: PrPc: STRUCTURE AND FUNCTION 
PrPc is a normal host encoded protein. The entire open reading frame (ORF) of 
PRNP is encoded on the short arm of chromosome 20.79 PRNP is highly conserved 
across mammalian species suggesting an important role maintained throughout 
evolution.28I The polypeptide product consists of 253 amino acids. There are several 
distinct domains including a 22 -amino acid N- terminal signal peptide, a series of 5 
proline and glycine rich octapeptide repeats, a central hydrophobic region and a 
Carboxy -terminal (C- terminal). The protein is synthesised in the rough endoplasmic 
reticulum and transits the Golgi on its way to the cell surface.282 
Several post -translational modifications occur during biosynthesis of PrPc including 
cleavage of the N- terminal signal peptide and addition of a glycophosphatidyl 
inositol (GPI) moiety at the C- terminal. This anchors the protein to the cell 
membrane.283 (See Figure 4.1) There are 2 possible sites for N- glycosylation,$2 
situated within a loop formed by a disulfide bond between two cysteine residues at 
codons 179 and 214. In PrPc and PrPs` both sites can potentially be glycosylated.284 
Available evidence suggests that the oligosaccharide chains and GPI anchors of PrPc 
and PrPs` do not differ, although complete structures have only been worked out for 
PrPs` 2821n vitro cell culture studies in which the glycosylation sites of PrPs` and 
PrPc were mutated showed that the PrPc molecule exhibited a limited number of the 
biochemical properties of PrPs`. The authors concluded that PrPc has an intrinsic 
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tendency to adopt some PrPse -like features during its normal conformational 
maturation but that the N- linked glycan chains protect against this.285 
Nuclear Magnetic Resonance spectroscopy analysis of recombinant PrPc has shown 
that the molecule consists of a long, flexible N- terminal tail, 3 a- helices and 2 small, 
anti -parallel 3- strands that flank the first a- helix. 286,287,288 The flexible N- terminal 
appears to be the site of binding of copper ions. 289,290 




Signal peptide \A GPI anchor 
Pro/ Gly repeats N- linked oligosaccharide 
Hydrophobic section S -S Disulfide bond 
PrPc is predominantly localised to synaptic membranes.291'292 It has been suggested 
that the protein is necessary for normal synaptic function,293 but the definite function 
of PrPc is still unknown. Localisation on the cell surface might suggest a role in cell 
adhesion and recognition, ligand uptake, or transmembrane signalling.282 
In vitro studies have suggested the protein may be involved in the metabolism of 
copper294 and that copper may stimulate endocytosis of PrPc from the cell surface. 
PrPc appears to influence the activity of superoxide dismutase (SOD) in the cell. 
This enzyme has a role in neuronal resistance to oxidative stress and PrPc, by 
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binding copper, may be fundamental to this process. Copper binds to the octapeptide 
repeat region towards the N- terminal of PrP. This appears to confer increased 
stability on the random coil structure of the amino terminal.290 Cells expressing 
amino -terminally truncated PrP, and hence missing the copper ion, are SOD 
deficient and have an increased sensitivity to oxidative stress. 295 PrPc has been 
found to affect glutamate uptake by astrocytes. This may be excitotoxic to neurones 
or may exacerbate neuronal degeneration.296 
Studies on mice with a disrupted or absent PRNP were devised to try and establish 
the function of PrPc. In one study Pre0 mice lines functioned and appeared 
phenotypically norma1.297 However in other similar studies neurophysiological 
abnormalities and alterations in circadian rhythm and sleep pattern were seen293'298 It 
is not known how significant these findings are as a Pre0 mouse model is one of 
congenital deficiency rather than of acquired deficiency in later life. In addition, 
other investigators could not reproduce these findings.299 
However, an adult deficiency model has been created using bigenic mice expressing 
inducible transgenes. These animals can be rendered PrP deficient in a controlled 
fashion by the administration of doxycycline. In one study these PrP deficient mice 
remained healthy for over 1.5 years.300 However, a third line of mice in another 
study developed ataxia and loss of cerebellar Purkinje cells.301 It has been suggested 
that a further protein, designated doppel, which is encoded for by a gene located 
16Kb downstream of PRNP, may have a role in provoking neurodegeneration. In the 
Pre0 mice that developed ataxia and Purkinje cell degeneration doppel was 
upregulated in CNS cells, but this did not occur in the ataxia -free mice.302 
In contrast to deficiency models, overexpression of PrPc in transgenic mice resulted 
in a spontaneous neurodegenerative disease, including the development of truncal 
ataxia, hindlimb paralysis and tremors.219 The mice developed a necrotising 
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myopathy in skeletal muscle. It has been suggested however that this was because 
the hamster PrP used may be more toxic to mouse muscle than native mouse PrP.303 
4.3: PrPs: STRUCTURE AND FUNCTION 
PrPsc is the major isoform of PrPc deposited in prion diseases. It is disease related 
and the dominant view is that PrPsC is in fact the transmissible agent, or a component 
of it. 1 
Figure 4.2: MODEL FOR TERTIARY STRUCTURE OF PrPc AND PrPs° 
From Prusiner et al. 304 
A: PrPc predominantly a -helix structure. 
B: PrPfeS predominantly n -sheet structure. 
PrPs has the same primary structure as PrPc, being transcribed from the same host 
gene. Mass spectrometry and Edman sequencing have supported this. In addition no 
modifications been identified in the GPI anchor or the 2 oligosaccharides linked to 
the molecule.305 Thus any difference in the 2 molecules seems to be due to a post - 
translational conformational change: PrPc has been shown to have a high a -helix 
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content (42 %) and little in the way of 13- pleated sheet content (3 %), in contrast PrPsc 
has a high f3 -sheet content (43 %) and an a -helix content of 30 %.86 
The structure of PrPs° is not yet fully established, although it is the N- terminal end 
and possibly part of one a -helix that may transform into (3- sheet.306 (See figure 4.2) 
The importance of the amino -terminal region in PrPs` is still a matter of some 
debate.307 However study of prion strains in THE has suggested that the drowsy and 
hyper strains have consistently different resistance to proteolysis and that this is 
related to the site of N- terminal proteinase K digestion.18 (See Chapter 5: Strain 
Variation) 
The increased f3 -sheet content of PrPs` confers different physicochemical properties 
on the protein. The structure is relatively protease resistant and it has a tendency to 
form amyloid structures, and sometimes amyloid plaques in the affected tissue. (See 
Table 4.1) 
Table 4.1: DIFFERENCES BETWEEN PrPc AND PrPs` 
PrPc PrPs` 
Mostly a -helix structure 
Soluble in detergents 
Relatively protease sensitive 
Normal cellular turnover 
Significant f3-sheet structure 
Tends to aggregate in detergents 
Relatively protease resistant 
Forms amyloid structures 
Amyloidosis occurs in a number of diseases, including Alzheimer's disease and 
CJD. In these conditions fibrillar proteins with a (3-sheet conformation are deposited 
extracellularly. The protein deposited in each disease differs and in prion disease the 
amyloid fibrils (SAF) have a characteristic morphology observed exclusively in 
these conditions.308 Like other amyloidogenic proteins, PrPs` has a tendency to 
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aggregate into rod shaped amyloids after treatment with proteinase K in vitro and it 
seems that PrPs` forms part of the protein deposit seen in prion diseases.309 (See 
Figure 4.3) 
Both PrPc and PrPs` undergo post -translational cleavage, removing a portion of the 
N terminus. The site is distinct in each conformer. In PrPs` cleavage occurs within 
the region attacked by proteinase K to yield PrP27 -30. It has been suggested that this 
may be important in the pathogenicity of PrPsc 3'° 
As stated previously it is unclear whether the pathogenesis in prion diseases is due to 
the expression of PrPs`, the loss of PrPc or a combination of both. Various studies 
have set out to establish the role PrPs` has to play in the neurodegeneration of CJD. 
Figure 4.3: ELECTRON MICROGRAPHS OF NEGATIVELY STAINED AND 
IMMUNOGOLD- LABELED PRION PROTEINS31 
A B C 
A: PrPc, B: PrPs`: Neither PrPc nor PrPs` forms recognizable, ordered polymers. 
C: Prion rods composed of PrP27 -30 were negatively stained. The prion rods are 
indistinguishable from many purified amyloids. 
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In vitro experiments with various neuronally derived cell lines have shown that only 
some cells appear to be susceptible to infection with scrapie prions. Surprisingly, 
although the infected cells continuously produce low levels of PrPs, they display no 
obvious cytopathology in the majority of cases.282 One study, in which the cells were 
derived from hypothalamic neurons (GT1 cells), demonstrated apoptosis in a 
subpopulation.312 
Other in vitro studies have used a synthetic peptide homologous with residues 106- 
126 of human PRNP. This region seems to be required for the conversion of PrPc to 
PrPSc,313 and to have a key role in conformational conversion. 314 Some studies with 
this peptide induced apoptosis and astro- gliosis in primary rat hippocampal 
neurones.315'316'317 However, a more recent study failed to confirm these findings.318 
This peptide has a tendency to form amyloid fibrils but it forms different secondary 
structures in different pH environments. Further in vitro experiments showed that 
neurotoxic effects occurred in the absence of amyloid fibrils using a wild type 
sequence, suggesting it is not the presence of amyloid that induces 
neurodegeneration.319 It has also been demonstrated that microglia were required for 
PrP'°6 -126 to have neurotoxic effects.32° 
However, a separate in vitro study has shown that it is residues 118 -135 of PrP that 
are important in the formation of amyloid fibrils, inducing liposome fusion, hence 
destabilising the cell membrane.j21 It is clear that the exact mechanism of 
neurodegeneration in prion disease is still not understood. There are considerable 
difficulties in extrapolating the results of in vitro studies to the in vivo situation, in 
which the physico -chemical environment of the cell and other unidentified factors 
may have a significant influence that may not be reproducible in an in vitro model. 
4.4: CONVERSION OF PrPc TO PrPs` 
How cells take up PrPs` during the initial stages of infection is still not clear.282 In 
addition, the mechanism for conversion from PrPc to PrPs° remains theoretical. The 
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event apparently takes place post- translation.322 It would require a large amount of 
kinetic or thermodynamic energy for the protein to spontaneously convert from one 
stable conformation to another.323 It has been suggested that stochastic fluctuations 
occur in the structure of PrPc so that at times it partially unfolds. This unfolded 
isoform could revert to the a -helix structure of PrPc or it could by random chance 
form the 13 -sheet structure of PrPsc 324 Studies of transgenic mice suggest that PrPc 
and PrPs` form a complex during conversion. 325, 326 Additional molecules of PrPs` 
would then be created in an autocatalytic reaction.282 
In infectious forms of the disease PrPs` might act as a template for the 
transformation of PrPc.327 Again this might become more likely in the presence of a 
less stable intermediate conformer. In hereditary disease PrP mutations would 
destabilise the structure of PrPc, increasing the chance of conversion to PrPs` or its 
intermediate.324 Sporadic CJD might occur if there is a chance conformational 
change of PrPc or if a somatic mutation occurs in PRNP.323 
It has been proposed that this transformation may require a molecular chaperone, 
provisionally designated protein X.328 A potential site for protein X has been 
proposed at the C- terminal end of PrP329 although protein X itself has not been 
identified and it is not even established if the molecule is a protein or not. 
Models of familial CJD using transgenic mice have been devised using PrP 
molecules carrying an insertional mutation. These were found to induce a 
neurodegenerative disorder characterised by ataxia, with changes of cerebellar 
atrophy, gliosis and PrP deposition seen neuropathologically. The mutant PrPs` 
molecules were seen to be mildly protease resistant and have a degree of detergent 
insolubility.33o This was proposed as supportive evidence of the presumed 
spontaneous conversion of PrPc to PrPs` in cases with a PRNP mutation. 
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Understanding the kinetics of the transformation of PrPc to PrPs` might also lead to a 
greater understanding of the mechanism of conversion. One study showed that PrPs` 
in infected cell line models appeared to be stable for as long as 24 to 48 hours 
whereas PrPc had a cellular turnover of 4 to 6 hours.322 Only a minority of PrPc 
molecules were converted to PrPs`. The remainder were degraded, presumably by 
pathways similar to those seen in uninfected cells.331 The kinetics of PrPs` formation 
in sporadic CJD are more difficult to comprehend if these figures are correct. It must 
take an exceptionally long time for sporadic CJD to become established and for the 
disease process to become clinically evident from a somatic mutation or chance 
transformation of PrPc into one PrPs` molecule. 
There is more than one model for the formation of PrPs` and there is still 
considerable debate over the details of conversion. Crucial to the understanding of 
this process is evidence of the physical state of PrPs` within the cell. In vitro 
experiments have created conditions where human PrP could switch between a 
soluble form (presumed PrPc) to a partially proteinase K resistant form (presumed 
PrPSc) 332 and PrPc has been converted to PK- resistant PrPs` in vitro when incubated 
with pre -exiting PrPs` in a cell -free environment. This might suggest a direct 
interaction between PrPc and PrPs` is sufficient for propagation of PrPs`.333 In vitro 
experiments have successfully converted recombinant PrPc to PrPs` but bioassays of 
such conversion products have not shown any detectable infectivity.334 
The areas of PrPc important in conversion to PrPs` are also not established. Some 
work has shown that the C- terminal end of the molecule is necessary for 
transformation.335 The degree of glycosylation may also be important, as blockade of 
glycosylation seems to cause the protein to misfold in some experiments.285 
However, in common with many of the in vitro studies, the results are often 
conflicting. In one experiment using recombinant PrP corresponding to human 
residues 91 -231 reduction of the disulphide bond between Cys179 and Cys214 resulted 
in a -helix conformational change to ß- sheet,336 however in other studies the 
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disulphide bond was required for PrPre' production.335 Evidently further research is 
required to fully establish the nature of conversion of PrPc to PrPse 
4.5: DETERMINANTS OF RATE OF ACCUMULATION OF PrPse AND 
REGIONAL DISTRIBUTION 
It is clear that many aspects of the pathogenesis of prion diseases remain unresolved. 
It is still not known if the presence of PrPse correlates with histopathological changes 
seen in the brain and how the disease process spreads to involve different brain 
regions. The influence of the structure of PrPc within different brain regions on the 
final structure of PrPse is also unknown. Other as yet unidentified factors such as the 
biochemical milieu within different cell types may also be involved. 
The distribution of PrPres within the brain of cases with a codon 178 mutation was 
studied to try and gain some understanding of the mechanisms involved. This is an 
interesting mutation because two distinct clinico- pathological phenotypes are 
recognised depending on the methionine/ valine polymorphism at codon 129: FFI, 
characterised by untreatable insomnia, dysautonomia and marked atrophy of the 
thalamic nuclei, is linked to the presence of methionine at codon 129 and familial 
CJD178 has a phenotype similar to sporadic CJD and is linked to a valine at codon 
129.1' The influence of the codon 129 genotype on the clinical features and 
pathology will be discussed later. However, the amount of PrPfeS was analysed in 
different regions of the brain in the two phenotypes. In this study the pathological 
process at the onset of the illness and the topographic progression seemed to be the 
same regardless of codon 129 genotype. 337 
Impaired neuronal function seemed to be a result of PrPfeS accumulation (or other 
unidentified factors) in the absence of significant pathology and the rate of PrP`es 
accumulation was dependent on disease duration but varied in different regions of 
the brain.337 Some areas such as the white matter seemed to have little if any PrP`es 
deposition. It appears that despite the ubiquitous presence of the codon 178 
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mutation, PrPres deposition selectively starts in subcortical areas and only later 
spreads to the cerebral cortex.338 In addition it seems that the overall amount and rate 
of accumulation of PrPres in different familial CJD mutations and in 
iatrogenic and sporadic CJD varies, suggesting a basis for the phenotypic variability 
of human prion diseases.339 
PrPc is a ubiquitous cellular protein that binds copper and seems to be 
involved in the function of SOD. 
PrPs` is a post -translationally modified form of PrPc. 
PrPs` is disease associated. It has a high 8-pleated sheet content and is 
relatively protease resistant. 
The conversion of PrPc to PrPs` is poorly understood but appears to be 
important in all forms of CJD, whether genetic, infectious or sporadic. 
78 
CHAPTER 5: STRAIN VARIATION 
5.1: SCRAPIE STRAINS 
The relevance of the conformation and structure of PrP becomes more important 
when considering strains of prion disease and the species barrier. It was recognised 
early on that different isolates of scrapie produced reproducible distinct clinical 
phenotypes in the same species in transmission studies. This was first demonstrated 
in goats in which two clinical syndromes, termed "nervous" and "scratching ", were 
consistently found following intracerebral inoculation.16 These differences were 
believed to be due to different strains of the prion agent. However, the existence of 
strain was difficult to reconcile with the absence of DNA.34o,34' 
Studies of strain variation have also looked at human TSEs. Strains of CJD were first 
described when sporadic CJD and Kuru were transmitted into a variety of primates, 
cats and rodents. The host range, incubation time, duration of illness and type of 
clinical disease varied amongst isolates. This work is slightly confusing in that 112 
different strains were apparently isolated, however, this was an indication of the 
number of different CJD and kuru patients used.342 
Some properties seemed to be transmissible from host to recipient. E.g. kuru plaques 
in a patient with a panencephalopathic variant of CJD also produced plaques in mice 
when the disease was transmitted to them.343 Transmission studies of iatrogenic 
(HGH) CJD to one hamster demonstrated a predilection for the cerebellum. It was 
proposed that this might represent a particular strain of CJD with a tropism for the 
cerebellum because HGH iatrogenic CJD also appeared to particularly affect the 
cerebellum.344 
A number of strain defining properties have been used over the years in transmission 
studies, predominantly in mice. These include clinical manifestations such as 
differences in incubation period72 and weight gain, possibly related to targeting of 
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the hypothalamus in disease.345 Other strain dependent properties of PrPs° included 
resistance to decontamination and susceptibility to thermal inactivation.346' 347 
Other parameters are neuropathological, such as neuronal vacuolation" and amyloid 
plaque deposition.348 Deposition of PrPs` also appears to be region -specific 
according to the strain inoculated.349,35o,351 From these markers a lesion profile can 
be constructed which is remarkably consistent and specific to different strains of 
scrapie.' 7 
A large number of phenotypically distinct strains of scrapie have now been identified 
in transmission studies. Some of these have emerged from serial passaging of 
scrapie -infected material through one species and then back to the original or into 
another host. Some of the properties of a particular strain (e.g. degree of vacuolation 
and amyloid plaque deposition) became permanently altered when passaged into 
another host and then back into the original host through serial passage.352 The 
literature can at times be confusing and some apparently new strains have turned out 
to be "re- isolation of the same strain ".353 
5.2: INCUBATION PERIOD 
The host genotype also has a strong influence on the incubation period. If the same 
bank of mice were inoculated with the Chandler scrapie isolate two alleles were 
identified termed s7 and p7, denoting short and prolonged incubation periods 
respectively. A mouse gene was proposed as the mechanism for this, denoted Sinc 
(for "scrapie incubation period "). The length of incubation was consistently short or 
long depending on which of two alleles were present in the mouse host,354 and on 
whether the mouse was homozygous or heterozygous for the allele. However, no 
major differences were seen in the lesion profile, although it has been suggested that 
the sinc gene has some influence on this. 355 
The sinc gene was co- dominant and the incubation period in s7 /p7 heterozygotes 
was intermediate between the short and long incubation period for a particular strain. 
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However, the chromosome location of sinc took some time to determine. It was 
originally tentatively associated with another gene termed prn p on mouse 
chromosome 2.356' 357 This raised the question of whether the 2 genes were 
congruent, 358 but it was not until 1998 that it was proven that sinc was part of mouse 
PRNP. The incubation period is controlled by dimorphisms at codon 108 and /or 189 
of mouse PRNP.359 
5.3: TITRE AND ROUTE OF INOCULUM 
Other factors influence the incubation period: It has been shown that there is an 
inverse relationship with the titre of inoculum.36° Experiments with the route of 
inoculation do not always reproduce the same result however. In some studies the 
route of infection, whether oral or intracerebral, did not seem to affect the incubation 
period, or the number of successful transmissions.361 In another study the brain was 
inoculated at various sites and this did not appear to affect the strain dependent 
distribution of PrPsc,362 but earlier studies had shown that amyloid plaque deposition 
depended on the site of inoculation, irrespective of strain.363 
In fact, the kinetics of accumulation of PrPs` has been shown to be dependent on the 
infecting strain of agent, the mouse genotype and the route of infection,364 and it can 
be difficult to isolate the host genotype influence on disease characteristics from the 
properties of different scrapie strains. As well as incubation period, the lesion 
profile353 and PrP staining pattern348 are both influenced to some extent by host 
genotype and are not just markers of strain. This fact has been used to support the 
protein only prion hypothesis, and it has been suggested that almost all the aspects of 
pathogenesis seen in prion diseases can be explained by an interaction between 
donor and host prion protein.365 
5.4: HOST -SPECIES BARRIER 
A further characteristic of the TSEs is the existence of the host -species barrier. 
Transmission of scrapie -infected material from one species to another is usually 
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accompanied by a prolongation of the incubation period in the first passage and 
incomplete penetrance of the disease. This was first described as a "species barrier" 
by Pattison47 but a possible species barrier was demonstrated as early as 1936 in 
Cuillé and Chelles' original study. Inoculation of sheep had a low transmission rate, 
however 3 years later they transmitted scrapie to goats with 100% success.366 
Subsequent passage in the same species occurs with a higher number of successful 
transmissions and shortened incubation times. Pattison also showed that the 
incubation period was shorter if the donor and host animal were of the same species. 
If transmission was into a different species, there tended to be atypical clinical signs 
and histopathology on first passage in the host.`' 
The species barrier can be overcome by using transgenic mice. If mice are passaged 
with hamster PrPs` they do not develop disease. However, if transgenic mice 
expressing Syrian hamster PRNP are passaged with the same hamster PrPs` they are 
highly susceptible to disease. The lesion profile produced is characteristic of hamster 
scrapie rather than mouse scrapie.367 This gives further support to the hypothesis that 
PrPs` acts as a template for the transformation of PrPc. 
Similarly, transgenic mice expressing human PRNP were more susceptible to PrPs` 
from a case of sporadic CJD than from mouse PrPs` This may be because human PrP 
differs from mouse PrP in 28 amino acids. The more homologous the host and 
infective PRNP, the easier it is to overcome the species barrier.368 A cell -free model 
for PrPc conversion to PrPs` also shows species -specificity; the species barrier 
corresponding to differences in amino acid residues.369 
5.5: MOLECULAR BASIS FOR STRAIN VARIATION 
A: IN VITRO STUDIES OF N- TERMINAL CLEAVAGE 
Strain variation has also been demonstrated in TME.370 Similar to the original studies 
on scrapie, a "hyper" (HY) and "drowsy" (DY) strain of THE was identified by the 
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third passage.371 These characteristics were independent of the host genotype and 
were not due to changes in the amino acid sequence. It was shown that DY PrPTME 
was more sensitive to protease digestion than HY PrPTME Proteolytic treatment 
resulted in a 1 to 2kDa difference in migration on polyacrylamide gels.18 
The proteolytic changes were later shown to correspond to cleavages at distinct N- 
terminal sites. It was proposed that this was consistent with different conformations 
of the two strains. If less of the N- terminal was bonded into a (3-sheet conformation, 
a larger piece could be cleaved by proteinase K. The two strains also appeared to 
localise to different areas of the brain.372 Conversion of PrPc into the two distinct 
strains of PrPTME has also been performed in vitro, suggesting the conformation of 
infecting PrPTME determined the structure of the newly formed PrPTME. This 
experiment was sensitive to chemical conditions however and cannot allow for 
possible differences in the chemical and physiological conditions within the brain.373 
Similar results were demonstrated when extracts from the brain of a patient with FFI 
was transmitted to transgenic mice with human PrP. This material contained PrPres 
with a molecular mass of 19kDA after deglycosylation. This was compared with 
extracts from patients with sporadic CJD and with familial CJD200. The PrPfes in 
these cases had a molecular mass of 21 kDa. When the two different PrPre$ products 
were transmitted to the transgenic mice, PrPres of two distinct molecular weights was 
produced: The PrPfeS produced in the FFI case was of 19 kDa and that produced in 
the sporadic and familial CJD200 cases was of 21 kDa. In addition there were 
corresponding differences in the incubation period and in the neuropathological 
distribution of disease.374 This appears to add weight to the theory that the 
conformation of the prion PrPres acts as a template for conversion of host PrPc. 
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B: IN VITRO STUDIES OF 13 -SHEET CONFORMATION 
A further study was performed using an immunoassay that is sensitive to different 
conformations of PrPs`. The assay was developed for transgenic Syrian Hamster 
expressing human PrP. This assay used monoclonal antibodies directed against the 
N- terminus of PrP. Different antibodies had different affinities for the a- helical and 
13 -sheet conformations, comparing denatured to native PrPs`. Eight different 
conformations of PrPs` were identified, believed to be indicative of prion strains of 
different conformation.375 Another study analysed PrPfeS from hamsters infected with 
three TSE strains by infrared spectroscopy. Differences in the amount of 13 -sheet 
between two of the strains were found.376 
Recently, 13-sheet breaker peptides have been used in in vitro experiments as a 
potential therapeutic agent for CJD. Variable results were obtained with PrPs` 
purified from different species and different strains, again supporting a difference in 
conformation or aggregation in distinct prion strains.377 
Further work with transgenic mice has shown that changes in prion strain 
characteristics depend on the sequences of PrP encoded by the host during multiple 
serial transmissions. The strain characteristics of the ancestral source did not seem to 
be important following serial passage. In this study two different strains were serially 
passaged through a transgenic mouse host to yield identical strains with respect to 
incubation time and pathology, implying prion strain diversity is restricted to a finite 
number of conformations of PrPsc 378 
C: PrP ISOTYPES IN CJD 
Following the identification of two isotypes of THE corresponding to the hyper and 
drowsy strains, the human TSEs were studied to look for a molecular basis for strain 
variation. When brain tissue from cases of CJD are treated with proteinase K and 
analysed by western blotting techniques two isotypes are identified of 19kDa and 
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21 kDa mobility.l4 The same isotypes have now been identified in all subtypes of 
CJD, whether infective, hereditary or sporadic. They have also been seen in kuru.379 
It is believed that these isotypes are surrogate markers of strains of CJD. 
The number and classification of the protein isotypes differ slightly between centres 
and will be discussed later but differences are likely to be due to alternative 
methodology and purification techniques.14 °20,380 
Analysis has shown the isotypes differ in the site of N- terminal truncation: It is 
known from studies on human neuroblastoma cells that PrPs` seems to be a longer 
molecule than PrPC and the N- terminal section seems to be the site of cleavage by 
proteinase K.310 Protein electrophoresis has a low resolution and provides limited 
information on the precise size and possible variety of the PrPsc fragments resistant 
to proteases. The N- terminal sequence has been analysed in more detail using mass 
spectrometry. Two primary sites of cleavage by proteinase K have been identified: In 
type 1 PrPs` the site is at residue G82 and in type 2 it is at residue S97. This would 
be consistent with molecular masses of 21 kDa and 19kDa respectively as seen on 
protein electrophoresis. 381 
This may not be the same in vivo. The site of cleavage may be affected by the 
quaternary structure of PrPc.20 Alternatively, an associated molecule, which is not 
attached covalently to PrP, may protect the cleavage site of the N- terminal. 
Possibilities for this molecule include sulphated proteoglycans,382 Protein X328 or 
other exogenous factors.383 The conformation of types 1 and 2 also seems to be 
dependent on metal ions, possibly zinc or copper, presumably by exposing a new 
proteolytic cleavage site, although these findings have not been demonstrated in all 
isotypes.384 
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D: GLYCOSYLATION 
It is known that glycosylation is an important modification in any protein and can 
affect many of its' properties, including increasing the stability of the molecule 
against proteolytic degradation.385 There are two potential sites for the attachment of 
a glycan to the prion protein.82 It appears that either none, one or both sites can be 
glycosylated on both PrPc and PrPsc 284 The degree of glycosylation is likely to 
depend to a certain extent on the chemical environment within different cell types 
and the relationship of the degree of glycosylation to prion strain is not clear. As 
with other aspects of the study of prion protein there is no definite conclusion at this 
stage on the importance of glycosylation in determining prion strains. 
If PrPs` is analysed by Western blotting techniques following treatment with 
proteinase K two different isotypes are identified of 19 and 21kDa, as shown 
previously. In addition differences are seen in the amount of unglycosylated, 
monoglycosylated and diglycosylated PrP produced. This is termed a glycoform 
ratio and, like the weight of the fragment sizes, this is maintained on passage in 
transgenic mice expressing human PrP.20 
It was shown in transgenic mice that deletion of one or other of the oligosaccharides 
altered PrPc trafficking and prevented infection with two prion strains. In addition 
the pattern of PrPs` deposition was altered. It was proposed that glycosylation 
modified the conformation of PrPc , affecting the affinity of PrPc for a particular 
conformer of PrPs` 386 Further transgenic mouse studies showed that brain regions in 
Syrian hamsters synthesised different glycoform ratios of PrPc, suggesting that PrPs` 
accumulation and vacuolation pattern are governed by neuron -specific differences in 
PrPc glycosylation. This may influence the targeting of specific brain regions by 
different PrPs` strains.387 The carbohydrate groups may influence the interaction of 
PrPc and PrPs` through protein recognition events or through modulation of the 
structure, dynamics and stability of PrP.388 
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At this stage it is not clear to what extent the glycoform ratio is strain specific and to 
what extent it is determined by the regional affinity of the host neuronal population. 
As PrP glycosylation occurs before conversion to PrP5c, particular PrPs` glycoforms 
may replicate most favourably in neuronal populations with a similar PrP glycoform 
expressed on the cell surface.389 Hence the glycosylation profile may simply be a 
reflection of the neuronal cell type, rather than the result of targeting of a specific 
area of the brain by a particular strain of scrapie. Glycosylation of PrPc did not 
influence species specificity in the cell free model.369 In addition other groups have 
suggested that the glycoform ratio is not maintained on serial passage and may 
change on the first or subsequent passage in transmission studies.390 
Figure 5.1: SDS -PAGE OF PrPres FROM VARIANT AND SPORADIC CJD 
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Because of this, the importance of glycosylation is not fully established. Although it 
seems likely that PrP conformation would be the primary determinant of strain type, 
the glycoform ratio has also been used as a marker of strain. Notably western 
87 
CHAPTER 5 STRAIN VARIATION 
blotting has shown that the mobility of the type 2 isotype seen in sporadic, familial 
and iatrogenic CJD is indistinguishable from variant CJD. The only difference is the 
glycosylation pattern; vCJD has a higher proportion of diglycosylated PrPres.381 This 
has been denoted type 2B (in contrast to type 2A seen in other forms of CJD.) (See 
Figure 5.1) Recently type 1B (i.e. 21 kDa mobility but with a high proportion of 
diglycosylated PrPres) has been seen in a familial case of CJD.38° 
The method used by the NCJDSU recognises two mobilities of PrPfe$ on SDS- 
PAGE; type 1 of 21 kDa and type 2 of 19 kDa. In addition, each isotype is further 
characterised by the glycoform ratio. Type 2 is further classified as A or B 
depending on this ratio. Type 2B has to date only been seen in vCJD. (High 
proportion of diglycosylated PrPres 
E: INFLUENCE OF GENOTYPE 
It has been shown already that it is often difficult to differentiate the influence of 
strain from the influence of the host, in particular the host genotype, on disease 
phenotype in prion diseases. In human prion diseases a common polymorphism at 
codon 129 of PRNP is important in the clinico- pathological phenotype of the 
disease. Either methionine or valine can be expressed on each allele. Methionine 
homozygosity has been shown to predispose to the development of sporadic CJD.13 
Heterozygotes and valine homozygotes tend to have an atypical clinical and 
pathological phenotype of disease. (See Chapter 6: Previous studies on the clinico- 
pathological phenotype of CJD) 
In hereditary CJD a mutation at codon 178 can be associated with two different 
disease phenotypes; FFI is linked to methionine at codon 129 but familial CJD178 is 
linked to valine at codon 129. In addition if the overall codon 129 genotype is 
homozygous (i.e. the affected and unaffected alleles have the same amino acid at 
codon 129), the clinical course is shorter than if the patient is heterozygous.15 
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Western blot of the electrophoretic mobility of the two diseases demonstrated a 
mobility of 21kDa in fCJD178 and of 19kDa in FFI.391 In addition the FFI isotype had 
less unglycosylated PrP`e5. In a human neuroblastoma cell model, the FFI PIT' had 
less of the unglycosylated form, making it less stable and more easily degraded.392 
These findings implied that the differences did not come from an abnormality of the 
primary structure of the protein i.e. the genetic mutation found in FFI/ fCJD178, but 
were related to the polymorphism at codon 129.391 It has been shown that residues 
129 and 178 of PRNP are connected by a hydrogen bond, suggesting an interaction 
which might influence the site of cleavage. Alternatively, the codon 129 
polymorphism may interact with another molecule, not yet identified.393 
Studies have shown that the codon 129 polymorphism also has a role in influencing 
the proteinase degradation site of PrPfeS: Type lA protein isotype tended to be seen 
with methionine at codon 129, whereas type 2A tended to occur with valine, 
suggesting the amino acid at codon 129 influenced the site of cleavage by proteinase 
K.380 The role that the degree of glycosylation had to play in this is not clear. 
Recently, protein sequencing was used to identify the proteinase K cleavage site of 
PrPs`. As shown previously, two primary cleavage sites are seen at residues 82 and 
97 for type 1 and type 2 respectively. In addition, there are a number of secondary 
cleavages around these two sites, suggesting that PrPfeS has a ragged terminus. 
Surprisingly, irrespective of whether the disease was infectious, sporadic or familial 
these sites seemed to be influenced by the genotype at codon 129.381 The N- terminal 
was less heterogenous in the familial cases however, possibly because the disease is 
derived from only one mutant allele rather than both alleles. 
Current thinking is that there are three main structural regions on the PrPs` molecule: 
an N- terminal region from residue 23 to residue 73 that is proteolysed by proteinase- 
K. This is probably unstructured as in PrPc; a C- terminal region from residues 103- 
231 that probably has a high f3-sheet content and is highly proteinase -K resistant; and 
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a variable region from residues 74 -102. This region is subject to conformational 
changes at various sites. This seems to be regulated by the codon 129 polymorphism. 
The presence of methionine or valine influences the size of the region and may also 
influence the amount of 13 -sheet transformation in PrPsc 381 (See Figure 5.2) 
Figure 5.2: STRUCTURAL VARIATION OF HUMAN PrPsc RELATED TO 
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F: BSE AND vCJD 
The use of transmission studies and western blotting techniques in demonstrating 
strain variation has been extended to studies on BSE and related prion diseases such 
as vCJD, FSE and the exotic ungulate encephalopathies: Brain extracts from BSE in 
eight unrelated cattle sources have been successfully transmitted by intracerebral 
inoculation to mice. A similar incubation period and lesion profile was produced 
from each source, suggesting each cow was infected with the same strain of agent.394 
Analogous incubation periods and lesion profiles were seen when TSEs in domestic 
cats, a greater kudu and a nyala were transmitted to mice, indicating these species 
were infected with the same strain of BSE.394'395 
Transmission studies to mice of vCJD and BSE have also produced very similar 
results, suggesting the same strain of agent is involved in the two diseases.104 
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Comparable results between vCJD and BSE have been produced in transgenic mice 
expressing bovine PrP.103 In addition, when analysed by Western Blot techniques, 
the glycoform ratio in BSE and vCJD were alike but distinct from other TSEs.20 
However, there is still some dispute over the mobility of vCJD. Parchi et al. found 
vCJD to have type 2 mobility with a different glycosylation pattern, termed type 
2B.14 Collinge and colleagues have found a slightly different mobility which they 
have termed type 4 but with a similar ratio of glycosylation.20 These differences in 
mobility may be due to technical differences in the process used by the two 
centres.381'396 
G: ISOTYPE HETEROGENEITY 
As shown previously, the glycoform ratio can vary between different areas of the 
brain in a neuroblastoma cell model.387 Piccardo et al. analysed a number of cases of 
GSS with the same PRNP mutation (P102L) and demonstrated heterogeneity of the 
glycoform ratio between cases. In addition, in one case, differences were found in 
glycoform ratio between different regions of the same subject.397 
However, there has also been one isolated case in the literature where both isotypes 
were found in the same brain.398 Parchi et al also found both isotypes in the cerebral 
cortex of a minority of patients.399 They surmised this may have been due to 
technical difficulties or that PrP`e5 forms different conformations in different regions 
of the brain. In the Puoti study the PrPreS isotype appeared to be predictable 
depending on the histopathology of the region. This might imply that various PrP' 
types have evolved simultaneously in the brain or that regional differences in the 
PrPc form may contribute to variability in PrPres.4 °° Clearly further analysis of the 
regional distribution of each isotype is required. 
Finally, different centres have proposed slight differences in the mobility of type 1 
and 2 prion protein.14.330 This is likely to be due to differences in methodology, 
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perhaps due to the chelation of heavy metals in the preparation of PrPreS However, a 
different classification of PrP isotype has been proposed, involving several more 
mobilities of PrPres and involving greater analysis of the glycoform ratio.20 Clearly, 
these differences need to be resolved in order to try an establish a uniform 
classification of PrPreS isotype, and to fully evaluate its application in the clinico- 
pathological phenotype of prion diseases. 
Transmissions studies of scrapie in mice suggest that strains of the prion 
agent exist. 
A molecular basis for this was identified in TME, in which 2 protein 
isotypes, related to different clinical phenotypes were identified. 
The same 2 isotypes have been identified in CJD and it has been suggested 
these relate to strains of the CJD agent. 
The importance of glycosylation of the prion protein is not clear. 
A molecular basis for the differences seen due to codon 129 genotype has 
also been suggested. 
BSE and vCJD have the same protein isotype, which is different from other 
prion diseases, suggesting these conditions are due to a distinct single strain. 
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PHENOTYPE OF CJD 
The diverse clinical and pathological features of sporadic CJD might indicate that 
different strains of the agent exist. However it is difficult to separate the influence of 
host genotype from the possible influence of strain on the clinico- pathological 
phenotype of the disease. As can be seen from the previous chapters a molecular 
basis has been suggested for the influence of both strain and host genotype. 
However, this is still speculative. Other reasons for the differences in phenotype 
cannot be excluded. One potential influence on the clinical characteristics is the site 
in the brain where the pathogenic process begins. This might influence the symptoms 
at onset and the subsequent progression of disease. 
Over the years a number of studies have analysed in detail the influence of the host 
genotype on the clinico- pathological phenotype of CJD. More recently, following 
the discovery of two different protein isotypes in CJD, which are believed to be a 
surrogate marker of strain, studies have set out to analyse trends in clinical and 
pathological features related to PrPfeS isotype also. 
6.1: INFLUENCE OF GENOTYPE 
Codon 129 of PRNP is the site of a well -known polymorphism. Adenosine or 
guanine can be expressed, resulting in the expression of either methionine (Met) or 
valine (Val).401 This was initially reported as a "double- allele" mutation in 1989 
402 
but in fact either allele is expressed with sufficient frequency to be a polymorphism; 
in a normal population of 106 individuals 51% were heterozygotes, 37% were Met 
homozygotes and 12% were Val homozygotes. 403 
The importance of this polymorphism became evident when it was reported that 4/7 
iatrogenic cases were Val homozygous at this site.403 (In the original description of 
the polymorphism both iatrogenic cases were also Val homozygous.402) A later 
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analysis of 22 definite sporadic CJD cases showed that 16 (73 %) were Met 
homozygous at codon 129 and 5 (23 %) were Val homozygotes. Overall 22 cases 
(95 %) were homozygous at codon 129.404 49% of the control population were 
homozygotes.403 This seemed to suggest that homozygosity at codon 129 
predisposed in some way to the underlying disease process. Further studies 
suggested that Val homozygotes and heterozygotes may have a longer duration of 
illness and atypical clinico- pathological phenotype. 
Nine papers have been published discussing the influence of codon 129 genotype on 
the clinico- pathological phenotype of a series of sporadic CJD cases in a Caucasian 
population. Each has analysed some or all of several variables, including the 
percentage ratio of each genotype, age at onset, duration of illness, and clinical and 
pathological features. There may well be overlap of cases between studies. In the 
following section some of the features discussed in each study and in iatrogenic and 
familial cases are described. I have amalgamated the data from each study, placed at 
the end of each section. The distribution of codon 129 within the normal population 
is considered first. 
The studies are: 
1. Palmer MS et al.404 22 definite Caucasian cases of sporadic CJD. 
2. Windl O et al.405 58 definite and probable cases referred to NCJDSU 
3. De Silva et al.4 °6 29 cases of definite sporadic CJD referred to NCJDSU. 
NB subset of Windls' study therefore pathology only considered. 
4. Laplanche J -L et aí.407 41 definite and probable cases referred to French 
surveillance group. 
5. Salvatore M et al.408 31 definite and probable cases referred to the Italian 
surveillance group. Stated "Caucasian ". 
6. Schulz- Schaeffer WJ et aí.409 47 definite cases of sporadic CJD. 
7. Miyazono M et aí.410 21 Japanese patients. 
94 
CHAPTER 6 THE CLINICO -PATHOLOGICAL PHENOTYPE OF CJD 
8. Hauw J -J et al411 70 patients referred to French surveillance system with 
definite pathology and PrP immunohistochemistry. 
9. Tranchant C et aí.412 14 deaths from sporadic CJD in a French hospital. 
A: NORMAL POPULATION 
The distribution of the codon 129 polymorphism within the normal population 
appears to be very different from that of sporadic CJD. However, only a few studies 
have been done and each has involved a relatively small number of cases. The source 
of controls is not identified in every study and it is conceivable that there may be a 
bias in some of the control populations used. Nevertheless, the resultant ratios have 
been broadly similar in many of the published studies; suggesting the codon 129 
distribution does not vary greatly within the general population. 
In Table 6.1 all published studies that have used a control population have been 
amalgamated to give an overall ratio for the codon 129 genotype within the normal 
population. Assuming these figures are representative, the overall incidence of each 
genotype is: 
Mean ( %) Median ( %) Range ( %) 
MM 42 42 35 -50 
M V 48 49 40 -54 
VV 10 10 0 -15 
However, many of these studies use a Caucasian control population. It is of note that 
figures for the Japanese population are different. They do not report the distribution 
of each genotype but instead give a Met: Val frequency of 0.958: 0.042.41' In 
comparison the UK allele frequency is 0.675: 0.325.414 A Val at codon 129 is seen as 
a point mutation rather than a polymorphism in Japan because it occurs so rarely. 
Collinge et al comment that they have found a similar frequency of Val expression to 
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the Japanese in a Thai population.415 This would suggest that the distribution of 
genotype within the Asian population is different from Caucasians. 
Table 6.1: AMALGAMATION OF CONTROL POPULATIONS 
REFERENCE SOURCE N= MM % MV % VV % 
Salvatore et al.40x Not stated 186 84 45 75 40 27 15 
Lampe et al.416 Not stated 57 23 40 29 51 5 9 
Medori et al.41' Not stated 20 9 43 8 42 3 15 
Zimmermann et al.418 Blood donors 300 129 43 146 49 25 8 
Collinge et al.40' Not stated 
Caucasian 
106 39 37 54 51 13 12 
Deslys et al.419 Not stated 69 25 36 37 54 7 10 
Laplanche et al.407 Blood donors 92 38 41 45 49 9 10 
Brown et al.42° Hypopituitary 
patients 
24 12 50 12 50 0 0 
Brown et al.66 Not stated 86 33 38 44 51 9 11 
Schulz- Schaeffer et 
al 
409 
Not stated 74 31 42 33 45 10 13 
Labauge et al.421 Not stated 45 19 42 22 49 4 9 
Gabizon et al.477 ** Healthy 
Libyan Jews 
66 25 38 33 50 8 12 
TOTAL 1125 467 42 538 48 120 10 
* *NB numbers don't add up in original paper. 
B: SUSCEPTIBILITY 
This raises the question of how consistent the frequency of each allele is in other 
populations and does this influence the incidence of CJD in these populations: The 
incidence of sporadic CJD is roughly similar throughout the UK. Any differences 
seen do not achieve significance and are likely to be due to chance.123 The reported 
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incidence of sporadic CJD varies slightly throughout countries in Europe (See Table 
6.2)122 but this depends on several factors including case ascertainment; methods 
used vary from country to country, as do post mortem rates. For example in Austria, 
where it is rare for autopsy not to be performed, annual incidence rates of CJD of up 
to 1.5 cases per million per annum have been reported.423 
Table 6.2: MORTALITY RATE OF CJD IN EUROPE: 1993 -95 
(Excluding iatrogenic CJD)122 







Alternatively, there may be a genuine difference between the incidences of sporadic 
CJD in different countries due to variation in the allele frequency at codon 129. An 
analysis of cases in Crete found a relatively high incidence of sporadic CJD and a 
higher rate of Methionine homozygotes in the background population.424 This would 
require further study but other relatively isolated populations with a low influx of 
"foreign genes" might also differ from the quoted "normal" population rates. 
Another possibility, albeit unlikely, is that Val homozygotes and heterozygotes die at 
a younger age. As sporadic CJD is in general a disease of the elderly, the excess of 
Met homozygotes might be representative of the elderly population as a whole. 
Similarly, the excess of Val homozygotes in the young may again be representative 
of this population. There is no age -stratified study of the normal population 
distribution of the codon 129 genotype with which to reject this unlikely hypothesis. 
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As far as we know the codon 129 genotype is not associated with ill health in any 
other form but it has recently been shown that there is an increased incidence of met 
homozygosity in cases of inclusion -body myositis.413 
The reported data on the increased number of Met homozygotes in cases of sporadic 
CJD and the increased incidence of Val homozygosity in iatrogenic CJD prompted 
further investigation of the importance of codon 129: A study of cases referred to the 
French Surveillance study between 1992 and 1993 showed over -representation of 
Met homozygosity in the 41 definite and probable sporadic cases but did not show 
an excess of Val homozygotes. Two studies of 31 definite and probable sporadic 
CJD patients in Italy,408 and 58 definite and probable sporadic CJD cases in the 
UK,40' identified a similar excess of Met homozygotes. A German study of 47 cases 
of definite sporadic CJD showed an excess of both Val and Met homozygotes.409 
Amongst iatrogenic cases the trend is slightly different: 102/128 cases (80 %) were 
homozygous at codon 129. However, although Met homozygotes made up the 
majority of dura mater cases, (74% of 43 cases), a greater proportion of HGH related 
cases were Val homozygotes (32% of 82 cases). The reasons for this are unclear.250 
The largest study of codon 129 in a population of sporadic CJD cases comes from 
European collaborative surveillance.13 Many of the cases included in this population 
will have been used in the individual studies cited above. They reported an overall 
frequency of each genotype in 748 cases of sporadic CJD, although they did not state 
if the figures included probable cases, or if only autopsy confirmed cases were 
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However, when the genotypes were analysed by 10 -year age bands, the Val 
homozygotes were significantly more frequent in the under 50 -age band and the Met 
homozygotes show a positive linear relationship with increasing age. Heterozygotes 
also seemed to be more frequent in the under 50 -age group but this result did not 
achieve significance. 
There are several possible reasons for this. There has been an increase in the number 
of young atypical cases of sporadic CJD identified since vCJD was described. Val 
homozygotes tend to be young and atypical and so there may be a bias in the 
surveillance system. In addition 14 -3 -3 protein has been identified as a sensitive and 
specific tool in the diagnosis of sporadic CJD in recent years.17' This test seems to be 
helpful in Val homozygotes, who often have a negative EEG,'24 and so cases who 
might previously have been missed may now be identified. Alternatively, older 
sporadic cases who are Val homozygous may have an atypical phenotype and could 
be missed in the current surveillance systems. 
All cases of vCJD to date have been Met homozygotes and it is not yet known if 
other genotypes will develop the disease.123 Kuru is the only other orally transmitted 
TSE and so information on the genotype in this condition might give some 
indication of the susceptibility of other genotypes to vCJD. 92 cases were examined 
in a retrospective study. Met homozygotes were over represented in the younger age 
groups and heterozygotes were over represented in the older age groups. 425 
Other factors may influence these data however. Different age groups may have been 
exposed to different types of cannibalism, and hence a different amount or route of 
the infectious agent. Both these factors have been shown in transmission studies to 
influence the incubation period and the chance of inoculation.41, 426 Therefore this 
may be a cohort effect rather than an indication of varying susceptibility between 
genotypes. 
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Table 6.3: GENOTYPE DISTRIBUTION 
Study No MM °'o MV `)/o VV % 
1 73 4 23 
2 83 9 9 
4* 71 19 10 
5 81 16 3 
6 66 17 17 
8** 56 16 29 
9 71 7 21 
* 7 cases in this study were excluded because they were "possible" sporadic C.ID. 2 
were MM and 5 were MV. It is possible these were cases of OD but atypical. 
** This study has a larger number of Val homozygotes and heterozygotes. There 
may be a post mortem bias towards atypical cases. 
Eight of the studies quoted the percentage of each genotype. These results are set out 
in table 6.3. The overall median value of Met homozygotes was 71% compared to 
42% in the general population, Val homozygotes constituted 17 %. and only 16% 
were heterozygotes in comparison to 10% and 49% in the general population 
respectively. These figures are similar to the amalgamated data for Europe.' 
Median % Range % 
MM 71 56 -83 
MV 16 4 -19 
VV 17 3 -29 
C: AGE OF ONSET AND DURATION OF DISEASE 
Codon 129 also influences the age of onset and duration of disease: This was first 
demonstrated within a family carrying the 144 base -pair insertion. Those dying 
under the age of 50 carried Met on the affected allele but those dying over the age of 
50 carried Val. 427 This was statistically significant. A similar relationship between 
codon 129 and the age at onset was also identified in the same family although only 
a small number of cases could be analysed.262 
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Because hereditary CJD is rare, within the setting of a rare disease, it is not always 
possible to identify the degree to which codon 129 influences the clinico- 
pathological phenotype compared to the natural variation that is seen in many of the 
mutations. Often case reports comparing the influence of codon 129 are of one or 
two individuals within the same family. 
Analysis showed that heterozygosity at codon 129 delayed the age of onset of the 
codon 178 familial CJD group, and prolonged disease duration of both familial 
CJD178 and FFI phenotypes.15'428 Although analysis of other kindreds with the same 
mutation did not support these findings.414,429 In familial CJD200 the genotype at 
codon 129 does not influence age at onset or disease duration.419 However, 
heterozygotes had a later age at onset of disease in the Indiana kindred of GSS,43° 
and a longer duration of illness with later onset in a family with the codon 187 
mutation.431 
Any analysis of the age at onset in HGH iatrogenic cases is hindered by the lack of 
data on date of exposure and dose required to develop disease. Both these factors 
may influence the incubation period in transmission studies.41'426 This in turn may 
influence the age at onset in iatrogenic cases and it is difficult to separate the 
influence of codon 129 genotype from the incubation period, (as well as other 
unidentified factors). 
There seems to be some evidence that heterozygosity at codon 129 prolongs the 
incubation period of HGH recipients.432 This evidence has been disputed however 
because of the difficulties of estimating the point of infection in a treatment which 
could have continued for some years.25° The incubation period for dura mater grafts 
is measured in months rather than years.59 However, there are insufficient data in the 
literature to comment on the influence of codon 129 genotype on the age at onset and 
duration of illness. 
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In kuru a shorter duration of illness was associated with homozygosity_425 
A larger number of cases can be compared in sporadic CJD. The case reports 
mentioned above often report disease duration and age at onset, occasionally with 
conflicting results. 
A French study showed disease duration was shorter in Met homozygotes than in 
heterozygotes.407 Patients with at least one Val allele (i.e. heterozygotes and Val 
homozygotes) were found to have a long clinical duration in a Japanese review.410 
twelve cases of sporadic CJD who were Val homozygous were reviewed by the UK 
surveillance system. The age at onset and duration of illness was in keeping with 
many unselected series of CJD cases. 433 However, in another study heterozygotes 
were associated with an older age at onset.411 
Table 6.4: AGE AT ONSET AND DURATION OF ILLNESS 
Study 
No 
Median Age at Onset (years) Median Duration Illness (months) 
MM MV VV MM MV VV 
2 65 65 65 3 3 3 
4 66 65 58.5 3 8.8 6 
5 60.9* 63.4* 55* 6.4 7.6 6.7 
6 68.7* 66.3* 58* ? ? ? 
7 ** ? -54- ? -33- 
8 68.4* 70.9* 59.6* 3.7* 8.9* 11.5* 
9 67 66 65 7 12 9 
*Mean value given not median 
* *Heterozygotes and Val homozygotes grouped together. Not possible to separate 
data. 
Amalgamation of data for Age of Onset: 
7 studies analysed the median age of onset. (See Table 6.4) The trend was for Val 
homozygotes to develop disease at a younger age although there was considerable 
overlap between all 3 genotypes. 
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Age Onset (years) Median Range 
MM 66.5 60.9 -68.7 
MV 65 54 -70.9 
VV 58.5 54 -65 
Amalgamation of data for duration of illness: 
7 studies analysed the median duration of illness. (See Table 6.4) Both heterozygotes 
and Val homozygotes tended to have a longer duration of illness, again all 3 
genotypes overlapped with cases of long and short duration in each group. 
Duration Illness (months) Median Range 
MM 3.7 3 -7 
MV 8.8 3 -33 
VV 7 3 -33 
D: CLINICAL FEATURES AND INVESTIGATION RESULTS 
Perhaps the most compelling illustration of the influence of codon 129 on disease 
phenotype comes from the study of fatal familial insomnia (FFI) and familial CJD18. 
These are two different phenotypes of disease attributable to the same guanine to 
adenine mutation at codon 178. One illness, (familial CJD18), first described in a 
Finnish family, is similar clinically and pathologically to sporadic CJD.'' The other, 
(FFI), is characterised by progressive insomnia, dysautonomia and motor signs. 
Pathologically there is marked atrophy of the thalamic nuclei and spongiform change 
is often scanty. 434 Further investigation showed that the codon 178 mutation is 
encoupled with Met at codon 129 on the mutated allele in FFI, and with Val in 
familial CJD.ID 
There are also isolated examples of codon 129 influencing the disease phenotype of 
some other mutations. Although there are few cases to compare, Val homozygosity 
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associated with a 193 base -pair insertion seems to be associated with a clinical 
picture of hypokinesia, rigidity and dementia,435 but Met homozygotes seemed to 
have prominent psychiatric and cerebellar symptoms.436 An atypical clinical and 
pathological phenotype was seen in a case of GSS with a codon 102 mutation,437 and 
a familial CJD117 case, both of whom were Val homozygotes.438 Analysis of GSS 
due to a codon 102 mutation within a Sicilian family found that although there was a 
remarkably diverse clinical picture, this was unrelated to the codon 129 
polymorphism.439 
In iatrogenic CJD codon 129 does not appear to affect the disease phenotype 
although only a small number of patients have been reviewed.406 
Influences on the clinical features of sporadic CJD have been described in case 
reports and studies: The UK study of Val homozygotes found that many presented 
with ataxia at onset. The subsequent clinical course was similar to the recognised 
pattern for sporadic CJD. However, typical EEG findings were absent in all the cases 
in whom an EEG was available.433 Val homozygosity has also been associated with 
an atypical clinical phenotype in isolated case reports.440.441 
There is also a report of the absence of a typical EEG and a negative 14 -3 -3 result, 
despite a fairly typical clinical course, in a heterozygote with sporadic CJD.442 A 
French review of 14 definite sporadic cases identified typical clinical findings in the 
homozygotes. However, they identified one heterozygote who presented with 
dementia and ataxia, had a duration of illness of 12 months, and amyloid plaques in 
the cerebellum.412 
Data on Clinical Onset: 
Analysis of the clinical onset suggested that Met homozygotes presented mainly with 
dementia and the other genotypes often had an ataxic presentation. (See Table 6.5) It 
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was not always possible to differentiate symptoms and signs at onset from those that 
developed during the course of the illness. 





MM MV VV 

















* * 7 cases chosen because of Val ` mutation" at codon 129. Therefore it was not 
possible to give a frequency for each allele. 6 cases were heterozygotes and 1 case 
was Val homozygous. The properties of the isolated Val homozygotes were not 
differentiated. 
Data on EEG results: 
A typical EEG was seen in most of the Met homozygote cases but was only reported 
in one other case. (See Table 6.5) The exact parameters for a typical EEG varied 
between studies and were not always stated 
E: NEUROPATHOLOGY 
Codon 129 also seems to influence the neuropathological findings of sporadic CJD: 
Analysis of 8 cases with Val on one or both alleles found they had kuru -type 
amyloid plaques in the cerebellum, not seen in Met homozygotes.42° This was 
demonstrated in 4 further studies in the UK, Germany and Japan.406,409,410,443 The UK 
study also demonstrated amyloid plaques in two of three Met homozygotes.4°6 
Amyloid plaques have been associated with CJD with a long clinical course.145 In 
familial CJD Val homozygosity was associated with amyloid plaque deposition in 
familial CJD200, 444.445 and familial CJD' 17.446 
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In Kuru, some studies have shown a correlation with pathology; plaques being 
associated with the Met allele, but this has not been demonstrated in all studies.447 
Quantatative analysis of the pattern of pathology in sporadic CJD showed that codon 
129 had some influence on the distribution of spongiform change. Val homozygotes 
showed greater involvement of the deep grey matter, particularly in terms of PrP 
deposition and astrocytosis,433 whereas an intermediate pattern was seen in 
heterozygotes. Met homozygotes tended to have predominantly cortical 
pathology.448 Concentration of spongiform change in the occipital cortex particularly 
of Met homozygotes has also been demonstrated.14 The same group showed plaque - 
like deposits in the cerebellum in the heterozygotes and Val homozygotes.399 
Analysis of 70 French cases, providing the largest published review of the 
neuropathological changes, supported these findings. However, like Parchi who only 
found kuru -type plaques to be a feature of heterozygotes, only one Val homozygote 
was identified with kuru -type plaques in this series and the plaques were mainly seen 
in heterozygotes 411 The plaques identified on PrP immunocytochemistry in Val 
homozygotes were analysed in a UK study. These were morphologically distinct 
from kuru -type plaques and have been described as "plaque -like ".433 
Amalgamation of data on pathology: 
5 studies analysed pathological data: Plaques were only seen in heterozygotes and 
Val homozygotes except for one study, in which two Met homozygotes also had 
plaques. In study 9 the amyloid plaques were differentiated as "kuru- type" in the 
heterozygotes and "plaque- like" in the Val homozygotes. Study 3 commented that 
the Val homozygotes tended to have spongiform change in the deep grey nuclei, 
whereas study 8 noted spongiform change in the occipital lobe of the Met 
homozygotes. (See Table 6.6) 
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Table 6.6: PATHOLOGY 
THE CLINICO -PATHOLOGICAL PHENOTYPE OF CJD 
Study 
No 
Plaques Areas of spongiform change 
MM MV VV MM MV VV 
3 2/20 2/4 3/3 Deep grey 
nuclei 
6 0/31 3/8 6/8 
7** ? 7/7 
8 0/39 6/11 1/20 occipital 




F: OTHER POLYMORPHISMS 
Other polymorphisms have been described: In the Japanese population a 
polymorphism at codon 219 was reported in which glutamic acid or lysine could be 
expressed. In cases of GSS, heterozygotes at this site were found to have a different 
clinico- pathological phenotype from glutamic acid homozygotes.449 Subsequent 
analysis has shown that all cases of sporadic CJD are glutamate homozygotes at 
codon 219, but that 88% of a control population are heterozygous, suggesting that 
heterozygosity has a protective effect against sporadic CJD.450 An analysis of 100 
Italian controls and 104 cases of sporadic CJD, familial CJD and GSS and members 
of their families did not identify this polymorphism in any of the cases.45' This 
suggests there may be an ethnic difference in this gene frequency (as there seems to 
be with codon 129 also). The numbers are small and this needs further analysis. 
There are also three polymorphisms, occurring at codons 117, 124 and 161 that do 
not result in amino acid substitutions.452.4 
3 
G: CODON 129 IN OTHER DISEASES AND OTHER GENETIC FACTORS 
Recently the relevance of codon 129 to Alzheimer's diseases has been analysed. The 
E2 variant of apolipoprotein E (Apo E) is known to have a neuroprotective effect in 
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dementia. It seems to delay the onset of disease in various dementing conditions, 
including sporadic CJD.443 It is possible that the Apo E4 variant, in conjunction with 
Val at codon 129, may be associated with amyloid plaque formation in sporadic 
CJD.443 
One small study has also shown that Met homozygosity is associated with inclusion 
body myositis.413 The importance of this is not clear. Prion protein has been 
identified in inclusion bodies 218 but there are no features of this condition that 
resemble other prion diseases. 
6.2: INFLUENCE OF ISOTYPE AND GENOTYPE 
It seems likely however that the genotype of the patient is not the only influence on 
disease phenotype. Sporadic CJD does not neatly subdivide into 3 distinct clinico- 
pathological phenotypes. As discussed previously, strain dependent properties, akin 
to those seen in studies of scrapie, have also been demonstrated in sporadic 
CJD.454'4" The differential distribution of PrPCJD in iatrogenic CJD (human growth 
hormone) compared with sporadic cases of CJD led to the suggestion that a different 
strain was responsible for the iatrogenic disease, preferentially selected by a 
peripheral route of inoculation.344 
A: STUDIES ON ISOTYPE AND GENOTYPE 
In a study of the clinico- pathological phenotype of sporadic CJD, Parchi et al. 
reported that two isotypes of PrP`eS were detectable with Western Blotting 
techniques 14 These were termed types 1 and 2. The isotypes differed in their 
electrophoretic mobility and in the ratio of glycosylation. The differences were 
consistent within the one individual, both in different sampling areas of the same 
brain, and in cases who had had a prior brain biopsy, temporally between early and 
late disease. When analysed along with the codon 129 genotype, there seemed to be 
consistent clinical and pathological features peculiar to each isotype.399 It was 
suggested that the isotypes were surrogate markers of strains of CJD and further 
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study of these isotypes has suggested a structural basis for this (See Chapter 5: Strain 
Variation) 
Parchi's initial study of 19 cases found that all Val homozygotes and heterozygotes 
displayed type 2 PrP's (VV -2, MV -2 respectively), but Met homozygotes could be 
type I or 2 (MM -1 and MM -2 respectively). The MM -1 group was the most 
common and displayed the typical features of sporadic CJD. The other groups were 
smaller and tended towards an atypical course of disease, with a longer duration, 
atypical EEGs, and differences in histopathology and Prres accumulation.14 
The original work was extended to 300 cases of sporadic CJD. In this study, type 1 
PrP`eS was also found in Val homozygotes and heterozygotes.399 Thus, six potential 








The majority of cases were in the MM -1 group, and the disease phenotype was that 
of classically described sporadic CJD. Heterozygotes and Val homozygotes tended 
to have a type 2 mobility. The cases that were not MM -1 tended to be atypical, either 
in disease duration or characteristics, investigation or pathology. 
Parchi et al. proposed that there were clinical and pathological features attributable 
to each group, suggesting that sporadic CJD could be classified according to 
genotype and protein isotype. They identified two phenotypes within the MM -2 
group, a thalamic form, analogous to sporadic familial insomnia and a cortical form, 
characterised by prominent dementia and cortical pathology.399 
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The picture is less clear cut however as Western blotting of cases by Cardone et al. 
has suggested two protein isotypes but of different molecular weight to those 
isolated by Parchi et aí.3ß° Collinge et al have identified three isotypes of sporadic 
and iatrogenic CJD, differing in electrophoretic mobility and glycosylation pattern.20 
These isotypes are grouped as follows: 
Type 1: Sporadic CJD/ Met homozygotes 
Type 2: Any genotype of sporadic CJD and 
Iatrogenic CJD/ Met homozygotes 
Type 3: Iatrogenic CJD by peripheral route and 
Iatrogenic CJD/ heterozygotes or Val homozygotes. 
Types 2 and 3 remain unchanged when passaged in transgenic mice expressing 
human PrP encoding valine at codon 129, but type 1 converts to type 2 on a similar 
passage.20 
The number of protein isotypes is still being debated. Parchi et al. have reported that 
the Collinge group types 1 and 2 match the Parchi type 1 and the Collinge type 3 
matched the Parchi type 2.379 To date Parchi et al. and other groups have only 
identified two PPPres isotypes on electrophoresis, despite analysing a case of kuru and 
cases of vCJD. The differences may be in methods used for Western blotting, c.g. 
copper binding may affect the mobility of different isotypes, but Collinge et al. have 
suggested that as techniques improve, further isotypes may be identified.396 
No matter which technique is used, further work will hopefully resolve some of the 
discrepancies in the results. It is known that glycosylation of PrPres is a co- and post - 
translational event.379 The importance of glycosylation as a marker of strain is 
unresolved, but recently a different glycosylation pattern of type 1 PrPreS has been 
identified in some cases of familial CJD102 and CJD200; type 1B. This pattern has not 
been reported in sporadic CJD.380 Transmission studies of each isotype may support 
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the differences found using Western blotting but the studies, by their nature, are 
slow. 
All cases of vCJD to date have shown a similar clinico- pathological phenotype. All 
those that have been tested have been Met homozygous at codon 129. (Personal 
communication, NCJDSU) There is concern that vCJD cases who are heterozygotes 
or Val homozygotes are being missed. It is possible that the disease phenotype in 
either of these genotypes is different, although it seems unlikely that a young person 
would die of an undiagnosed neurodegenerative condition and not have an autopsy. 
Two retrospective reviews of deaths in the UK have been performed, and it is 
believed unlikely cases of CJD, in particular vCJD, have been missed.125 '126 
Only one isotype of variant CJD has been identified. All cases to date have had a 
type 2 mobility and a distinct glycosylation pattern with a predominance of the 
unglycosylated form. This pattern has been reproducible and is distinct from that 
seen in other forms of CJD.20,381 The pattern is maintained on passage through mice 
and is similar to that of BSE.2° This would support the use of protein isotype as a 
marker of strain in CJD. 
Isolated cases reports of young people with atypical sporadic CJD are emerging. 
Most recently a case was reported of a 27- year -old man with sporadic CID, whose 
genotype was Val homozygous.441 He is included in the VV -1 group in this study. 
The definitive test in such cases will be transmission studies, but this takes up to 2 
years. Until then the diagnosis rests on the neuropathological findings and PrP 
isotyping. 
There are fewer data on isotypic variation in familial and iatrogenic CJD: Details of 
only five cases of iatrogenic CJD with isotyping results have been published. Of 
these two were MM -1 and three were VV -2. There was no obvious clinical 
distinction between the two groups.381 There are studies of the isotype in some 
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familial cases.444 These are again isolated reports and the numbers are too few to 
comment on trends. 
B: AMALGAMATION OF DATA 
Various papers have discussed the influence of codon 129 on the clinical and 
pathological phenotype of all forms of CJD but each has only looked at a small 
number of patients. More recently the PrP isotype data of 300 cases has been 
analysed but again the numbers in some subsets are very small. A meta -analysis of 
all the papers discussing sporadic CJD might give a more meaningful result. 
Furthermore, discrepancies between the different studies might be illustrated: 
Having described 19 cases of sporadic CJD in 199614 Parchi went on to discuss 300 
cases of sporadic CJD which he divided into 7 groups (there were 2 subsets in the 
MM -2 group).399 Isolated case reports440.442 and two further reviews412'456 of cases 
with both genetic and isotype data have been subsequently published. I have 
combined the data from all of these reports and studies. It is possible that some of the 
cases reported by Parchi et al. are duplicated in some of the other reviews as they 
amalgamated 300 European and North American cases, but I could not extract these 
cases from the data as a whole. (One case report of a VV -1 case was excluded 
because it was believed to be one of Parchi's 300 cases.441) 
The following studies were amalgamated: 
1. Parchi et aí.399 Review of 300 cases of definite sporadic CJD from Europe 
and USA. 
2. Zerr et al.455 Review of 108 cases of definite sporadic CJD in whom full 
clinical, genetic and neuropathological data was available. 
3. Tranchant et aí.412 14 cases of sporadic CJD who died in the hospital at which 
the authors are based. 
4. Isolated report of a case who is MV -2442 
5. Isolated report of a case who is VV -144° 
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It is difficult to perform direct comparisons of the data, partly because there may 
well be duplication of cases, but also because the data are presented in different 
ways. Eg. Zerr et al. have commented on symptoms and signs at any point in the 
illness but Parchi et al. have divided the data into symptoms at onset and symptoms 
during the illness. It is also not clear how the data has been extracted. It is impossible 
to avoid a degree of observer variation and in some cases the data may be 
retrospective. Nevertheless, some trends are apparent (See Table 6.7) 
A: Age at Onset and Duration of Illness 
Parchi et al. found the VV -2 and MV -2 groups to be significantly younger at onset 
than the MM- lgroup. The VV -1 and MM -2 (thalamic) groups tended to be younger 
but this was not significant. Zerr et al. showed the VV -1 group were significantly 
younger but there was no significant difference between the other groups. In both the 
Parchi and Zerr studies the MM -1, MV -1 and VV -2 groups had a shorter duration of 
illness but, as with the genotype data, the variables overlapped considerably between 
each group. 
B: Symptoms and Signs 
Clinically, the Heidenhain variant, with visual symptoms at onset leading to cortical 
blindness, was peculiar to the MM -1 group. The VV -2 group tended to present with 
ataxia and cognitive problems were delayed, if present at all. Parchi found cerebellar 
signs to be common in the MV -2 group but this was not a feature of the Zerr cases. 
However an isolated MV -2 case in the literature also had prominent cerebellar 
features, though not at onset. This case was also atypical because of the presence of a 
peripheral neuropathy and she later developed the syndrome of inappropriate 
antidiuretic hormone secretion.442 
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1 203 68 65.5* 3.9* 70 33 26 46 
2 70 65 68 ** 5.2 ** 77# 19# 41# 80 
3 10 71 67 ** 7 ** 70 0 20 90 
MM -2 
1- 12 4 58.3* 15.7* 83 33 0 0 
2 3 3 63 14 67 33 0 33 
MV -1 
1 8 3 62.1* 4.9* 50 75 12 71.4 
2 8 7 63 3.4 75 25 0 75 
3 1 7 66 12 100 100 0 0 
MV -2 
1 27 9 59.4* 17.1* 74 81 0 7.7 
2 10 9 62 17.4 50 20 1 30 
4? 1 68 29 100 0 0 0 
VV -1 
1 3 1 39.3* 15.3* 100 0 0 0 
2 2 2 27 25.5 100 0 0 0 
5 1 49 15 100 100 0 0 
VV -2 
1 47 16 61.3* 6.5* 27 100 0 7.1 
2 15 14 62 7.5 33 47 20 0 
3 3 21 65 9 0 100 0 0 
Divided into 2 groups by original authors and joined together for the purposes of 
this analysis. (See later) 
? May be included in Zerr figures. 
* Not stated if mean or median. 
* *Median 
# Not clear if symptoms at onset. 
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Parchi et al. divided the MM -2 group into two subsets, a thalamic and cortical 
variant. The thalamic variant would be regarded as sporadic fatal insomnia, 
characterised by progressive insomnia and psychomotor agitation at night, the 
absence of a typical EEG and prominent thalamic and olivary atrophy. In the cortical 
variant dementia is prominent and the duration of illness is longer, but again the 
EEG does not show the typical periodic sharp waves. The pathology is characterised 
by prominent confluent vacuoles with relative sparing of the cerebellum. These two 
subsets have not been described elsewhere. 
C: Investigations 
The EEG is an important aid to the diagnosis of sporadic CJD. Parchi et al. found a 
typical EEG in 80% of the MM -1 and 71.4% of the MV -1 groups. Although they do 
not clarify if all cases has repeated EEGs. It is possible that in some cases the EEG 
was only performed once and if it was not suggestive of CJD it was not repeated. 
Zerr et al. specifically set out to study the results of EEG, CSF analysis and MRI 
scanning. (See table 6.8). 
The numbers in each group are small except for the MM -1 group. However, they too 
found that the MM -1 and MV -1 groups tended to be the only cases with a positive 
EEG. 
They note that analysis of 14 -3 -3 protein and the MRI may aid in the diagnosis when 
the EEG is negative. The majority of cases in each group, apart from the MV -2s, had 
a positive 14 -3 -3 result. The MRI also seemed to be positive in some cases in whom 
the EEG was negative. In particular, the MV -2 group seemed to have a negative 
EEG and 14 -3 -3 result but the MRI was positive in 8/9 cases. The isolated MV -2 
case in the literature also had a negative CSF and EEG but positive MRI. However, 
this case may be included in the above analysis by Zerr et al. 
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Table 6.8: RESULTS OF INVESTIGATIONS IN STUDY BY ZERR et al.455 
(n =108) 
PSWC in EEG (n) 14 -3 -3 Protein in CSF (n) Positive MRI (n) 
MM -1 (56/70) 80% (67/70) 96% (13/19) 68% 
MM -2 (1/3) 33% (3/3) 100% (0/2) 0% 
MV -I (6/8) 75% (8/8) 100% (2/2) 100% 
MV -2 (0/10) 0% (3/10) 30% (8/9) 89% 
VV -1 (0/2) 0% (1 /1) 100% (0/1) 0% 
VV -2 (0/15) 0% (15/15) 100% (7/10) 70% 
The isolated VV -1 case reported in the literature had a negative EEG and MRI and 
there is no comment made on CSF analysis. Zerr et al. found the only positive 
invesitigation in their VV -1 case was 14 -3 -3 protein. Three VV -2 cases reported by 
Tranchant had negative EEGs but there is no information about CSF or MRI 
analysis. Finally Kovacs et al. have reported 12 VV -2 cases. These are included in 
my analysis and so are not discussed further here.433 
D: Pathology 
Parchi et al. also noted specific pathological features in each group: The MM -1 and 
MV -1 groups showed the "classical" changes of sporadic CJD, with variable 
spongiform degeneration. The occipital lobes were most affected in 47% of cases. 
PrP staining tended to be "synaptic ". 
The VV -1 group tended to show severe spongiform change in the cerebral cortex and 
striatum, with relative sparing of the brainstem nuclei and cerebellum. PrP staining 
was in a faint synaptic pattern. 
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The MM -2 group was characterised by two phenotypes. The cortical group showed 
large confluent vacuoles with perivacuolar PrP staining in all cortical layers. There 
was little change in the cerebellum. The thalamic group had prominent atrophy of 
the thalamus and inferior olive with no spongiform change in these areas. 50% did 
not demonstrate PrP staining and it was extremely sparse in the other cases. 
The MV -2 and VV -2 groups had prominent change in the limbic and subcortical 
grey matter with relative sparing of the cortex. Plaque -like deposits were present in 
the VV -2 group. Some areas showed coarser PrP staining as well as a prominent 
perineuronal pattern. In the MV -2 group the pattern was similar but there were 
definite kuru -type plaques well as plaque -like deposits. 
Zerr et al. did not comment on the pathological changes in their series. Tranchant et 
al. found similar changes to Parchi et al. in their MM -1 and VV -2 cases. The single 
MV -1 case they had showed kuru -type plaques in the cerebellum unlike Parchi who 
only identified these changes in MV -2 cases. The pathological changes in the VV -1 
case reported by Hillier et aí.440 were similar to Parchi's cases. 
Methionine homozygosity at codon 129 predisposes to sporadic and variant 
CJD. 
Valine homozygotes and heterozygotes at codon 129 tend to be of younger 
age at onset and the disease tends towards a longer duration. 
Genotype at codon 129 influences the pathological findings. 
Protein isotype also appears to influence the disease phenotype. 
Isotype 2 tends to be associated with an atypical form of the disease. 
There are 6 potential groups, related to genotype and isotype. There is some 
evidence that these groups can be distinguished by their clinical and 
pathological features. 
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7.1: BACKGROUND 
The National CJD Surveillance Unit was established in the UK in 1990 in response 
to the recommendations of the Southwood Inquiry.'' The unit has a responsibility 
for monitoring all cases of CJD throughout the UK. (Most cases seen are sporadic or 
variant CJD but the incidence and detail of iatrogenic and familial cases are also 
monitored.) Prior to this CJD had been studied in England and Wales retrospectively 
between 1970 -1979128,137 and prospectively from 1980 -1984.134'458 Further 
retrospective analysis has been performed in the intervening years until 1990.117 
Hence there is information available on most cases of CJD in the UK from the past 
20 years. 
The UK CJD Database consists of data from several sources: 
1970 -79: retrospective records based primarily on death certificate 
notification (England and Wales) 
1980 -84: prospective ascertainment of cases (England and Wales) 
1985 -April 1990: retrospective records (England, Scotland, Wales and 
Northern Ireland) 
May 1990 -present: prospective ascertainment of cases (England, Scotland, 
Wales, Northern Ireland) 
The NCJDSU relies on the referral of possible cases by physicians throughout the 
UK, Notifications are normally made by neurologists, but referrals are also received 
from psychiatrists, geriatricians and other specialties, including 
neurophysiologists.459 In addition, cases identified at post mortem are referred by 
neuropathologists or other pathologists. Every six months a review is made of death 
certificates coded under the rubrics 046.1 and 331.5 in the 9th ICD revision. (This 
has recently been changed to A81.0 and F02.1 in the l Otl' ICD revision.) If possible 
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the clinical and pathological details are reviewed and if it is appropriate, relatives of 
the case will be interviewed. Evidence suggests that very few cases of CJD are 
missed when these multiple methods of cases ascertainment are used.'25'126 
7.2: PATIENT REFERRAL AND VISIT 
Patient's studied in this project included several from the Oxford prospective study 
and the intervening retrospective analysis but the majority are from the ongoing UK 
surveillance project. 
The majority of referrals to the NCJDSU are in- patients, made by the physician in 
charge of their care. In order not to miss atypical cases, physicians are encouraged to 
refer any suspected case as well as "typical" cases of CJD. If appropriate, and if the 
patient and their relatives agree, a research registrar and research nurse will travel to 
the hospital or patient's home. The patient (if cognitively able) and their relatives 
must be aware that a diagnosis of CJD is being considered. 
During a visit the relatives will be asked to complete an epidemiological 
questionnaire with the aid of the research nurse. A research nurse has been in post 
since 1998. Prior to this, the research registrar completed the questionnaire. On 
occasion, if the nurse cannot attend, the research registrar will still complete the 
questionnaire. Ideally, for reasons of consistency in the ongoing case -control study, 
one member of the family answers the questions. 
The questionnaire details the patient's past medical history including previous 
surgery, hospital attendances, drug history and vaccinations. If possible a list of 
previous residences, schools and jobs with dates, dietary history, family history and 
details of any exposure to animals is obtained. 
The registrar examines the patient neurologically and a second questionnaire is filled 
out. This details the history of the patient's illness (with further information obtained 
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from the patient, if possible, and their relatives), examination on admission and at 
the time of visit, past medical and drug history and results of investigation. Where 
possible, the EEG and scans are reviewed. The patient is then classified according to 
current NCJDSU criteria. (See Appendices C and D) 
It is not always possible to visit the patient. They may die before the team can make 
a visit or the family may not feel able to see members of the unit. In other cases a 
diagnosis is not made until post mortem or the unit may only become aware of the 
case after the biannual review of death certificates. If this occurs, where possible, the 
relatives are visited to obtain details of the clinical history and epidemiological 
details. The case notes will also be requested and reviewed. Sometimes it is not 
possible to contact a family or they do not feel able to see us, in which case if 
possible, the case notes are reviewed. Cases of familial and iatrogenic CJD are not 
generally visited. 
In view of this, the available information on each of the reviewed cases in the study 
is variable. In most there will be a full epidemiological and clinical questionnaire as 
well as case notes, results including CSF analysis, EEG, MRI and genetic analysis. 
On a few, some or most of this will be missing. In addition the results have been 
collected at various intervals over the last 20 years, during which time the 
questionnaires and relevant information analysed have varied. 
Since 1990, 740 cases of definite and probable CJD of all types have been referred to 
the NCJDSU. In total 1483 referrals of suspect CJD have been made up to 4/2/02. 
Only 151 cases have been included in this study as these are the cases on which full 
genetic and protein isotypic data is available. They have not been selected in any 
way other than because brain tissue was held and permission was available to use the 
tissue for research purposes. (Hence allowing protein isotyping.) It is possible that 
the cases used in this study were subject to selection bias and this is discussed later. 
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In each case, all the available notes have been searched to look for clinical 
information. An attempt has been made to obtain MRI, EEG, CSF and genetic 
analysis on each patient. In addition, a pathological report from the unit has been 
reviewed in most cases. In the remaining cases, an autopsy report from the referring 
hospital was available for review. 
7.3: CLINICAL SYMPTOMS/ SIGNS 
The information collected in the NCJDSU notes is based on the history obtained 
from relatives and perusal of the case notes at the time of the research registrar's 
visit. A decision about the presence or absence of a particular symptom or sign was 
made at the time of the registrar's visit and this could usually be confirmed by re- 
examining the case notes. In the remaining cases that were not seen in life, the 
clinical details were obtained from the available cases notes that varied from full in- 
patient notes to a discharge summary. 
A decision was made about: 
Date of onset 
Duration of illness 
Presence of various symptoms and signs 
Timing of each symptom/ sign if present 
Presenting symptom 
A: DATE OF ONSET 
The date of onset was estimated from the clinical history, usually obtained from the 
relatives and hospital case notes at the time of the registrar visit. Occasionally the 
patient was able to give a history. In some cases, General Practitioner (GP) notes 
were available at a later date and the date of onset may have been altered at that time 
if further information became available. 
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If it was suggested that the symptoms began at the beginning or end of a month then 
the first or last day were used respectively. If it was not clear at which point in the 
month the illness began the 15`h of the month was used. The timing was often 
difficult to establish and a "best guess" estimate from the first attendance at the 
patient's GP was often used. 
B: DURATION OF ILLNESS 
Clearly the date of death was more readily available, and from these two dates the 
duration of illness was calculated in months. 
C: PRESENCE OF SYMPTOMS AND SIGNS 
The presence and timing of clinical symptoms and signs was more difficult to obtain. 
For example, a patient may have been described as unsteady at onset, but there may 
be no reference to cerebellar signs in the case notes. By the time of examination the 
patient may have been bed bound and unable to co- operate. In this case it would be 
unclear whether the unsteady gait was apraxie, ataxic, extrapyramidal or other in 
nature. Clearly the description of the gait is also a matter of interpretation by the 
individual examining. 
If a clinical sign has not been noted or has been stated as absent it has been 
designated "don't know ". It cannot be assumed from review of case notes that a sign 
was truly absent if it is simply not mentioned as it may not have been recorded in 
error. Similarly, if for example cortical blindness was not present when the research 
registrar visited the patient, it is possible that cortical blindness developed at a time 
after the visit. For this reason only the definite presence of symptoms or signs has 
been used. The absence of a particular symptom or sign has not been analysed. 
Certain terms have been interpreted as suggestive of the presence of a particular 
symptom or sign; e.g. "walking as if drunk" has been used to indicate the presence of 
cerebellar signs, but "unsteady" has not, because there are a number of different 
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causes of an unsteady gait. Clearly, in cases where there is some doubt a decision has 
to be made in a fairly arbitrary way about the nature of a particular symptom and 
sign. This was sometimes difficult but if there was sufficient doubt then the 
symptom was classified "don't know ". The categories assessed and some of the 
terminologies used that were considered sufficiently indicative of a symptom or sign 
are detailed in Appendix A. 
D: TIMING OF SYMPTOMS AND SIGNS 
An attempt was made to time the onset of each symptom or sign from review of the 
history and case notes and their interpretation. If the patient was noted to be ataxic 
on admission and the clinical history suggested they were unsteady for two weeks 
prior to admission it has been assumed that onset of cerebellar symptoms was two 
weeks prior to admission. This is obviously not a terribly accurate assessment. 
Symptoms or signs have been designated as occurring at onset if they were the first 
symptom or sign to be reported. Otherwise, they were designated as occurring early, 
mid or late based on their timing in the first, second or third portion of the overall 
course of the illness. The best possible approximation of their timing was used. 
E: PRESENTING SYMPTOM 
A decision was made about the symptom at onset of the disease in each patient. This 
is because it is perhaps the most reliable symptom that is obtainable from the history. 
In addition it might give some information about the beginnings of the disease 
process within an individual. In most cases there was more than one symptom 
present. If the onset was monosymptomatic and purely cognitive, cerebellar or visual 
this was analysed separately. 
The psychiatric symptoms in variant CJD are a prominent feature of the illness222 
and have been analysed in more detail than in sporadic, familial and iatrogenic CJD. 
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7.4: INVESTIGATIONS 
The investigation of cases referred to the unit is at the discretion of the physicians in 
charge of the patient's care, although advice may be asked of the NCJDSU based on 
the unit's experience. For several reasons not all patients will have had an EEG, CSF 
analysis and MRI performed. The relevant results are documented at the time of a 
visit by the NCJDSU. In those cases notified after death, the case notes are requested 
and investigation results are documented at that time. 
Where possible the EEG and MRI are viewed at the time of a visit and copies are 
requested. It has not been possible to obtain a copy of the MRI in all cases in which 
it has been performed for various reasons e.g. archive copies may have been 
destroyed, or we were unable to trace the films. In addition MRI was not widely 
available 10 years ago and was not performed in many of the earlier cases. Similarly, 
14 -3 -3 protein analysis has only been used in the last few years and so has not been 
tested in all of the patients. 






I reviewed all available EEGs myself and reclassified them for the purposes of this 
study. (See Appendix B) If there was no EEG available for review, the classification 
made by the research registrar at the time of the visit was used or failing that an 
interpretation of the EEG report was made. For statistical purposes a "highly 
suggestive" or "typical" EEG was classified as diagnostic. This is because in a 
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clinical setting a "highly suggestive" EEG would carry much the same weight as a 
"typical" EEG in supporting a diagnosis of CJD. (See Figure 7.1) 
It was not possible to do a blinded analysis of the EEGs. 
B: CSF analysis 
Dr Alison Green performed analysis of the CSF for brain specific proteins. 46o The 
methods are set out in Appendix E. (Some early cases were analysed in the USA by 
Dr Paul Brown before the test was fully validated.) 
C: MRI 
All MRIs were requested from the original hospitals if they were not already 
available. The planes and sequences of the scans were dependent on local 
radiological practice. Dr D Collie, consultant neuroradiologist at the Western 
General Hospital in Edinburgh, reviewed the scans. He was blinded to a diagnosis of 
sporadic or variant CJD or to an alternative diagnosis. 
Each scan was assessed for the presence of high signal in the putamen, caudate 
nucleus and pulvinar and graded +, ++ or + + +. For statistical purposes, a positive 
scan in sporadic or iatrogenic CJD showed high signal in the putamen and caudate 
nucleus graded ++ or + + +, and a positive new variant scan had the same gradc of 
changes in the pulvinar. A possible scan was noted in some sporadic CJD cases in 
whom + high signal was noted in the putamen and/ or the caudate. White matter 
changes and atrophy were also noted in the sporadic CJD scans. 
D: GENETIC ANALYSIS 
Blood is taken for genetic analysis at the time of a visit by the research registrar. 
This is only done if the patient or their relatives give informed consent. Matthew 
Bishop then performs analysis on the blood sample at the NCJDSU. Previously, Lisa 
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Strain and Kathy Estibeiro have performed genetic analysis. Prof J Collinge from the 
Prion Unit in St Marys Hospital, London has also provided results. 
The deoxyribonucleic acid (DNA) was purified from peripheral blood leucocytes 
and amplified by polymerase chain reaction (PCR) using primers A2 and A3 (which 
are specific for the prion protein open reading frame (ORF)) and standard cycling 
conditions. Polyacrylamide gel electrophoresis was used for fragment separation and 
the product analysed for mutations. 
The Met/Val codon 129 polymorphism was distinguished by digesting the PCR 
product with the restriction enzyme digest Nspl. 
7.5: PATHOLOGY 
Preparation of brain tissue for pathological analysis is not always done at the 
NCJDSU. Tissue is received in a variety of ways. Professors Ironside or Bell may 
perform the entire autopsy or a fixed brain may be sent for preparation. Sometimes 
pre -prepared slides are sent for an opinion. Prof Ironside or Prof Bell report the 
prepared histology from whichever source. 





For the purposes of this study the areas most affected by spongiform change and the 
degree of neuronal loss and gliosis were estimated. In addition, the presence of other 
abnormalities, such as kuru plaques, were noted. These details were taken from the 
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pathology report. Some cases were reviewed with Professor Ironside. The changes 
were not documented by any quantitative methods for the purposes of this study. 
B: IMMUNOCYTOCHEMISTRY 
Serial sections were also stained with immunocytochemistry using two anti -PrP 
antibodies and a consensus protocol. The pattern of PrP deposition was taken from 
the report and again other changes such as plaque deposits were noted. The results 
were not analysed by a quantitative method. 
The pattern seen was described as: 
Vacuolar: granular positivity around and between confluent vacuoles 
Diffuse/ synaptic/ reticular: Generalised staining of the neuropil with small dot -like 
granular deposits of chromagen 
Neuronal: pericellular punctuate or granular immunopositivity around unstained 
neuronal perikarya. Sparse intracellular punctate immunoreactivity 
Immunoreactive granular deposits and plaque -like deposits: dense positivity in a 
granular or plaque -like formation not visible in H &E sections, occasionally 
surrounding a solid centre 
C: PrPfeS ISOTYPE 
PrP`es isotyping was performed by Dr Mark I Iead and Tristran Bunn, with the help of 
Suzanne Lowry. 
The results were classified according to electrophoretic mobility: Type 1 (21kDa) 
and Type 2 (19kDa). The proportion of the three glycoforms were assessed (di -, 
mono- and non -glycosylated PrP), further classifying each isotype as A or B. (See 
figure 7.2) Predominantly di- glycosylated PrPfeS is present in type 2B, seen in variant 
CJD. Types 1 and 2A are seen in sporadic, familial and iatrogenic CJD. The 
glycosylation pattern is an estimate and not a qualitative result at this time although 
work is being done at the unit to quantify the ratio. 
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Figure 7.2: Examples of PrP Isotype 1, 2A and 2B 
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METHODS 
A: Western blot analysis of prion protein (PrP) in variant CJD brain tissue 
with ( +) or without ( -) prior digestion with proteinase K. Proteinase K results 
in complete degradation of PrPc and in N- terminal truncation of PrPsc. The 
remaining protease- resistant PrP (PrPreS) occurs in di -, mono -, and non - 
glycosylated forms. 
B: Western blot analysis of protease- resistant prion protein (PrPfCS) in 
sporadic (S) and variant (V) CJD brain. Nonglycosylated PrPres occurs as 
either a 21kDa band (termed type 1) or a more extensively truncated 19kDa 
band (termed type 2). Variant CJD exhibits a characteristic predominance of 
the diglycosylated band ( *) and this protein isotype is termed type 2B to 
distinguish it from the type 2A isotype seen in sporadic CJD where the 
diglycosylated form does not predominate. The cases shown were 
homozygous for methionine (MM) or valine (VV) at codon 129 of the PRNP 
gene. 
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7.6: CLASSIFICATION AND DIAGNOSIS 
When a member of the NCJDSU sees a patient a decision is made which type of 
CJD the case is most likely to fall into. Generally this relates to whether the case is 
sporadic or variant. 
Secondly the case is classified on the likelihood that this is CJD, i.e. whether they 
would be defined as definite, probable or possible CJD or CJD is unlikely. The 
classification of sporadic CJD has changed slightly over the years of surveillance 
although it has remained broadly similar (see Appendix C). The most recently agreed 
criteria were used to classify each case during this assessment. (Rotterdam 1998). A 
classification of probable sporadic CJD carries approximately 95% specificity. 
Classification criteria for vCJD have recently been published 
Appendix D) To date the specificity of these criteria is 100% 
recently been reassessed using the up to date MRI data at the 
sensitivity of 92 %. (Personal communication, NCJDSU) 
CLASSIFICATION 






and validated." (See 
and the sensitivity has 




4.1 CJD unlikely 
4.2 Not CJD- Patient improved or other clinical diagnosis 
4.3 Not CJD- Other pathological diagnosis 
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7.7: STATISTICAL ANALYSIS 
Statistical analysis was performed by Dawn Everington. The clinical features and 
results of investigations were analysed using both parametric and non -parametric 
tests depending on distribution. Because of the different group sizes it was not 
always possible to perform a statistical analysis. In addition a large number of 
statistical tests were performed because of the large number of symptoms and signs 
considered. A correction should be used to take account of multiple testing in this 
context. However, this would mean using a p -value far less than the usual level of 
5% and this has not been done. The relevant statistical test used is detailed with each 
set of results because different tests were used throughout. 
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A total of 151 cases of CJD were included in the study. Full genetic, 
neuropathological and protein isotypic data were available on 99 sporadic CJD 
cases. There were a further 3 sporadic cases who were classified as intermediate and 
6 sporadic cases who had been isotyped in another centre and classified differently. 
Genetic and isotypic data were also available on 43 variant cases. (See Table 8.1): 
Table 8.1: BREAKDOWN OF 151 CASES 
TOTAL CASES of which 
Sporadic 108 99 NCDSU classification 
3 Intermediate 
6 Alternative classification 
Variant 43 
All but 4 of the 151 cases were from the current NCJDSU project. The timing of 
these cases span over the 10 year period of CJD surveillance in the UK. Two 
sporadic cases were from the retrospective study and 2 sporadic cases were from the 
Oxford study (lof intermediate mobility), data having been collected prior to 1990 
retrospectively. This means that patients and relatives were interviewed by a 
succession of research fellows from the NCJDSU. I have seen approximately one 
third of the sporadic and variant CJD cases in this series. 
I studied all cases in which full genotype and isotype data were available. They were 
therefore preselected and were chosen simply because the results were available for 
analysis. However, they would have been selected by the NCJDSU for various 
reasons: There would have been permission from the family for blood to be analysed 
for genetic mutations; In addition pathological material would have to be available 
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and permission would have been given for further analysis to be performed. It is 
possible that more atypical cases would have been selected by this process as 
clinicians and relatives may be more likely to proceed to post mortem if the 
diagnosis in life is uncertain. Furthermore if the pathological changes were atypical 
the case might be more likely to be referred to the NCJDSU for a second opinion, 
meaning material is available for future study. This potential bias is discussed later. 
The statistics of the NCJDSU sporadic CJD cases collected since 1990 are as 
follows: 
Median age at onset 65 years (range 15 -94) 
Median age at death 67 years (range 20 -95) 
Median duration of illness 4 months (range 1 -74) 
Methionine homozygotes 67% 
Heterozygotes 16% 
Valine homozygotes 17% 
This is similar to the statistics of the cases included in this study. 
The NCJDSU data were also compared with data on cases that were isotyped 
according to a different classification, termed group B. The numbers of cases in each 
of these groups were too small to perform a statistical analysis and these cases are 
discussed in appendix F. 
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8.1: SPORADIC CJD: MAIN RESULTS 
A: CASE DATA 
83 (84 %) of the 99 cases of sporadic CJD were examined in life by a member of the 
NCJDSU. The relatives were interviewed directly in 91 cases (92 %) and the hospital 
notes were available for perusal in 68 cases (69 %). All but 3 cases were from the 
current NCJDSU project. Of the remaining 3 cases, 1 VV -1 case was from the 
Oxford study and an MM -1 and MV -2A case were from the retrospective study. 
The 99 cases of sporadic CJD were divided according to their PRNP codon 129 
genotype: 
No cases 
MM 64 65% 
MV 17 17% 
VV 18 18% 
The genotype at codon 129 was available in all of the cases, but full sequencing of 
PRNP had not been performed in 12 cases because consent was not available. The 
relatives had been interviewed in 10 of these cases, and there was no family history 
of dementia. In the others a family history was available from case notes and again 
there was no record of a dementing illness in the family history. In addition, the 
pathology in each case was not suggestive of hereditary CJD. 
In one case there was a polymorphism at codon 117. This is a silent mutation and has 
not been shown to be disease associated, nor to influence disease phenotype. 
451 
The distribution of the PrP27 -30 isotype was as follows: 
Typet 62 63% 
Typet 37 37% 
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It was therefore possible to analyse six different groups, according to genotype and 
isotype: 
Table 8.2: SPORADIC CJD: CLASSIFICATION OF CASES 
GENOTYPE: 
MM MV VV 
ISOTYPE 1 54 (55%) 5 (5%) 3 (3%) 
ISOTYPE 2A 10 (10%) 12 (12%) 15 (15%) 
In general all statistical analyses were complicated by the fact that the MM -1 group 
was very large (54 cases) compared to all the other smaller groups. In the sections 
where it has been possible to make a meaningful analysis the statistical significance 
will be mentioned. 
B: GENDER DISTRIBUTION 
The ratio of males to females varied from 0.5:1 to 2:1, with a varying ratio in the 6 
groups. (See Table 8.3) The overall ratio was 0.8:1 reflecting the general ratio seen 
in sporadic CJD. 
Table 8.3: SPORADIC CJD: GENDER DISTRIBUTION 
GROUP MALES FEMALES RATIO M:F 
MM -1 24 30 0.8:1 
MM -2A 4 6 0.7:1 
MV -1 2 3 0.7:1 
MV -2A 4 8 0.5:1 
VV -1 2 1 2:1 
VV -2A 8 7 1.1:1 
TOTAL 44 55 0.8:1 
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There was a slight excess of males in the valine homozygotes (M:F 1.1 -2:1), whereas 
in all other groups there was a slight excess of females (M:F 0.5- 0.8:1). This result 
did not achieve statistical significance. 
C: AGE AT ONSET AND DEATH 
Age at onset followed a normal distribution. The overall median age at onset and 
death was in the early 60s in the MM -1, MV- 2A and VV -2A groups, broadly similar 
to that reported in sporadic CJD. (See Table 8.4) 
The Kolmogorov- Smirnoff test shows a significant difference between the groups 
(p= 0.044). The VV -1 group had a significantly younger median age of onset at 41. 
However, there were only 3 cases in this group with a large range in age; the cases 
were aged 26, 41 and 78 at disease onset. The MM -2A group was also younger at 
onset, the median being 54 years. (This result was statistically significant when a 
pairwise comparison was made with the MM -1 group, p =0.001 and the MV -2A 
group, p= 0.009.) 
Table 8.4: SPORADIC CJD: AGE AT ONSET AND DEATH 
AGE AT ONSET (years) AGE AT DEATH (years) 
median mean range median mean Range 
MM -1 64 65 43 -86 65 66 44 -86 
MM -2A 54 54 39 -72 55 56 41 -72 
MV -1 75 62 15 -79 76 63 20 -80 
MV -2A 64 65 51 -78 65 66 54 -78 
VV -1 41 48 26 -78 42 49 28 -78 
VV-2A 66 63 46 -79 64 63 47 -80 
In contrast, the MV -1 cases had a median age of onset at 75 years, older than the 
other groups. Again this was a small group of only 5 cases with a range of 15 -79 
years at onset. However, the data is skewed by one very young case. The others were 
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aged 61, 75, 78 and 79 at onset, suggesting this group does predispose to an older 
age at onset. 
The age at death followed a similar pattern to the age at onset and again, the VV -1 
and MM -2A groups also had a younger median age at death (42 and 55 years 
respectively), and the MV -1 group had an older median age at death (76 years). 
D: DISEASE DURATION 
The MM -1, MV -I and VV -2A groups were all of short duration, median 3 months 
(MM -1) to 5 months (MV -1, VV -2A). In the MM -1 group this was significantly 
lower than all other groups except for the MV -1 cases. (Mann -Whitney test, 
p <0.001- 0.009). The VV -2A group were also of significantly shorter duration than 
the other groups except for the MM -1 and MV -1 cases (Mann- Whitney test, 
p <0.001- 0.009) The duration of illness in the remaining groups was considerably 
longer, the median from 11 months in the MV -2A and VV -1 groups to 14 months in 
the MM -2A group. Again this was associated with a wide range in each group, with 
considerable overlap between the groups. (See Table 8.5) 
Table 8.5: SPORADIC CJD: DISEASE DURATION 
Median (months) Average (months) Range (months) 
MM -1 3 4 1 -17 
MM -2A 14 17 8 -37 
MV-1 5 14 2 -54 
MV -2A 11 16 3 -51 
VV -1 11 16 8 -29 
VV -2A 5 5 2 -11 
However, the distribution of disease duration did not follow a Normal distribution. 
Of the overall cases, 84% of cases were of duration 12 months or less, 10% of cases 
were of duration between 1 and 2 years, 3% were of duration between 2 and 3 years, 
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and the remaining 3% were of durations 37, 51 and 54 months. When the data were 
divided like this into each subgroup there were marked differences. (See Table 8.6) 
The majority of MM -1 (87 %) and VV -2A (80 %) cases had durations of less than 6 
months and nearly all of the cases in these groups had durations of illness less than 1 
year (94% and 100% respectively). The MV -1 group may have a similar distribution: 
4 of 5 cases (80 %) of duration less than 1 year. However, 1 of these, of duration of 
only 2 months, died suddenly from a pulmonary embolus and the group also includes 
the case of longest duration. The number of cases is too small to draw firm 
conclusions. 
Table 8.6: SPORADIC CJD: DISEASE DURATION BY SUBGROUPS 
n <6 mths % <1 yr % 
MM-1 53 46 87 50 94 
MM-2A 10 0 0 5 50 
MV-1 5 3 60 4 80 
MV-2A 12 1 8 6 50 
VV-1 3 0 0 2 67 
VV-2A 15 12 80 15 100 
The MM -2A and MV -2A groups seem to have similar distributions to each other. No 
cases were of less than 6 months duration, 50% were of between 6 months and a year 
and the remaining longer than this. The VV -1 group may also follow this pattern but 
there are too few cases to be sure. 
When the data are transformed by taking logs a Normal distribution is achieved 
(with the exception that the cases of duration 51 and 54 months are still outliers). A 
highly significant difference between the groups is seen (p <0.001). The MM -1 group 
has the shortest duration and differs significantly from the MM -2A, MV -2A and 
VV -1 groups. (Kolmogorov- Smirnoff test, p <0.001) 
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There seemed to be a significant correlation between duration and age of onset; the 
older ages tending to have a shorter duration of illness. However, scatter plots of the 
data showed that the significance of this result is largely because relatively few cases 
were of long duration. There were 6 cases with durations over 2 years, only one of 
whom was aged over 60 years. Of the cases with durations less than 2 years, 70% 
were aged over 60 years. 
If the MM -1 group, by far the largest, is analysed there was no association between 
duration and age at onset. It was not possible to say whether this was a feature of the 
subgroup itself, or that this relationship does not apply to the cases with a shorter 
duration of illness. When an analysis of covariance was used to adjust for possible 
differences in age distribution between the groups, it was shown that the overall 
shorter duration of the MM -I group was not due to the older ages within this group. 
E: SYMPTOMS AND SIGNS 
Each group was analysed for the overall presence of various symptoms and signs. 
The timing in relation to the onset of the illness was also assessed. As with the 
analysis of all the variables in this study, it was difficult to quantify the statistical 
significance of these results because of the relative sizes of each subgroup. However, 
the presence of rapidly progressive dementia, cerebellar or visual symptoms at onset 
was looked at to see if statistical significance was achieved. 
These particular symptoms are of interest because of the well described Brownell - 
Oppenheimer (cerebellar symptoms at onset) and Heidenhain variants (visual 
symptoms at onset leading to cortical blindness) of sporadic CJD. In addition, the 
onset of the disease is probably the symptom that can be analysed most accurately in 
terms of timing and nature. It might give an indication of where the pathological 
process begins in the disease, which might in turn be influenced by protein isotype. 
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i): Rapidly Progressive Dementia 
Dementia was present in 98 of 99 cases (99 %). 1 of the MM -1 group was not clearly 
demented from examination of the notes. A rapidly progressive dementia was 
defined as a dementia with a progressive course in which a significant deterioration 
occurred over a year or less, leading to significant functional impairment. All the 
cases in whom dementia was present fulfilled these criteria, despite an illness of 
greater than 1 year's duration in several cases. The overall incidence of a rapidly 
progressive dementia was therefore also 99 %. (See Table 8.7) 
Table 8.7: SPORADIC CJD: PRESENCE OF RAPIDLY PROGRESSIVE 
DEMENTIA 
RPD present % Sole Presentation 13/0 
MM -1 53 98 23 43 
MM -2A 10 100 8 80 
MV -1 5 100 1 20 
MV -2A 12 100 3 25 
VV -1 3 100 3 100 
VV -2A 15 100 3 20 
Dementia as the sole presenting symptom was also analysed. There was an excess of 
MM -2A cases with a purely dementing onset; 8 cases were observed but 4 were 
expected. (Fishers Exact test p= 0.007.) All 3 of the VV -1 cases also presented with a 
pure dementia. The figures are so small in each group that this would not be 
considered a reliable analysis. 
Table 8.8: SPORADIC CJD: TIMING OF DEMENTIA 
Early N= % Mid N= % Late N= % Not noted N= % 
MM -I 38 70 14 26 1 2 1 2 
MM -2A 9 90 1 10 0 0 0 0 
MV -I 5 100 0 0 0 0 0 0 
MV -2A 6 50 6 50 0 0 0 0 
VV -1 3 100 0 0 0 0 0 0 
VV -2A 9 60 6 40 0 0 0 0 
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Dementia appeared early on in the illness in 70 cases (71 %). There was a suggestion 
that it appeared less early on in the MV -2A and VV -2A groups. (See Table 8.8) 
ii): Cerebellar symptoms and signs 
Cerebellar problems were definitely present in 62 of all 99 cases (63 %). They 
definitely occurred in 34 (63 %) of the MM -1 group. (See Table 8.9) There were an 
additional 11 cases (20 %) who probably had cerebellar signs but it was not possible 
to be sure. 2 of these cases may have been dyspraxic. The others were noted to be 
unsteady or un- coordinated but the underlying nature was not clear. In 22 cases 
(41%) the symptoms occurred within the first few weeks of the illness. In 11 cases 
(20 %) the signs were first noted midway. 1 case (2 %) did not develop signs until late 
on. 
In the MM -2A group cerebellar symptoms were noted in 3 cases (30 %) midway into 
the illness. A further 5 cases (50 %) were noted to be unsteady or clumsy but there 
was no definite mention of cerebellar signs. 1 of these cases was thought to be 
apraxic but this was not clear and so the case was classified "don't know ". 
Table 8.9: SPORADIC CJD: CEREBELLAR SYMPTOMS AND SIGNS 
Cerebellar onset 
N= 
% Cerebellar present 
N= 
% 
MM -1 7 13 34 63 
MM -2A 0 0 3 30 
MV -1 0 0 3 60 
MV -2A 4 33 11 92 
VV -1 0 0 0 0 
VV -2A 3 20 11 79 
In the MV -1 group cerebellar symptoms were noted early on in 1 patient (20 %) and 
after some weeks in 2 further cases (40 %). The remaining 2 cases became unsteady 
early on but were classified "don't know" as there was insufficient information. 
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know N= % 
MM -1 22 41 11 20 1 2 9 17 11 20 
MM -2A 0 0 3 30 0 0 2 20 5 50 
MV -1 1 20 2 40 0 0 0 0 2 40 
MV -2A 10 83 1 8 0 0 0 0 1 8 
VV-1 0 0 0 0 0 0 2 67 1 33 
VV -2A 9 60 2 13 0 0 1 7 3 20 
10 of the MV -2A group (83 %) had cerebellar symptoms at onset or early on. 1 other 
case developed loss of balance at onset but was classified "don't know" as the cause 
was unclear. 1 further case (8 %) developed cerebellar symptoms and signs midway. 
None of the VV -1 group had definite cerebellar changes. 1 case was unsteady after 
some months but the cause was unclear. 
9 (60 %) of the VV -2A group had definite early cerebellar problems. A further 3 
were classified don't know and of these 2 were unsteady from the onset. 2 cases 
(13 %) developed cerebellar problems after some months. (See Table 8.10) 
A purely cerebellar onset was noted in 7 (13 %) of MM -1, 4 (33 %) of MV -2A and 3 
(20 %) of VV -2A. This might suggest the MV -2A group cases are more likely to 
develop cerebellar problems at onset but the result did not achieve statistical 
significance. However, analysing the presence of cerebellar signs or symptoms at 
any point during the illness, 92% of MV -2A cases did have cerebellar signs and 
symptoms at some point. This result achieved statistical significance. (Fishers exact 
test, p= 0.009) 
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iii): Visual Symptoms and Signs 
46 cases (46 %) had visual symptoms at some point. An onset of illness with purely 
visual symptoms was present in 10 MM -1 cases (19 %) and 1 VV -1 case (7 %). 61% 
of the MM -1 group, 40% of each of the MM -2A, MV -1 and VV -2A groups and l 
MV -2A case (8 %) developed visual symptoms at some point during the illness. 
MM -1 cases were shown to be statistically more likely to have visual symptoms 
(Fishers exact test, p= 0.006) (See Table 8.11) 
Visual symptoms were variable, ranging from burred vision, smearing across vision 
to diplopia. 20 (37 %) of MM -1 cases complained of an upset in vision early on in the 
illness but 1 case of MM -2A and MV -1 (10% and 20% respectively) and 2 VV -2A 
cases (13 %) also complained of symptoms early on. 11 cases (20 %) of MM -1 
complained midway and 3, 1, 1 and 4 cases of MM -2A (30 %), MV -1 (20 %), MV- 
2A (8 %) and VV -2A (27 %) respectively complained of symptoms as the illness 
progressed. 4 (2 %) of MM -1 cases developed visual symptoms late on. (See Table 
8.12) 
Table 8.11: SPORADIC CJD: VISUAL SYMPTOMS 
Visual Present 
N= 
% Visual Only 
N= 
% 
MM -1 33 61 10 19 
MM -2A 4 40 0 0 
MV -1 2 40 0 0 
MV -2A 1 8 0 0 
VV -1 0 0 0 0 
VV -2A 6 40 1 7 
Cortical blindness was noted in 28 cases (52 %). An additional 9 cases (17 %) were 
classified don't know. 21 of the 28 cases (75 %) had visual symptoms prior to 
developing cortical blindness and 7 (25 %) did not. There was little difference in the 
number of cases developing cortical blindness between the groups. (See Table 8.13) 
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MM -1 20 37 11 20 2 4 0 0 21 39 
MM -2A 1 10 3 30 0 0 6 60 0 0 
MV -1 1 20 1 20 0 0 3 60 0 0 
MV -2A 0 0 1 8 0 0 11 92 0 0 
VV -1 0 0 0 0 0 0 3 100 0 0 
VV -2A 2 13 4 27 0 0 9 60 0 0 
The Heidenhain variant of sporadic CJD is characterised by early visual symptoms 
leading to cortical blindness, in association with a rapidly progressive dementia and 
other features of sporadic CJD. 11 MM -1 cases (20 %) would fit with this 
description. 










MM -I 18 33 15 83 7 13 
MM -2A 3 30 2 67 0 0 
MV -I 2 40 1 80 0 0 
MV -2A 1 8 0 0 I 8 
VV -1 0 0 0 0 0 0 
VV -2A 4 27 3 75 I 7 
2 VV -2A cases (13 %) complained of diplopia early in the illness (1 of these had a 
purely visual onset), long before dementia developed. Both were noted to have 
trouble with dizziness and coordination and I complained of visual blurring, blaming 
the problem on new spectacles. Both went on to develop cortical blindness, although 
it is not clear at what point in the illness this occurred. These cases might have been 
the Heidenhain variant but it is not certain. 
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Other cases complained of visual symptoms as the illness progressed and some of 
these went on to develop cortical blindness but this would not fall within the 
definition of the Heidenhain variant. 
iv): Other Symptoms 
All cases were examined for the presence of other symptoms. There were a large 
number of variables to consider and once again the odd sizes of each subgroup made 
statistical analysis of the results difficult. (See Table 8.14) As explained in Methods, 
it was difficult to know if symptoms and signs were absent or, for various reasons, 
not recorded in the notes. This means that there is likely to be an under -reporting of 
symptoms and signs. The definitions of each category are given in Appendix A. 
The following symptoms and signs were looked at: 


















MM-1 14 26 12 26 7 13 1 2 15 28 2 4 
MM-2A 2 20 0 0 3 30 0 0 1 10 2 20 
MV-1 3 60 1 20 1 20 0 0 0 0 0 0 
MV-2A 2 17 0 0 1 8 1 8 7 58 2 17 
VV-1 1 33 0 0 0 0 0 0 0 0 1 33 
VV-2A 5 33 7 47 2 14 1 7 6 40 1 7 
P= prodrome; Di =dizzy S= sensory; He= hearing; Ha-hallucinations; De= delusions 
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Onset of Illness 
3 MM -1 cases (6 %) had a sudden onset of illness, described as "stroke- like ". There 
was a suggestion of a prodrome (see Appendix A) in 27 cases (27 %). No particular 
subgroup was affected. 
Dizziness was another common complaint early in the illness. 20 cases (20 %) 
complained of dizziness at some point. Dizziness was present at onset in all the cases 
who complained of this symptoms except for 1 MM -1 and 1 VV -2A case. They are 
distributed as follows: 
MM -1 12 cases 26% 
MV -1 1 case 20% 
VV -2A 7 cases 47% 
Sensory Symptoms 
14 cases (14 %) complained of a sensory upset at some point. In 10 cases (10 %) this 
was in the early stages of the disease. They are distributed as follows: 
MM -1 7 cases 13% 
MM -2A 3 cases 30% 
MV -1 1 case 20% 
MV -2A 1 case 8% 
VV -2A 2 cases 14% 
Of the MM -1 cases, 5 cases (9 %) complained of a sensory upset at onset or early on 
in the illness. 2 cases (4 %) developed the symptoms midway. 3 cases complained of 
a numb limb, 1 case complained of burning feet. 2 cases complained of tingling in a 
limb and 2 complained of cold feet. (1 case had both tingling in the right upper limb 
and cold feet). 
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Of the MM -2A cases, 2 cases (20 %) were at onset. 1 case had a painful arm and the 
other complained of a sensation of "blood- boiling ". 1 further case complained of 
non -specific back -pain and headaches some months into the illness. (She had a 
history of kyphosis and had a Harrington rod inserted as a teenager). 1 MV -1 case 
(20 %) had paraesthesia in the fingers of the right hand at onset. 1 MV -2A case (8 %) 
had paraesthesia in the legs early on in illness. There were no sensory symptoms in 
the VV -1 group. 2 VV -2A cases (14 %) had sensory symptoms 1 complained of 
paraesthesia from onset (7 %) and the other complained of pain in the arms and legs. 
This occurred early in the illness and was initially intermittent but became persistent. 
Sensory features are a prominent symptom in vCJD, often occurring early in the 
illness. Because of this the cases were looked at to see if there was a bias towards 
asking about sensory symptoms after vCJD was described in 1996: 6 of the 14 cases 
(43 %) were seen prior to 31/12/1995 (by which time it is assumed the NCJDSU 
registrar would have been aware of the symptoms of vCJD). The remaining 8 cases 
(57 %) all died and were seen after 1/1/1996. 
In addition, vCJD tends to occur in a younger age group. The cases seen before the 
end of 1995 had a median age at onset of 60 years (range 43 -79), however, the cases 
seen after the end of 1995 had a median age of onset of 55 years (range 42 -76). This 
does not support the theory that sensory symptoms might be looked for preferentially 
in the younger cases. 
Hearing 
A disturbance of hearing is unusual in CJD. Only 3 cases (3 %) overall had 
symptoms involving hearing. 1 MM -1 case (2 %) complained their hearing was "not 
right" in the early stages of their illness. 1 MV -2A case (8 %) developed cortical 
deafness and 1 VV -2A case (7 %) complained of a buzzing in the ears at the onset of 
their illness. 
147 
CHAPTER 8 RESULTS 
Hallucinations 
29 cases (29 %) complained of hallucinations. They are distributed as follows: 
MM -1 15 cases 28% 
MM -2A 1 case 10% 
MV -2A 7 cases 58% 
VV -2A 6 cases 40% 
The hallucinations usually developed after some months of illness, except for 1 of 
the MV -2A cases, who had audio- visual hallucinations, developing early on in the 
i I lness. If the nature of the hallucinations were defined (21 of the 29 cases), they 
were nearly always visual in nature. 1 of the VV -2A cases had audio -visual 
hallucinations in addition to the MV -2A case already mentioned. 
Delusions 
8 of the cases (8 %) developed delusions, distributed as follows: 
MM -1 2 cases 4% 
MM -2A 2 cases 20% 
MV- 2A 2 cases 17% 
VV-1 1 case 33% 
VV -2A 1 case 7% 
The delusions were persecutory or paranoid in nature in all the cases, usually 
developing after some weeks to months except for 1 MM -2A case who was paranoid 
from early on in their illness. 
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NO: Other Signs 
Many of the sporadic CJD cases were seen late on in their illness, by which time a 
number of clinical signs, both extrapyramidal and pyramidal were present. In 
addition the examination of a severely demented patient, who is unable to cooperate 
can be difficult. 
The following signs were looked for in the case notes. (See Table 8.15) 
Pyramidal signs 




Other movement disorders 
Eye movements 













MM-1 32 59 18 33 38 70 51 95 23 43 13 24 
MM-2A 5 50 3 30 8 80 9 90 2 20 1 10 
MV-1 3 60 0 0 5 100 5 100 1 20 2 40 
MV-2A 2 17 5 42 8 67 9 75 1 8 0 0 
VV-1 1 33 1 33 3 100 3 100 2 67 0 0 
VV-2A 9 60 6 40 10 67 13 86 4 27 6 40 
P= pyramidal; E= extrapyramidal; PR= primitive reflexes; M= myoclonus; 
MD= movement disorder; EM =eye movement disorder 
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Pyramidal signs 
Pyramidal signs were noted in 52 cases (53 %). There seemed to be a slightly lower 
percentage of MV -2As with pyramidal signs. (Only 2 cases (17 %)). In general about 
half of each group had evidence of pyramidal tract abnormalities. 
Lower motor neurone signs 
Lower motor neurone signs were seen in 5 cases (5 %) of whom 2 were MM -1 cases 
(6% of this group.) 1 case was diagnosed with motor neurone disease due to the 
presence of widespread fasciculations, reduced tone and reflexes. 1 case had a 
history of Guillain -Barré Syndrome and had absent reflexes. 
3 of the VV -2A cases (20 %) also had lower motor neurone signs: 1 case had lower 
motor neurone type muscle wasting, 1 had fasciculations and another had both 
muscle wasting and fasciculations. In general these changes were reported on by the 
local clinicians and the definition of lower motor neurone signs were not always 
strictly defined. 
Extrapyramidal signs 
Extrapyramidal abnormalities, i.e. bradykinesia, or tremor and rigidity of an 
extrapyramidal nature (including gegenhalten) were noted in 33 cases (33 %). The 
distribution was approaching a third in each group apart from the MV -1 cases in 
whom extrapyramidal signs were not noted in any of the cases. 
Primitive reflexes 
Some or all of the various primitive reflexes (i.e. grasp, rooting, palmomental and 
pout reflexes) were noted in 72 cases (73 %). They were noted in 67 -100% of each 
group. 
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Myoclonus 
86 of the 99 cases (87 %) developed myoclonus. The majority of cases in each group 
developed this sign in the mid to late stages of the disease. 6 (11 %) of the MM -1 
cases and 1 (10%) of the MM -2A cases developed myoclonus in the early stages of 
the disease or at onset. 
Other Movement Disorders 
Some form of chorea or dystonia was noted in 33 cases (33 %). This was usually 
described as a dystonic posturing of the upper limb or choreoathetoid movements of 
the trunk and limbs. A movement disorder was seen in 20 -67% of each subgroup, 
except for the MV -2A group, in which only 1 case (8 %) developed a dystonia. In 2 
VV -2A cases and 1 MM -1 case facial grimacing was described. In 1 MV -1 case 
(20 %) eyelid apraxia was noted. 
Alien limb has been described as a presenting feature of sporadic CJD.15455 It was 
not always possible to be sure whether alien limb was present or not but it was 
definitely noted in 1 VV -2A case, and 2 MM -1 cases. It was not the presenting 
feature of any of these cases. 
Eye Movements 
22 cases (22 %) were noted to have abnormalities of eye movement. In 65 cases 
(66 %) however there was no mention of eye movements at all. Reduced upgaze or a 
general paucity of eye movements was noted in the majority of these cases (i.e. 6 
VV -2A cases, 1 MM -2A case and 3 MM -1 cases). However, 2 MV -1 cases and 9 
MM -1 cases were noted to have nystagmus. One other MM -1 case had jerky pursuit. 
vi): Swallowing and Artificial Feeding 
Swallowing abnormalities were noted in 38 cases (38 %) in the terminal stages of the 
disease. Others could have developed problems after the research registrar saw them 
and this information could have failed to reach the NCJDSU. 1 MM -1 and 1 VV -2A 
151 
CHAPTER 8 RESULTS 
case developed swallowing problems early on but in the other cases, the problems 
did not seem to appear until late in the illness. There was no particular group with 
predominance or under representation of swallowing problems. 
There was information on artificial feeding, either nasogastric (NG) or parenteral 
gastrostomy (PEG) in a limited number of cases. These cases were analysed in 
relation to their age and duration of illness. (See Table 8.16) 
Table 8.16: SPORADIC CJD: NASOGASTRIC FEEDING 





60 15 MM-1 
64 3 MM -1 
72 17 MM -1 
76 5 MM -1 * 
67 2 MM -1 
63 2 MM -1 
64 9 MM -1 * * 
71 8 MM -1 
62 3 MM -1 
15 54 MV -I 
54 6 VV -2A 
NG tube sited day before death 
Case notes discuss planned NG tube but no information whether definitely 
sited 
Of the 11 cases in which there is definite information about parenteral feeding, 6 
(55 %) had an illness of duration greater than 6 months. The majority were MM-1 
cases. Only 2 cases were aged less than 55 years. The 15- year -old case was seen 5 
months into their illness and a PEG was inserted not long after. They survived in a 
state of akinetic mutism for 49 months after this. Obviously, swallowing problems 
are a reflection of bulbar problems and not always a sign of disease progression to 
near terminal stages. 
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vii): Akinetic Mutism 
Many of the cases were seen before they reached a state of akinetic mutism. It was 
often not possible to establish whether or not patients went on to develop this state 
after the registrar had visited. Other cases were noted to be either mute or immobile 
but the term "akinetic mutism" was not strictly used. Akinetic mutism occurred in all 
of the subgroups with relatively similar frequencies. (See Table 8.17) 






Mutism N= % 
MM-1 22 41 9 17 31 57 
MM-2A 1 10 0 0 3 30 
MV-1 1 20 1 8 . 2 40 
MV-2A 3 25 0 0 5 42 
VV-1 2 67 0 0 2 67 
VV-2A 8 53 1 7 9 60 
F: INVESTIGATIONS 





I reviewed the EEG in 61 of the 99 cases and reclassified the record according to the 
NCJDSU criteria set out in appendix B. 10 cases had 2 EEGs performed (4 MM -1, l 
MM -2A, 1 MV -1, 1 VV -1 and 3 VV -2A cases) and 3 cases had 3 EEGs (1 MM -1, 1 
MM -2A and 1 VV -2A cases). In all of these cases, the final EEG or the final report 
(if the EEGs were not available for review) was used in the analysis. No one had a 
second or third EEG performed if they had an initial diagnostic or highly suggestive 
EEG. In all but 1 case in whom more than one EEG was performed, there was some 
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progression of the EEG (although not necessarily a change in classification). In 1 
MV -1 case the first EEG done at 3 months was suggestive and the second, done 19 
days later, was non -specific. 
The EEG was classified as typical, highly suggestive, suggestive or non -specific. Of 
the EEGs in the 41 MM -1 cases seen by me, the classification would be different 
according to the criteria used in this study in 13 cases. 10 would be classified as 
highly suggestive (originally classified as typical) and 3 would be classified as 
suggestive (originally typical). 
In the other groups I reviewed the EEG in 20 further cases. (6 MM -2A, 3 MV -1, 3 
MV -2A, 2 VV -1 and 6 VV -2A cases.) In these groups I agreed with the 
classification given at the time of review. 
In 31 cases the EEG was not seen by me but reported locally or by the person who 
visited the patient: 10 MM -1, 3 MM -2A, 1 MV -1, 7 MV -2A, 1 VV -1 and 9 VV -2A 
cases. 4 of the MM -1 cases were reported as typical. All other cases were reported as 
non -specific or suggestive. The classification of these EEGs is unlikely to have 
affected the overall classification of the patient. However, in 3 cases the EEGs seen 
at the time of the NCJDSU visit were classified as typical, but were reclassified 
suggestive by me. It is therefore possible that 1 or 2 cases might be over classified. It 
is unlikely that any of the cases were under classified, as I did not increase the 
classification in any case. 
Six cases apparently did not have an EEG performed, or at least there was no record 
of an EEG result in the NCJDSU case notes. 
Taking the final EEG in each case. The EEG was reported as highly suggestive or 
typical in 33 cases (33 %). 32 cases were MM -1 (59 %) and 1 case was an MV -1 
(20 %). The EEG was reported as suggestive or non -specific in 60 cases (60 %). This 
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included 20 (37 %) of MM -1 cases, 3 (60 %) of MV -1 cases, and in all other cases in 
whom an EEG was performed. A diagnostic EEG was therefore significantly 
associated with the MM -1 group. (chi square test, p <0.001) 














MM-1 13 24 19 35 14 26 5 9 3 6 10 19 
MM-2A 0 0 0 0 5 50 5 50 0 0 3 30 
MV-1 0 0 1 20 1 20 2 40 1 20 1 20 
MV-2A 0 0 0 0 4 33 6 50 2 17 7 58 
VV-1 0 0 0 0 1 33 2 67 0 0 1 33 
VV-2A 0 0 0 0 1 7 14 83 0 0 9 60 
T= typical HS= highly suggestive; S= suggestive; NS-non-specific; ND =not done: 
N =not seen 
The MV -1 case with a highly suggestive EEG was done 3 months into an illness of 5 
months duration. The MM -1 cases were done a median oft months (range 1 -10 
months) into an illness of median duration 3 months (range 1 -17 months). 
ii): CSF 
The CSF was often reported as normal but the exact values were not necessarily 
given. In addition the laboratory upper limit of normal was not always specified. An 
arbitrary protein level of 0.7 mg /L was regarded as significantly raised in the 
absence of greater than 5 red cells. A white cell count of greater than 5 was also 
considered as abnormal. 
Of the MM -1 cases, the CSF results were missing or not analysed in 15 cases. In 4 
cases the protein was raised (0.72, 0.8, 0.78, 1.22 mg /L) with no note of a raised red 
cell count. The white cell count was not raised in any cases without a significantly 
raised red cell count. In the other groups, 10 cases had no available result or the CSF 
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was not analysed. In all the other cases the CSF results were within the above 
parameters. 
14 -3 -3 and S -100b 
14 -3 -3 and S -100b was tested in 31 cases. (See Table 8.19) In 2 of these S -100b was 
not tested: 1 MV -1 and 1 VV -2A case. In total the 14 -3 -3 protein was positive in 21 
cases (68 %). There was a trace positive in 2 cases and the fluid was heavily 
bloodstained in 2 cases. The result was negative in 6 cases (19 %). 
The positive results were performed a median of 3 months (1 -11) in an illness of 
median duration 5 months (2 -11). The equivocal results were performed a median of 
3.5 months (3 -4) into an illness of median duration 6.5 months (5 -9), and the 
negative results were performed a median of 12.5 months (7 -25) into an illness of 
median duration 19 months (8 -54). 
Table 8.19: SPORADIC CJD: 14 -3 -3 AND S -100b RESULTS 
14-3-3 5-100b 
N +ve % -ve % +/- % inc % norm % 
MM-1 15 12 80 0 0 3 20 14 93 0 0 
MM-2A 4 1 25 3 75 0 0 3 75 1 25 
MV-1 3 1 33 1 33 1 33 1 33 1 33 
MV-2A I O 0 1 100 0 0 1 100 0 0 
VV-1 1 0 0 1 100 0 0 1 100 0 0 
VV-2A 7 7 100 0 0 0 0 6 86 0 0 
+ve= positive. -ve= negative; +/- = equivocal; inc = increased; norm= normal 
12 of the MM -1 cases had a positive 14 -3 -3 (80 %). Of the 3 equivocal cases 2 were 
bloodstained, 1 so heavily that S -100b could not be analysed either, and 1 showed a 
trace of 14 -3 -3. All were associated with a raised S- 100b.The positive results were 
performed a median of 2 months (1 -5) into an illness of median duration 3 months 
(2 -10). The equivocal results were performed at a median of 3 months (3 -4) into an 
illness of duration 5 months (5 -9). 
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All 7 of the VV -2A group that were assessed (100 %) had a positive 14 -3 -3. 6 were 
for S -100b and it was raised in each case. The test was done at a median of 5 months 
(1 -1 1) into an illness of median duration 6 months (4 -11). 
In the remaining groups very few cases were tested. One (25 %) of the MM -2A group 
had a positive 14 -3 -3 (performed at 6 months into an illness of 8 months duration) 
and 3 had a raised S -100b. 3 of the MM -2A cases (75 %) were negative, tested for at 
a median of 17 months (8 -14) into an illness of median duration 17 months (16 -21). 
One case (33 %) of the MV -1 group was positive, associated with a raised S -100b 
(performed at 3 months into an illness of 5 months duration), and another showed a 
trace of 14 -3 -3 protein, the S -100b was normal (performed at 4 months into an 
illness of 8 months). One case had a negative result, performed at 25 months into an 
illness of 54 months. 
Both the MV -2A and VV -1 groups had 1 case tested. In both cases the result was 
negative with a raised S -100b. The MV -2A case was tested at 7 months in an illness 
of 8 months and the VV -1 case was tested at 16 months in an illness of 28 months 
duration. 
The S -100b was only raised if the 14 -3 -3 was positive in all groups apart from the 
MV -2A and VV -1 cases, in which there was a raised S -100b in the absence of a 14- 
3-3 result. 
iii): MRI 
The MRI was available for analysis at the NCJDSU in 44 cases. Fourteen of these 
(32 %) were classified positive. Fifteen (34 %) were classified possible (i.e. mild high 
signal in the caudate and /or the putamen ), and the remaining 15 scans (34 %) were 
negative. The high signal seen in the caudate nucleus and putamen was at times 
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asymmetrical. One case had a positive scan reported locally but the changes in the 
putamen and caudate were not reported in any of the other cases. (See Table 8.20) 
Overall, the timing of the scans was: 
Positive 3 months (1 -22) illness duration 5.5 months (3 -29) 
Possible 3 months (1 -19) illness duration 5 months (2 -54) 
Negative 3 months (1 -18) illness duration 5 months (1 -37) 
Table 8.20: SPORADIC CJD: MRI RESULTS 
N= positive % possible % negative % 
MM -1 22 6 27 9 41 7 32 
MM -2A 6 1 17 1 17 4 66 
MV -1 2 0 0 2 100 0 0 
MV -2A 4 3 75 0 0 1 25 
VV-1 2 1 50 1 50 0 0 
VV -2A 8 3 38 2 25 3 37 
A scan was available for review in 22 MM -1 cases: 
Scan result N= % Median date (months) Median duration (months) 
Positive 6 27 2 (1 -4) 3.5 (3 -4) 
Possible 9 41 2 (1 -6) 5 (2 -10) 
Negative 7 32 2 (1 -7) 3 (1 -9) 
Other abnormalities included white and grey matter high signal in 9 cases. Atrophy 
was noted in 14 cases. The pulvinar had some slight high signal in 2 cases. One scan 
was normal. Only 1 of these scans was reported as positive by another centre. 
(Reported in 1998. The Finkenstaedt review of the MRI in sporadic CJD was 
published in 1996.8) 
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In 25 cases no scan was performed or there was no report available and we were 
unable to obtain a copy of the scan. The remaining 7 cases had a scan but were not 
reviewed by us. Of these 3 had non -specific white matter changes or atrophy, 1 had a 
mucus retention cyst, I had a porencephalic cyst and 2 were reported normal. 
Six MM -2A cases had a scan available for review by the NCJDSU: 
Scan result N= % Median date (months) Median duration (months) 
Positive 1 17 12 2I 
Possible 1 17 4 16 
Negative 4 66 6 (2 -18) 14 (8 -37) 
Other abnormalities noted included mild atrophy in 3 cases. Two cases had high 
signal within the cortex. One scan was considered normal. Of the remaining MM -2A 
cases in whom the scan was not seen by us, 2 scans were normal and I showed some 
atrophy. The final case had no scan performed. 
Two MV -1 cases had a scan available for review. Both had slight change in the 
putamen and would be considered possible. They were performed after 3 and 19 
months of illness. The illness duration was 8 and 54 months respectively. Other 
changes included atrophy in both and 1 had some white matter changes. One further 
scan, not see by us, was reported as normal and 2 other cases did not have a scan 
performed. 
In 4 of the MV -2A cases we were able to review a scan. Three of these (75 %) had a 
positive scan. The final scan was the wrong weighting and so could not be assessed. 
(The scan was performed at 2 months in an illness of duration of 3 months.) In the 
other cases the median time to scanning was 5 months (range 3-11 months). The 
median illness duration was 9 months (range 7 -21 months). 
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Other changes included atrophy in all 3 cases, high signal in the cortex in 1 case and 
in the grey matter in another. Two cases also had some high signal in the pulvinar. 
No scan was performed in 6 cases. In the remaining 2 cases, in whom we could 
review the radiology report, I had ischaemic changes and 1 was atrophic. 
Of the 2 VV -1 cases who had a scan available 1 was strongly positive at 22 months, 
(duration of illness 29 months) and 1 would be considered possible after 1 month, 
(duration of illness 11 months). Both had atrophic changes. The final case had no 
scan performed. 
Eight VV -2A cases had a scan performed: 
Scan report N= % Median date (months) Median duration (months) 
Positive 3 37 3 (3 -5) 6 (5 -11) 
Possible 2 25 3 (1 -5) 4 (2 -6) 
Negative 3 37 4 (1 -5) 7 (5 -7) 
Additionally, atrophy was seen in 2 cases and 1 case had slight signal change in the 
pulvinar. Two cases had normal scans. Of the remaining cases a scan report was 
available in 3: 2 had atrophic change and I had minor ischaemic change. 
The scan was performed more than once in 7 cases. In 4 of these both scans were 
negative. (2 MM -1, 1 MM -2A and 1 MV -1 case) In 2 other cases (1 MM -1 and I 
VV -2A) the scan was positive on both occasions. Finally, in 1 VV -1 case the first 
scan at 10 months was negative, but the second scan, performed 1 year later, 22 
months into the illness was positive. 
G: PATHOLOGY 
i): Histopathology (See Table 8.21) 
MM -1: In general there was microvacuolar and areas of confluent spongiform 
change throughout the cortex in all cases. The changes were noted to be patchy in 2 
160 
CHAPTER 8 RESULTS 
cases. In 33 cases the occipital lobe was noted to be one of the areas most affected. 
In 10 cases the temporal lobe was particularly affected, in 6 cases the parietal lobe 
and in 9 the frontal lobe. Two cases commented on marked involvement throughout 
the cortex. (Some cases had marked involvement in more than 1 lobe.) 
Five cases had areas of status spongiosis. The median duration of illness in these 
cases was 15 months (1 -17 months), in comparison to the overall median duration of 
illness of 3 months (1 -17 months) of the MM -1 group as a whole. An MRI was 
available for review in only 1 of these cases, in whom widespread severe atrophy 
was noted. 
In general, involvement of the hippocampus was patchy if present at all. 
Involvement of the basal ganglia was patchy in 4 cases but otherwise tended to 
mirror the spongiform change of the cortex. In 2 cases the basal ganglia changes 
were more marked than in the cortex. 1 of these cases had marked dystonic posturing 
during the illness. The other was a classical Heidenhain variant. Gegenhalten was 
noted but no other extrapyramidal features. In addition this case was the only MM -1 
with marked thalamic spongiform change. There were no particular thalamic features 
to the illness. Thalamic involvement in most cases was generally less marked and 
was patchy in 23 cases. 
These findings were similar in the cerebellum where 30 cases were noted to have 
patchy involvement, although 1 case was noted to have the most marked spongiform 
change in the cerebellum. Brainstem involvement was only commented on in 12 
cases and was invariably mild and patchy. 
There were no amyloid plaques in any case. Gliosis and neuronal loss was prominent 
in the cortex and often the cerebellum and basal ganglia. In 4 cases the thalamus had 
prominent gliosis and neuronal loss, in 2 cases this was the most striking area. 
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Other changes noted included age -related changes or evidence of arteriosclerosis in 
20 cases. Three cases had ß amyloid plaques and the changes of Alzheimer's 
disease. One case had a calcified 4th ventricle meningioma. 
MM -2A: In 1 case only a frontal lobe biopsy was available. This merely showed 
spongiform change. In the remaining cases histology was available from all areas of 
the brain. Spongiform change was present throughout the cortex. In 5 cases this was 
reported as confluent. In 2 other cases it was patchy. The frontal and /or temporal 
lobes were the most heavily involved areas in 6 patients. In 3 patients the occipital 
lobes were heavily involved and in 1 patient the parietal lobe showed marked 
change. 
Spongiform change was present in the basal ganglia in all 9 cases, in general the 
changes were less marked than in the cortex and particularly so in the thalamus. 
However, in 1 patient the basal ganglia showed marked change. Spongiform change 
was present in the cerebellum but to a lesser extent and in 8 cases it was patchy. 
Three cases were noted to have slight involvement of the brainstem. 
In 5 patients neuronal loss and gliosis was present throughout the cortex, 
concentrated usually in the area of most marked spongiform change. One case had 
marked neuronal loss and gliosis in the thalamus and stem. In this case spongiform 
change was patchy except in the temporal cortex. There were no amyloid plaques 
seen. 
One case was noted to have an incidental small vascular malformation. 
MV -1: All 5 cases had tissue available for examination. One case of 54 months 
duration showed the changes of status spongiosis. The remaining 4 cases had 
spongiform change throughout the cortex. (3 mainly in the occipital lobes, 3 in the 
frontal lobes, 2 in the temporal lobes and 1 in the parietal lobe; most cases with more 
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than 1 area overlapping.) In 1 case this was microvacuolar, in another it was 
confluent and in another it was both. Spongiform change was present in the basal 
ganglia, thalamus and cerebellum but here the changes were in general patchier. 
Gliosis was present in areas of the cortex in 4 cases and in the cerebellum in 3 cases. 
Neuronal loss was roughly similar but was also present in areas of the deep grey 
matter in 3 cases. Kuru -like plaques were noted in the cerebellum in 1 case prior to 
staining. 
Two cases were noted to have the changes of arteriosclerosis in the brain. 
MV -2A: The spongiform change was mild to moderate throughout the cortex in all 
12 cases. The change was confluent in 2 cases and there were changes in the 
hippocampus in 8 cases. Spongiform change was more marked in the basal ganglia 
than in the cortex in 9 cases and in general the changes were patchier in the 
thalamus. There was no excess of extrapyramidal signs in the MV -2A cases. One 
case had marked spongiform change in the hypothalamus. The changes in the 
cerebellum were patchy in 4 cases and in the remaining cases there was generally 
less marked spongiform change in the cerebellum. The brainstem was involved in 10 
cases but only slightly. 
Gliosis and neuronal loss was most marked in the cortex in 7 cases. In 2 other cases 
both the cortex and the cerebellum were involved. In 1 case the cerebellum was 
severely involved. In 2 cases the caudate and putamen changes were the most 
marked. 5 cases had kuru type plaques in the cerebellum and cortex, and in a further 
case kuru type plaques were also seen in the hippocampus. In 3 cases the plaques 
were predominantly in the cerebellum. Three cases had no plaques. 
Three cases had age related senile plaques in the hippocampus and another had 13- 
amyloid plaques and Hirano bodies in the hippocampus. One case had the changes of 
163 
CHAPTER 8 RESULTS 
moderately severe arteriosclerosis and another had pallidal siderosis and lacunar 
infarcts. 
VV -1: There were only 2 cases with histology available in this group. One case, 
whose illness duration was 11 months, had changes of status spongiosis throughout 
the cortex and basal ganglia. In the other case spongiform changes were present 
throughout the cortex but were most marked in the basal ganglia. The changes were 
patchy in the thalamus and cerebellum in both cases. There was neuronal loss and 
gliosis in the cortex in both cases and also in the basal ganglia in the case with status 
spongiosis. 
VV -2A: Spongiform change was present throughout the cortex in all cases. The 
changes were patchy in 3 cases. In all but 1 case the changes were more marked in 
the basal ganglia. The final case had only patchy spongiform change in the basal 
ganglia. In general the changes in the thalamus and cerebellum were less marked. 9 
of the cases were noted to have slight patchy spongiform change in the brainstem. 
Neuronal loss and gliosis was variable and present in most areas. No cases had any 
amyloid plaques. 
Table 8.21: SPORADIC CJD: PATTERN OF SPONGIFORM CHANGE 
CORTEX BASAL 
GANGLIA 
THALAMUS CEREBELLUM AMYLOID 
PLAQUES 
MM -1 Occipital Some 
patchy 
Patchy Patchy No 
MM -2A Frontal /temporal Present Patchy Patchy No 
MV-1 Frontal /occipital Present Patchy Patchy Present 
MV -2A Present Most 
marked 
Patchy Patchy Present+ 
VV -1 Present Most 
marked 
Patchy Patchy No 
VV -2A Present Most 
marked 
Patchy Patchy No 
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ii): Immunohistochemistry (See Table 8.22) 
MM -1: Immunohistochemistry was not done in 1 case. In the other cases there was a 
reticular and perivacuolar deposition of PrP. In occasional cases there were granular 
or perineuronal deposits. In 29 cases the occipital lobe was again noted to have the 
most marked involvement. A further 3 cases were noted to have more marked 
involvement of the frontal lobe, 6 in the temporal lobe, 1 in the parietal lobe and 1 
throughout the cortex. (Again, some cases had marked involvement of more than 1 
lobe.) These changes were mirrored in the basal ganglia but tended to be more 
reticular in the thalamus and often less marked. A few cases had a perivacuolar 
deposition in the thalamus. 
Deposits in the cerebellum also tended to be reticular but more granular in the 
granular layer. Eight cases had some perivacuolar deposits and 1 case had some 
perineuronal deposition. In 27 cases slight patchy, predominantly reticular deposition 
was seen in the brainstem. 
MM -2A: Immunohistochemistry was not performed in the frontal biopsy case. In the 
remaining 9 cases deposition in the cortex was perivacuolar and synaptic, usually 
concentrated in the area of greatest spongiform change: 2 with changes most marked 
in the occipital lobe, 1 in the frontal lobe, 1 in the frontal and temporal lobes and 2 
throughout the cortex. One case also had perineuronal deposition. In the basal 
ganglia and thalamus, deposition was synaptic and perivacuolar, again 1 case also 
had some perineuronal deposits. In the cerebellum, 2 cases had perivacuolar and 
plaque -like deposits. One case had some focal deposition of plaques. Two other 
cases had some synaptic and focal deposits. The brainstem had patchy involvement 
noted in 1 case. 
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Three of the MM -2A cases were remarked on for their unusual pathology. One had 
change of the thalamic variant, 1 had unusual PrP deposition in the occipital and 
temporal cortex and in 1 case the pathology was similar to GSS. 
MV -1: Immunohistochemistry was done in all cases. Again the staining pattern 
usually mirrored the areas of greatest spongiform change. 4 cases had marked 
involvement of the occipital lobe, 2 the frontal lobes and 1 the temporal lobe, again 
more than I area was involved in each case. In the cortex, synaptic deposits were 
present in 4 cases with additional perivacuolar changes in 2 of the cases. Two cases 
had plaque -like deposits. The changes elsewhere tended to be more synaptic in the 
deep grey nuclei and cerebellum, with the same 2 cases showing plaque -like deposits 
throughout. One case also had plaque -like deposits in the brainstem. 
MV -2A: Immunohistochemistry was performed in all cases. PrP was deposited in 
the cortex in a variable reticular, perivacuolar and perineuronal pattern. 8 cases had 
plaque -like deposits or plaques. The pattern was similar in the basal ganglia, 
thalamus and cerebellum although the pattern tended to be more reticular and 10 
cases had plaques or plaque -like deposits in this area. These were particularly 
marked in the cerebellum. Most cases had reticular deposits in the brainstem 
although these were less marked and plaques were deposited in 5 cases. One case 
was noted to have an unusual GSS type of staining. 
VV -1: Immunohistochemistry for PrP was present in a variable reticular, 
perivacuolar and perineuronal pattern in the cortex, basal ganglia and cerebellum. 
Deposition was also present in the thalamus in the case with status spongiosis. 
VV -2A: Immunohistochemistry showed a predominantly linear and perineuronal 
deposition of PrP in the cortex. Eleven of the 15 cases had plaque -like deposits. Five 
of the cases had greatest involvement in the temporal lobes, 3 in the frontal lobes and 
2 in the occipital lobes (with overlap). The hippocampus was the area of greatest 
involvement in 3 cases. 
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The changes in the basal ganglia were generally more reticular with a perivacuolar 
pattern also present. Plaque -like deposits were present in 7 cases. In the thalamus the 
changes tended to be reticular with plaque -like deposits in 8 cases. Plaque -like 
deposits were present in the granular layer of the cerebellum in all 15 cases and 
reticular deposition was present in the molecular layer. Seven cases were noted to 
have some reticular deposition in the brainstem. 
Table 8.22: SPORADIC CJD: PATTERN OF IMMUNOHISTOCHEMISTRY 
Cortex Basal Ganglia Cerebellum Plaques 
MM -1 Reticular Reticular Patchy No 
MM -2A Synaptic/ Perivacuolar throughout No 
MV -1 Synaptic Synaptic Synaptic Plaque -like 
MV -2A Reticular Reticular Reticular Plaques+ 
VV -1 Reticular Reticular Reticular No 
VV -2A Linear Reticular Plaque -like Plaque -like 
H: CLASSIFICATION 
Each case was reclassified by me and given the highest possible classification in life 
(without neuropathological information) according to the most recent criteria. (See 
Appendix C). 
i): Probable cases 
An EEG result of "typical" or "highly suggestive" was used to indicate a probable 
case. In all, 46 cases (49 %) were classified probable. Of these, 37 (69 %) belonged to 
the MM -1 group. Seven VV -2As (47 %) were also classified as probable. Only 1 
MM -2A and 1 MV -2A would have been probable cases in life. (See Table 8.23) 
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Table 8.23:SPORADIC CJD: DIAGNOSTIC CRITERIA 
RESULTS 
PROBABLE % POSSIBLE % CJD unlikely % 
MM -1 37 69 14 26 3 6 
MM -2A 1 10 17 70 2 20 
MV -1 1 20 3 60 1 20 
MV -2A 0 0 9 75 3 25 
VV -1 0 0 1 33 2 67 
VV -2A 7 47 7 47 1 6 
ii): Possible cases 
Possible cases fulfilled the clinical criteria for sporadic CJD but did not have 
supportive investigations, i.e. the EEG was not typical or the 14 -3 -3 protein result 
was negative. Their results were as follows: 
In the MM -1 group 10 cases were "possible ". 
No EEG/ 14 -3 -3 
EEG non -specific/ no 14 -3 -3 
EEG suggestive/ no 14 -3 -3 





In the cases with a suggestive EEG the record was performed at a median of 4 
months (range 2 -4 months). The non -specific EEG records were performed at 1 
month. One of these cases had a positive MRI result. 
Seven MM -2A cases were classified as "possible ": 
4 had a non -specific EEG performed at 6, 7, 9 and 14 months. 
3 had a suggestive EEG performed at 4,12 and 12 months. 
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The 14 -3 -3 was not performed in 4 cases and in the remaining 3 cases it was 
negative. None had a positive MRI. 
Three of the MV -1 group were classified "possible ": 
1 case did not have an EEG or 14 -3 -3 performed. 
1 case had a suggestive EEG after 1 month and no 14 -3 -3 performed. 
1 case had a non -specific EEG at 4 months and a trace of positive 14 -3 -3 
protein. 
The MRI was negative in all these cases. 
Nine of the MV -2A cases were classified as "possible ": 
1 case did not have an EEG or 14 -3 -3 performed. 
4 had a non -specific EEG at 3, 5, 11 and 19 months. 
4 had a suggestive EEG at 2, 9, 12 and 13 months. 
14 -3 -3 was not analysed in all 9 cases. 
2 of these cases had a positive MRI scan. 
Only 1 VV -1 was a "possible" case: 
The EEG was suggestive at 6 months and 14 -3 -3 was not analysed. No MRI 
imaging was performed. 
Seven of the VV -2A group were classified as "possible" cases: 
In all the cases the EEG was non -specific, performed a median of 3 months 
(range 1 -12 months). 
14 -3 -3 was not analysed in any of these cases. 
None of the cases had a positive MRI scan, although 1 case had some very 
slight high signal in the caudate nucleus. 
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iii): CJD Unlikely 
Fourteen cases were given a classification of "CJD unlikely ". This included only 3 
(6 %) of the MM -1 cases and 1 (6 %) of the VV -2A cases. Their details follow. 
MM -1 cases: 
Patient 1: 69- year -old male whose illness lasted 2 months. A member of the 
NCJDSU did not see the patient in life and the relatives were not interviewed. There 
was no note made of a dementing process in the case records. There were cerebellar 
features but also lower motor neurone changes and a working diagnosis of motor 
neurone disease was made. The EEG was non -specific. 
Patient 2: A 53- year -old woman who died after 3 months of illness. She was 
examined by a member of the NCJDSU, and the relatives were interviewed but the 
hospital notes were not available. She had an early dementia and visual and 
cerebellar features were present but no myoclonus, pyramidal or extrapyramidal 
signs were noted and she was not seen at a time when there was akinetic mutism. 
The EEG was non -specific and CSF was not analysed for the presence of 14 -3 -3 
protein but the MRI was positive. 
Patient 3: A 63 -year -old woman who died after 2 months of illness. There was only 
limited information of her case from the interview of her relatives. The patient was 
not seen during life and the hospital notes were not available. She had an early 
dementing illness and was unsteady but there is no definite note of cerebellar, 
pyramidal or extrapyramidal features. She developed visual symptoms late on but it 
is not clear if she became cortically blind or developed akinetic mutism. She 
developed myoclonus late in the illness. The EEG was highly suggestive but 14 -3 -3 
protein was not performed and the MRI results are unavailable. 
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VV -2A case 
A 65- year -old woman with an illness of 6 months duration. She was seen in life by 
the NCJDSU and the relatives were interviewed. The hospital notes were also 
available. She presented with dizziness and cerebellar signs. Dementia appeared 
after some weeks. There was no note of pyramidal or extrapyramidal problems, 
myoclonus, cortical blindness or akinetic mutism however. The EEG was non- 
specific, 14 -3 -3 was not done and the MRI would be considered possible. 
8 other cases were classified as "CJD unlikely ": 2 of these cases (20 %) were in the 
MM -2A group. Both had an illness of duration greater than 2 years. A member of the 
NCJDSU saw neither case, but both presented with dementia. One case developed 
definite cerebellar problems and had some choreoathetoid movements but these may 
have predated the illness, as the patient had been on neuroleptic medication for many 
years. The other case was unsteady but no specific cerebellar features were noted. 
Myoclonus developed late on in the illness and so it is conceivable they may have 
been classified as "possible ". Neither case had a typical EEG and 14 -3 -3 protein was 
not analysed. Only 1 MRI was available for review but neither was reported as 
showing high signal in the putamen or caudate nucleus. 
One (20 %) MV-1 case was a classified as unlikely. This was simply because the 
duration of illness was greater than 2 years, other wise she would have been 
classified as "possible ". The EEG was non -specific, the 14 -3 -3 was negative and the 
MRI was also "possible ". 
Three (25 %) of the MV -2A cases were classified as "CJD unlikely ". Two of these 
cases would have been classified as possible but for the long duration of illness. The 
EEG was only done in 1 case and showed non- specific changes. 14 -3 -3 was not 
analysed and an MRI was not performed in either. The third patient was a 61 -year- 
old woman who died after 8 months of illness. Only the hospital notes were 
available. She presented with cerebellar features and dementia but there was no note 
171 
CHAPTER 8 RESULTS 
of pyramidal, extrapyramidal signs or cortical blindness or akinetic mutism. There 
was no note of myoclonus although startle was commented on. The EEG was non- 
specific, 14 -3 -3 was not performed and the MRI was reported as showing only 
atrophy. 
Two (67 %) of the VV -1 cases were given the classification "CJD unlikely ". One 
case would have been classified as possible but for the long duration. The EEG was 
non -specific and the 14 -3 -3 was negative but the MRI was strongly positive. The 
second case was a 41 years old man who died after 11 months. The presentation was 
with dementia and he was noted to be unsteady but there were no definite cerebellar, 
pyramidal or extrapyramidal signs. Myoclonus was noted late on but he was not 
noted to develop cortical blindness and akinetic mutism was not stated although he 
became mute and immobile. The EEG was non -specific and 14 -3 -3 was not 
performed. The MRI was considered possible. 
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8.2: SPORADIC CJD; INTERMEDIATE CASES 
A: CASE DATA 
Three sporadic cases were of intermediate mobility, i.e. between 19 and 21 kDa. 
Two of these cases were Met homozygous and the other was Val homozygous. In 2 
cases a member of the unit had examined the patient and the hospital notes were 
available in 1 case. One case was from the Oxford study and the other 2 were from 
the current study. 
B: GENDER DISTRIBUTION 
There were 2 males and 1 female (ratio 2:1). 
C: AGE AT ONSET 
The median age of onset was 76 years (range 68 -82). 
D: DISEASE DURATION 
The median duration of illness was 5 months (range 3 -9). The case whose duration 
of illness was 9 months was fed by PEG. 
E: SYMPTOMS AND SIGNS 
The onset involved cerebellar symptoms in all 3 cases. One case also had visual 
symptoms at onset and a hemisensory burning sensation, which progressed to pins 
and needles. Dementia and myoclonus developed in all 3 cases. 
F: INVESTIGATIONS 
All 3 cases had a typical or highly suggestive EEG, although in the case with a 
typical EEG I did not review the record. None had 14 -3 -3 protein analysis and I had 
an MRI reported as showing cerebellar atrophy. 
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G: PATHOLOGY 
There were no distinguishing features to the pathology in any of the 3 cases. There 
was microvacuolar spongiform change throughout the cortex. In some areas it was 
confluent. One case (of 9 months duration) had areas of status spongiosis. Spongy 
change was less marked in the deep grey matter and cerebellum. There were areas of 
neuronal loss and gliosis but no amyloid plaque formation. PrP immunochemistry 
was not performed in 1 case. In the other 2 there was a reticular deposition 
throughout the cortex and deep grey matter. In 1 case there were perivacuolar areas 
in the cortex. Staining was more granular in the cerebellum. 









EEG MRI Pathology 
VV 76 5 Cerebellar Typical (not 
seen) 
Not done 








MM 82 3 Dementia Highly 
suggestive 
Not done 
H: GROUP B CLASSIFICATION 
Both the Met homozygous cases were classified "type 2" by Group B. The Val 
homozygous case was not classified by Group B. (See Appendix F) 
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8.3: SPORADIC CJD: GENOTYPE ONLY 
As previously discussed, the genotype alone seems to influence significantly the 
phenotype of cases of CJD. The Group A cases were therefore analysed, considering 
genotype only. 
A: CASE DATA 
The cases were distributed as follows: 
MM 64 65% 
MV 17 17% 
VV 18 18% 
As discussed previously, the Met homozygotes and heterozygotes had a greater 
proportion of females but the Val homozygotes were more likely to be male. This 
was statistically significant (p <0.5) (See Table 8.25) 
C & D: AGE AT ONSET & DISEASE DURATION 
Age at onset was not significantly different between the genotypes; there was 
considerable overlap between all 3 groups. (Kruskall- Wallis test, p =0.5) (See Table 
8.25) However the MV group had a significantly longer duration of illness than the 
MM and VV groups. (Kruskall- Wallis test, p= 0.002) 






MM 63 (39 -86) 3 (1 -37) 0.8:1 
MV 65 (15 -79) 9 (2 -54) 0.6:1 
VV 60 (26 -79) 6 (2 -29) 1.3:1 
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E: SYMPTOMS AND SIGNS 
Most of the cases in each group presented with a rapidly progressive dementia (24- 
48%). A cerebellar presentation was also seen in each group but it seemed to be 
commoner in the heterozygotes (24 %) and the Val homozygotes (18 %). Presentation 
with visual upset was seen in 17% of the Met homozygotes. One Val homozygote 
(6 %) also presented with visual symptoms. This result did not achieve statistical 
significance. (Fishers exact test, p =0.1) (See Table 8.26) 
Table 8.26: SPORADIC CJD: GENOTYPE ONLY: CLINICAL FEATURES 
AT ONSET 
RPD only Cerebellar only Visual only 
N= % N= % N= % 
MM 31 48 7 11 10 17 
MV 4 24 4 24 0 0 
VV 6 33 3 18 1 6 
The disease progression is set out in tables 8.27, 8.28 and 8.29. Dizziness was more 
common in the Val homozygotes and visual upset was more common in the Met 
homozygotes. In addition, swallowing problems seemed to be more common in the 
Val homozygotes. 
Table 8.27: SPORADIC CJD: GENOTYPE ONLY CLINICAL SYMPTOMS 
P % Di % RPD % S % He % V % Ha % De % 
MM 16 25 12 19 63 98 10 16 1 2 37 58 16 25 4 6 
MV 5 29 1 6 17 100 2 12 1 6 3 18 7 41 2 12 
VV 6 33 7 39 18 100 2 11 1 6 6 33 6 33 2 11 
P= Prodrome, Di= Dizzy, RPD= Rapidly Progressive Dementia, S= Sensory, 
He= Hearing, V= Visual upset, Ha= Hallucinations, De= Delusions 
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Table 8.28: SPORADIC CJD: GENOTYPE ONLY: CLINICAL SIGNS 
RESULTS 
C %P %E % PR % M % MD % EM % 
MM 37 58 37 58 21 33 46 72 60 94 25 40 14 22 
MV 14 82 5 29 5 29 13 72 14 82 2 12 2 12 
VV 11 61 10 56 7 39 13 72 16 89 6 33 6 33 
C= Cerebellar, P= Pyramidal, E= Extrapyramidal, PR= Primitive Reflexes, 
M= Myoclonus, MD =other Movement Disorders, AL =Alien Limb, EM =Eye 
Movements 
Table 8.29: SPORADIC CJD: GENOTYPE ONLY: TERMINAL STAGES 
Swallowing Cortical Akinetic 
% Blindness % Mutism % 
MM 23 36 21 33 34 53 
MV 4 24 3 18 7 41 
VV 10 56 4 22 11 61 
F: INVESTIGATIONS 
Of the records that I reviewed, the EEG was typical or highly suggestive in 52% of 
Met homozygotes, 7% of heterozygotes and no Val homozygotes. This result was 
statistically significant. (Chi- square test, p <0.001) (See Table 8.30) 
14 -3 -3 protein was positive in 68% of Met homozygotes and 88% of Val 
homozygotes. Only 33% of heterozygotes had a positive 14 -3 -3 analysis. 
Table 8.30: SPORADIC CJD: GENOTYPE ONLY: INVESTIGATIONS 
EEG typical 
N= % 




MM 32 /61 52 13/19 68 7/28 25 
MV 1/14 7 1/4 33 3/6 50 
VV 0/18 0 7/8 88 4/10 40 
Half of the heterozygotes had a positive MRI and 25% and 40% of the Met and Val 
homozygotes respectively also had a positive MRI. 
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G: PATHOLOGY 
One Met homozygote did not have PrP staining and one Val homozygote had no 
pathological tissue for analysis. (See Table 8.31) 
i): Histopathology 
In general spongiform change was seen predominantly in the cortex in Met 
homozygotes, and more prominently in the basal ganglia in heterozygotes and Val 
homozygotes. Kuru -type plaques were seen prior to PrP staining in only the 
heterozygotes. These were seen in 10/17 cases (59 %). 
ii): Immunohistochemistry 
After PrP staining, 2 Met homozygous cases had plaque -like aggregates in the 
cerebellum and 1 had them in the basal ganglia. Of the Val homozygotes, 15 (83 %) 
had plaque -like deposits in all or some of the cortex, basal ganglia and thalamus. 
Plaques and plaque -like deposits were seen in the cerebellum. Eleven (65 %) of the 
heterozygotes had plaques and plaque -like deposits throughout the brain. 





% PrP Plaque- 
like & plaques 
% 
MM cortex 0 0 3/63 5 
MV basal ganglia 10/17 59 11/17 65 
VV basal ganglia 0 0 15/18 83 
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8.4: SPORADIC CJD: ISOTYPE ONLY 
In order to assess whether changes seen could relate purely to isotype, the Group A 
data were analysed for trends relating to protein isotype 1 and 2A. 
A: CASE DATA 
Of all the cases, 62 were classified type 1 (63 %), and 37 (37 %) were type 2A. 
B: GENDER DISTRIBUTION 
The male to female ratio was 0.8:1 in each group. (See Table 8.32) 
C & D: AGE AT ONSET AND DISEASE DURATION 
The median age of onset was 64 years (range 15 -86) -and 61 years (range 39 -79) in 
types 1 and 2A respectively. This was not statistically significant. (Mann- Whitney 
test, p= 0.070) The duration of illness was 3 months (range 1 -54) and 8 months (2- 
51) respectively. This was statistically significant (Mann- Whitney test, p <0.01) 






Type 1 64 (15 -86) 3 (1 -54) 0.8:1 
Type 2A 61 (39 -79) 8 (2 -51) 0.8:1 
E: SYMPTOMS AND SIGNS 
44% of the type 1 group presented with dementia only and 38% of the type 2A had 
this presentation. A purely cerebellar onset was seen in 11% and 19% of types 1 and 
2A respectively and 16% and 3% respectively of each group presented with a visual 
onset. This last result is of borderline significance (Fishers exact test, p= 0.049) (See 
Table 8.33) 
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Table 8.33: SPORADIC CJD: ISOTYPE ONLY: CLINICAL FEATURES 
AT ONSET 
RPD onset Cerebellar Visual onset 
N= % onset N= % N= % 
Type 1 27/62 44 7 11 10 16 
Type 2A 14/37 38 7 19 1 3 
The clinical symptoms and signs are set out in tables 8.34, 8.35 and 8.36. Most of 
the symptoms and signs occurred with similar frequency in both groups. However, 
visual upset occurred in type 1 more than type 2A (56% compared to 30 %). In 
general all the symptoms were noted more frequently in the type I group, except for 
hallucinations, which were more frequent in the type 2A group. However, in all 
cases the signs were noted more frequently in the type 1 group. 
TABLE 8.34: SPORADIC CJD: ISOTYPE ONLY: CLINICAL SYMPTOMS 
P % Di % RPD % S % He % V % Ha % De % 
Typel 18 29 13 21 61 99 8 13 1 2 35 56 16 24 3 5 
Type 
2A 
9 24 7 19 33 100 6 16 2 35 11 30 14 38 5 14 
P= Prodrome, Di= Dizzy, RPD= Rapidly Progressive Dementia, S= Sensory, 
He= Hearing, V= Visual upset, Ha= Hallucinations, De= Delusions 
TABLE 8.35: SPORADIC CJD: ISOTYPE ONLY: CLINICAL SIGNS 
C % P % E % PR % M % MD % EM % 
Type 
1 
37 60 36 60 19 51 46 74 59 95 26 42 15 24 
Type 
2A 
25 68 16 43 13 38 26 70 31 84 7 19 7 19 
C= Cerebellar, P= Pyramidal, E= Extrapyramidal, PR= Primitive Reflexes, 
M= Myoclonus, MD =other Movement Disorders, EM =Eye Movements 
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Table 8.36: SPORADIC CJD: ISOTYPE ONLY: TERMINAL STAGES 
RESULTS 
Swallowing Cortical Akinetic 
% Blindness % Mutism % 
Type 1 25 40 20 32 35 56 
Type 2A 12 32 8 22 17 46 
F: INVESTIGATIONS 
The EEG was typical or highly suggestive in 57% of the type 1 group but none of the 
type 2A. This was statistically significant (Chi- square test, p <0.01) 14 -3 -3 analysis 
was positive in 68% of the type 1 cases, and 67% of the type 2A cases, and the MRI 
was positive in 27% and 39% of the types 1 and 2A respectively. (See Table 8.37) 
Table 8.37: SPORADIC CJD: ISOTYPE ONLY: INVESTIGATIONS 
EEG typical 14 -3 -3 +ve MRI +ve 
N= % N= % N= % 
Type 1 33/58 57 13/19 68 7/26 27 
Type 2A 0/35 0 8/12 67 7/18 39 
G: PATHOLOGY 
1 of the type 1 cases had no pathological tissue for analysis and 1 had no PrP 
staining. The results of the pathological changes are set out in table 8.38 
i): Histopathology 
The majority of type 1 cases had spongiform change predominantly in the cortex. In 
the type 2A cases about half were concentrated in the cortex and half in the basal 
ganglia. Kuru plaques were seen in 1 type 1 case (2 %) and 9 type 2A cases (37 %). 
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ii): Immunohistochemistry 
PrP staining revealed plaque -like deposits and plaques in 3 of the type 1 cases (5 %). 
These were sparse in the basal ganglia, thalamus and cerebellum. of the type 2A 
cases, 25 (68 %) had these deposits. 





% PrP Plaque -like 
& plaques 
% 
Type 1 cortex 1/61 2 3/60 5 
Type 2A Basal ganglia/ cortex 9/37 24 25/37 68 
8.5: SPORADIC CJD; GROUP B CLASSIFICATION 
48 sporadic CJD cases were classified by Prof J Collinge at the Prion Diseases Unit, 
St Marys Hospital, London. He has published his results in several papers and has 
proposed several more isotypes than Parchis' group.2° The classification differs 
slightly from the NCJDSU isotypes (see Chapter 6). The London classification is 
termed Group B and the NCJDSU classification Group A. 
The results of this analysis are set out in appendix F. There are a larger number of 
groups and only a few cases in each group so statistical analysis was not possible. 
The data at this stage add little to this analysis but are discussed in chapter 9 as they 
might become more meaningful in the future when more cases can be analysed. 
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SUMMARY OF SPORADIC CJD FINDINGS 
The MM -1 cases form the largest group and are typical of classically 
described sporadic CJD. 
In these cases the age at onset is typically in the 50 -70 age group and the 
duration of illness is a few months. The disease follows a rapidly progressive 
course, characterised by dementia. Myoclonus, pyramidal and cerebellar 
problems typically develop. A state of akinetic mutism is often seen prior to 
death. The EEG is usually positive. 
The VV -2A cases tend to present with cerebellar signs and follow a fairly 
typical course. The EEG is usually negative but 14 -3 -3 seems to be positive 
in most cases. 
The MV -1 cases are also similar to classical sporadic CJD. 14 -3 -3 protein or 
the EEG may be useful in this group. 
The MV -2A cases also seem to present with more cerebellar signs but 14 -3 -3 
protein and the EEG do not appear to be helpful in investigation. 
The MM -2A group tends to include cases of younger onset and of longer 
illness duration. These cases usually followed an atypical course and 
investigations were largely unsupportive of sporadic CJD. 
The VV -I group was very small, making it difficult to comment on trends. 
These cases weRe generally atypical. 
Pathological changes were largely attributable to codon 129 genotype only. 
There was considerable overlap between groups and it was not possible to 
establish the influence of isotype or genotype alone on the data as a whole. 
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8.6: VARIANT CJD 
RESULTS 
A: CASE DATA 
Full genetic analysis and protein isotyping was available in 43 cases of variant CJD. 
Five patients were not seen by a doctor from the NCJDSU. The relatives were 
interviewed in all cases. The full hospital notes were not available in 2 cases. All the 
cases come from the current surveillance project. 
B: GENDER DISTRIBUTION 
The number of males and females was 24 and 19 respectively ratio (1.3:1). 
C: AGE AT ONSET 
The median age at onset was 26 years (range 14 -53). 
The median age at death was 27 years (range 15 -54). 
D: DURATION OF ILLNESS 
The median duration of illness was 14 months (range 7 -39). 
E: SYMPTOMS AND SIGNS 
The clinical course in all the cases was similar to the features of vCJD when it was 
first described »°° 
i): Prodrome 
In 2 cases (5 %) the family noted some form of prodromal illness: one patient had an 
ear infection and lost his hearing and another had a flu -like illness prior to the onset 
of the first symptoms of vCJD. One patient had Bells palsy prior to the onset of their 
illness and another was diagnosed and treated for thyrotoxicosis at the onset of their 
first symptoms of vCJD. 
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ii): Psychiatric Symptoms 
Psychiatric symptoms were part of the presenting complaint in all but two patients 
(95 %). One of these cases presented with a hemi- sensory disturbance but very 
quickly developed depressive symptoms. In the other there was insufficient data to 
be sure that psychiatric symptoms were present from early on but the patient was 
anxious and irritable later on in the illness. The presenting symptoms were often 
non -specific, for example moodiness, in some put down to normal teenage 
behaviour. Patients went on to develop more marked psychiatric symptoms. (See 
Table 8.42) 
Depression was present in 30 cases (70%), often diagnosed by the GP and anti- 
depressant medication was prescribed in some cases. The depression was sometimes 
thought to be reactive, in 2 cases, related to the death of a relative. In another case 
depression developed and the break up of a relationship ensued. In this case the 
relationship break up may also have been related to the onset of other features of 
vCJD. 
Anxiety symptoms were present in 30 cases (70 %). This varied from panic attacks 
and tearfulness to preoccupation with things that would not normally have been of 
concern. For example, in one case the patient was excessively worried about forth 
coming exams and despite passing the exams held a fixed belief he had failed. This 
was very out of character. Five patients suffered from anxiety and fear mainly at 
night. 
Sleep patterns were commonly altered. 21 patients (49 %) were excessively tired and 
would sleep during the day as well as sleeping all night. 11 cases (26 %) suffered 
from insomnia. One of these patients went on to become excessively sleepy later in 
the course of their illness. Two cases were unable to sleep because they were 
awaking screaming and crying in the night. Another patient couldn't sleep later in 
her illness because she suffered from nocturia and frequency. 
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Anorexia and weight loss was present in 23 patients (53 %). Two of the 23 cases 
complained of dysgeusia and 1 other had this symptom but we have no record of 
anorexia or a change in weight. Two of the patients with anorexia initially ate 
excessively but subsequently lost weight. There is a suggestion of possible weight 
gain in one patient. 
Anger or aggressive was noted in 25 patients (58 %) usually towards the beginning of 
their illness. Behaviour ranged from being rather bad tempered to outbursts of 
aggression. In all but 2 cases this was extremely uncharacteristic. 
Hallucinations were present in 15 cases (35 %) and were possibly present in a further 
2 cases. In 9 cases the hallucinations were visual and in 1 case they were auditory. In 
the remaining cases they were mixed visual and auditory hallucinations. 
Delusions were present in 16 cases (37 %). They were predominantly paranoid but 
one person thought she was pregnant and another thought he was on a plane. One 
case had hallucinations and delusions from the onset of their illness but in most cases 
the symptoms appeared some months into the illness. 
Table 8.42: VARIANT CID: PSYCHIATRIC SYMPTOMS 
Symptom N= % 
Depression 30 70 
Anxiety 30 70 
Hypersomnia 21 49 
Insomnia 11 26 
Anorexia 23 53 
Aggression 25 58 
Hallucinations 15 35 
Delusions 16 37 
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Three patients had a past medical history of psychiatric illness, ranging from long- 
term emotional and psychological problems to a previous history of psychotic illness 
4 years prior to the onset of vCJD. Another had a family history of learning 
difficulties and epilepsy and had had problems with learning difficulties himself. 
One other patient had a history of cerebral palsy and behavioural problems. In some 
of these patients the onset of vCJD was often thought to be related to their past 
medical history and made initial diagnosis more complicated. 
ii): Dementia 
Dementia was present in all cases of vCJD but was only present at onset in 6 cases 
(14 %). Most cases presented with psychiatric symptoms with or without sensory 
symptoms. It was sometimes difficult to establish at what point dementia appeared 
and the nature of the symptoms. As the age of the variant cases tends to be younger, 
relatives were sometimes reluctant to accept symptoms of confusion or memory loss 
as dementia. For example one patient did very badly in exams he was expected to do 
well in. However, the family was insistent that he was functioning normally and did 
not feel this was indicative of cognitive problems. 
iii): Sensory Symptoms 
Persistent sensory symptoms were present in 28 cases (65 %) and in 6 (14 %) the 
symptoms were present from the onset. In a further 7 cases sensory symptoms were 
possibly present but it was unclear whether or not they were persistent so they have 
been classified as "don't know ". The sensory symptoms varied from limb pain, often 
poorly described and localised to pins and needles or dysaesthesia. Symptoms were 
sometimes lateralised. 
The sensory symptoms of the first 50 cases of vCJD were reviewed by myself and 
have been published elsewhere.223 These showed that sensory symptoms were 
present in 63% of cases and in 31% these were present from the onset of the illness. 
The symptom most commonly described was limb pain, which was often non- 
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specific and poorly localized. Other symptoms included cold feelings, dysaesthesia, 
paraesthesia and numbness. These symptoms are believed to be of thalamic origin. 
iv): Visual upset 
Twelve cases (28%) complained of visual upset, 2 of these from the onset of the 
illness. Two of the patients complained of blurred vision but the others complained 
of double vision. Many of those with diplopia could be seen to shut one eye some of 
the time. 
v): Auditory upset 
Only 2 patients (5 %) complained of hearing problems. One patient became very 
sensitive to noise midway through their illness and the other patient complained of 
hearing loss following an ear infection at the onset of the illness. 
Table 8.43: VARIANT CJD: OTHER SYMPTOMS 
Symptom N= % 
Dementia 43 100 
Sensory 28 43 
Visual 12 28 
Hearing 2 5 
vi): Cerebellar problems 
Cerebellar signs, predominantly ataxia, were present in all but 2 of the cases (95 %). 
In these 2 cases, neither was seen until she was bed bound. Both their families noted 
they were unsteady on their feet. However, cerebellar signs were not specifically 
mentioned in the case notes and so it cannot be assumed they were definitely present. 
Three (7 %) of the cases had symptoms of unsteadiness, later found to be ataxic, from 
the onset of their illness. Of the others, 9 (21 %) were unsteady from early on and 27 
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(63 %) of the others developed ataxia in the middle months of illness. In the final 3 
(7 %) ataxia was not noted until late on. 
vii): Pyramidal signs 
Pyramidal signs were noted in 37 (86 %) of the patients. 
viii): Primitive reflexes 
Primitive reflexes were noted in 25 cases (58 %). 
ix): Extrapyramidal signs 
Extrapyramidal signs were only noted in 3 cases (7 %). 
x): Movement Disorders 
Myoclonus was noted in 33 patients (77 %) but other movement disorders were also 
prominent. Choreaform and dystonic movements were noted in 29 of the cases 
(68 %). In 5 cases (12 %) chorea or dystonia was present in the absence of 
myoclonus. 
xi): Eye movements 
Twenty cases (47 %) had abnormal eye movements: in 2 of these cases, pursuit was 
noted to be jerky but the others had a reduction in up gaze, there was a suggestion of 
this in one other patient. 
xii): Cortical Blindness 
Cortical blindness was noted in only one case (2 %). 
xiii): Akinetic Mutism 
Twelve cases (28 %) went on to develop akinetic mutism and another cases was 
noted to be mute. However, no note was made of immobility. 
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Table 8.44: VARIANT CJD: OTHER SIGNS 
Sign N= % 
Cerebellar 41 95 
Pyramidal 37 86 
Myoclonus 33 77 
Movement disorder 29 68 
Extrapyramidal 3 7 
Eye movement 20 47 
Cortical blindness 1 2 
Akinetic mutism 12 28 
Swallowing 19 44 
xiv): Swallowing problems 
Abnormal swallowing was noted in 19 cases (44 %) and at least 9 patients were fed 
by a nasogastric tube or by PEG feeding (21 %). In 1 further patient a PEG was sited 
but could not be tolerated and was removed. The median duration of illness of cases 
who were NG or PEG fed was 18 months (range 11 -39 months). In comparison, the 
cases in whom we have no information (it is likely that some of these cases were NG 




All cases had at least one EEG performed during their illness. The EEG was not 
diagnostic in any cases of vCJD. In 2 of the 43 cases it was reported as normal. In 39 
cases it was described as non -specific. Two cases had an EEG that could be regarded 
as suggestive of CJD by our criteria, i.e. there were triphasic complexes but these 
were not sustained or truly periodic. The EEG was performed a median of 9 months 
(range 2 -24 months) into the illness of median duration 14 months (7 -39). The final 
EEG record was used if more than one EEG was performed. 
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ii): CSF Analysis 
The basic CSF glucose, protein and cell count was considered normal or non- 
specifically abnormal in all cases. The value of CSF protein was missing in 3 cases 
and reported normal in 3 cases but there is no record of the exact value. In the 
remaining cases protein ranged from 0.09 to 1.61 mg /L (with 119 red cells). In 8 
cases the protein was greater than 0.6 mg /L. In 6 cases the white cell count is 
reported as "normal ". The result was missing in 5 other cases and in the remainder 
there were less than 5 white cells. 
14 -3 -3 was analysed in 33 cases. In 15 cases the result was negative (45 %) and it 
was positive in 13 cases (30 %). One result was positive but heavily bloodstained. 
The remaining 4 cases were analysed twice. In 2 cases the first analysis showed a 
trace and the second result was positive. In one case the result showed a trace the 
first time and the second was negative. The final case was negative in both analyses. 
This gives an overall positive value in 15 cases (45 %). 
The level of S -100b was analysed in 29 cases. A level greater than 0.381.1g /L is 
considered abnormal. The result was normal in 3 cases, all of whom had a negative 
14 -3 -3 result. The result was raised in the remaining 24 (83 %), ranging from 0.41 to 
2.71 µg /L. In 13 of these cases the 14 -3 -3 was also positive. Two cases were tested 
twice. In 1 case the 14 -3 -3 was negative on both analyses but the S -100b was 
0.25µg /L and 0.84µg /L. In the second case the 14 -3 -3 result was trace then positive 
and the S -100b was 0.41 then 0.69µg /L. 
Looking at only the results analysed once, the positive 14 -3 -3 results were associated 
with a mean S -100b of 1.46µg /L. The negative 14 -3 -3 results associated with an 
abnormal 14 -3 -3 were in general lower with an average result of 0.88µg /L. 
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iii): MRI 
All 43 cases had an MRI of the head performed during their illness. In 33 cases 
(77 %) significant high signal was present in the pulvinar area of the thalamus and 
the scan would be regarded as positive. Three of the cases (7 %) had a negative scan. 
A further case had high signal in the pulvinar but also in the putamen and caudate. 
Two other cases were reported as equivocal (5 %). The scans were performed a 
median of 9 months, range 2 -24 months into the illness. 
More than 1 scan was performed in 10 cases. In 5 the first scan was positive. In 1 
case both were negative and in another both were equivocal. In 2 the second scan 
was positive. In these cases, the first scan (negative). was performed at 2 and 6 
months and the second scan (positive) was performed at 7 and 8 months. Finally one 
case had a positive first scan. The second scan was also probably positive but was 
technically difficult to interpret. 
Of the 39 scans reviewed by the NCJDSU, 85% were definitely positive. The MRI 
was not seen by the NCJDSU in 4 cases. Of these, 2 were reported normal, 1 was 
reported positive and there is no report available for the final scan. The 2 that were 
reported normal were performed and reported on prior to the publication of the MRI 
findings in vCJD. It is possible that in retrospect these scans would be considered 
positive. 
Table 8.44: VARIANT CJD: INVESTIGATIONS 
Investigation N= % 
Typical EEG 0/43 0 
Positive 14 -3 -3 15/33 45 
MRI positive 33/39 85 
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G: PATHOLOGY 
To date the pathological findings in all the cases of vCJD have been remarkably 
consistent. Tissue blocks or the whole brain parts thereof were available for analysis 
in all cases. Significant cortical atrophy was seen in 4 cases, all of whom had a long 
duration of illness (25, 29, 33 and 39 months). Mild to moderate cerebellar atrophy 
was seen in 11 cases. (The cerebellum was not available in all cases). An incidental 
cavernous angioma was found in 1 case. 
i): Histopathology 
Mild to moderate spongiform change was seen throughout the cortex in all but 1 
case, in whom there was status spongiosis. The changes were patchy but in areas of 
severe change there was neuronal loss and gliosis. The occipital cortex was the area 
of the cortex most affected in 20 cases, along with the frontal cortex in 2 cases, the 
temporal cortex in 1 case and the parietal cortex in 1 case. In 1 other case the fronto- 
parietal cortex was the worst affected. In general the hippocampus was rarely 
involved. 
The basal ganglia were the area of most severe spongiform change, in particular the 
caudate nucleus and putamen. This was often accompanied by marked neuronal loss 
and gliosis. In the thalamus there was severe neuronal loss and gliosis, often with 
only mild spongiform change, although the spongiform change was marked in 9 
cases. In 3 cases there was also marked neuronal loss and gliosis in the 
hypothalamus. 
In 12 cases there was mild spongiform change in the brainstem, in 1 case associated 
with marked neuronal loss and gliosis. Five other cases had marked neuronal loss 
and gliosis in the brainstem. The cerebellum was involved to varying degrees, again 
with associated neuronal loss and gliosis. 
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ii): Immunocytochemistry 
The most striking feature in all the vCJD cases was the widespread deposition of 
florid plaques. These were present throughout the cortex and deep grey matter and 
also in the cerebellum. Plaques were particularly concentrated in the basal ganglia. 
More plaques were demonstrated on PrP immunohistochemical staining. 
In addition there was widespread staining, usually pericellular and perivascular in 
the cortex and cerebellum. The staining was more linear in the basal ganglia, 
sometimes with a synaptic and perineuronal picture. 
H: NCJDSU CLASSIFICATION 
Thirty-two cases (74 %) fulfilled criteria for probable vCJD during life. 
Eight cases were considered possible; in these cases we were unable to view the scan 
in 2 cases, 2 patients had an equivocal scan and 3 had a negative scan. 
Three cases were classified "CJD unlikely ". In 2 there was insufficient information 
to be sure of cerebellar and sensory signs and symptoms and in I there were 
insufficient data to be sure of a psychiatric onset and there were no persistent 
sensory symptoms. Two of these cases had a positive scan. 
I: GROUP B CLASSIFICATION 
All cases of vCJD have been classified type 4 by Group B. I have therefore not 
compared the results. 
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SUMMARY OF VARIANT CJD CASES 
The variant cases have a relatively distinct clinical and pathological 
phenotype. 
This is fairly consistent in all cases. 
Cases tend to be of younger onset and of longer illness duration. 
Psychiatric symptoms are prominent at the onset. 
Sensory symptoms, usually painful and persistent are also common. 
The terminal stages of the illness are similar to sporadic CJD. 
The EEG is usually non -specific. 
14 -3 -3 protein supports a diagnosis of CJD but does not distinguish from the 
sporadic form of the disease. 
The pulvinar sign on MRI is highly specific and sensitive in variant CJD. 
The pathological changes are distinct from sporadic CJD. 
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9.1: INTRODUCTION 
The clinical and pathological features of sporadic CJD have been well described for 
many years. Most cases follow a typical clinical course and have characteristic 
pathology, however unusual cases are well described. In 1996 a new variant of CJD 
was reported, subsequently linked to BSE.10° Recently, analysis of the genotype and 
protein isotype in cases of THE has suggested a molecular basis for phenotypic 
changes seen in cases of this TSE. This study was extended to human spongiform 
encephalopathies and it has been suggested that the codon 129 genotype and protein 
isotype are responsible for the phenotypic variation seen in cases of CJD.399 It has 
also been suggested that the protein isotype is a surrogate marker of agent strain, and 
that the different phenotypes seen in sporadic CJD are due to different strains of the 
agent. To date, only one protein isotype has been identified in vCJD, associated with 
a reasonably consistent clinical course and pathology. This supports the theory that 
this may be due to a single, different strain of prion agent. However, an alternative 
UK study has categorised the protein isotypes differently and has suggested further 
molecular variation and further evaluation of the methodology and typing of protein 
isotyping is required.- 
Two large European studies have noted trends in six genotype and protein isotype 
groups related to variations in age at onset, duration of illness, clinical features, 
investigation results and pathology in sporadic CJD, familial and iatrogenic 
CJD.399'455 The data from these studies were pooled from North American and 
European monitoring data. Few of these countries have a dedicated surveillance 
system and it is unlikely that many of the cases were seen in life. No information 
was given about the source of data. In addition it is not stated how investigation 
results were obtained and if they were reviewed again for the purposes of the study. 
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This study extends the analysis of the genetic and protein isotypic influence on cases 
of sporadic CJD seen by the UK surveillance system. Cases date back to 1990 when 
surveillance began at the NCJDSU, and also includes several retrospective cases 
from an Oxford based study prior to this date, and retrospective cases from the 
intervening years. I have reviewed all the records available at the NCJDSU in each 
case. In as many cases as possible this includes records of a detailed interview with 
relatives or the patient and detailed examination of the patient performed by a 
dedicated NCJDSU registrar. In about a third of cases this is myself. In addition I 
have reviewed and reclassified as many EEG records as possible and I have obtained 
the original MRIs and reviewed them with a neuroradiological colleague. It is 
believed that the data in this study is as complete as possible for such a rare disease. 
In the following sections the discussion aims to: 
9.2 Highlight the problems of surveillance of CJD and the problems encountered 
in this study 
9.3 Look for trends in the 6 groups to support a relationship between the 
clinico- pathological phenotype and protein isotype and genotype. The results 
of this study are compared to an amalgamation of data from previous studies. 
9.4 Look at analysis of genotype or isotype only 
9.5 Compare with analysis by Group B 
9.6 Discuss the variant CJD cases and the differences compared to 
atypical sporadic CJD cases. 
9.7 Discuss the basis for protein isotype as a surrogate marker of strain variation 
9.8 Discuss future possible research 
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9.2: PROBLEMS 
A: DATA COLLECTION 
This study uses data collected on over 10 years of UK surveillance of cases of CJD. 
Some cases predate this: 3 cases originate from the Oxford study and 5 cases are 
retrospective cases from the intervening years. A member of the NCJDSU saw the 
majority of cases in life. 
In a population of 56 million people approximately 50 to 60 cases of sporadic CJD 
would be expected each year. This means that the number of cases for analysis of 
such a rare disease is relatively small. Additionally a proportion would not have a 
post mortem, or permission would be given for only a limited autopsy and not 
further research. This means that brain tissue would not be available for protein 
isotyping in all cases referred to the NCJDSU, further reducing the number of cases 
available for review. It is conceivable that some atypical cases have died and not had 
an autopsy; potentially skewing the data towards "typical" sporadic CJD although 
look -back studies have suggested this is unlikely to be the case.125.126 
Clinical information was available in most cases from interview with relatives, case 
notes and the CJD registrar visit. However, for various reasons, not all of the cases 
were willing to be seen or would have relatives who were prepared to be 
interviewed. Case notes were not always easily obtainable. Of the 99 sporadic cases 
in this study, 16% of patients were not seen or examined by a member of the 
NCJDSU, 8% of relatives were not interviewed and in 32% there were no case notes 
available for review. Case notes were normally photocopied at the time of the 
NCJDSU registrar visit; information on subsequent clinical course was rarely 
available, as the notes were not requested again after death. 
B: ASSESSMENT OF SYMPTOMS AND SIGNS 
One of the difficulties inherent in a surveillance system for CJD is making an exact 
assessment of the presence or absence of any symptom or sign and the timing of it. 
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Many of the observations on any particular variable were made at the time of a visit 
by the CJD registrar. Following the visit, the NCJDSU team did not see the patient 
again and there was often little communication, if any, with the hospital staff looking 
after each individual. It is therefore possible that symptoms or signs that were absent 
at the time of the visit developed later in the disease. 
Often the history related to events before being seen by a doctor, and so the onset 
and presence of symptoms and signs was difficult to define. Many of the patients 
were cognitively impaired by the time they were seen and so were not usually 
reliable historians. For this reason the history was normally obtained from the case 
notes and a relative, who may not have lived with the patient, or have been around 
for some of the illness. In the cases not seen in life by the NCJDSU there may only 
be a history available from a relative. In some cases the interview was conducted 
months, if not years, after the death of the relative and so the accuracy of the history 
was further potentially decreased. 
For example, a relative may have stated that the patient was unsteady for about 2 
months prior to admission to hospital. The accuracy of timing the onset of this was 
often rather vague, influencing the duration of the illness. Also, unsteadiness may be 
due to cerebellar, extrapyramidal, apraxic or other problems, making it difficult to be 
sure of the signs at onset. In such a case there could be uncertainty about whether a 
case was truly a Brownell- Oppenheimer variant (i.e. presenting with progressive 
cerebellar ataxia). 
The onset of psychiatric and cognitive problems in vCJD cases was particularly 
difficult to define. For example, in one case a student was living away from home at 
the onset of their illness and the history from a member of the family was deduced 
from telephone conversations with the patient. In another case, the family denied any 
cognitive problems in their son but it later became evident that he had failed exams 
he was expected to pass at a time when the family believed there were no cognitive 
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problems at all. For cases that were not seen in life there was often even less 
information. 
For these reasons, the timing of the illness onset and development of symptoms and 
signs was at times inaccurate and a "best guess ". Additionally, the frequency of the 
various symptoms and signs was probably underestimated in the study, often being 
classified "don't know" if there was doubt about their presence. In view of the fact 
that as many as possible cases were seen in life in this study, and the registrar had as 
long as they wanted to interview the patient or their family, unlike in a busy clinical 
setting, it is difficult to see how more accurate information could be obtained. 
It is possible that some of the symptoms and signs looked at were more susceptible 
to bias than others, potentially biasing the results. Signs such as akinetic mutism, 
which appear late in the illness, may not have developed by the time of the NCJDSU 
visit and information about their development after the visit may be absent. 
Additionally, once a diagnosis of CJD is reached there may be a tendency to 
examine a patient less, in order not to cause unnecessary stress, meaning that signs 
appearing late in the illness are likely to be under -estimated. 
Allowing for the above difficulties in categorising data, age of onset and duration of 
illness are easily measurable. Previous studies have consistently suggested a 
relationship with the genotype and protein isotype. Clearly there are other possible 
reasons for this. The duration of illness could be influenced by other factors, such as 
whether supportive feeding was used, if infections were treated or if other underlying 
diseases or conditions were present. 
As sporadic CJD progresses the diagnosis often becomes more obvious; there are not 
many conditions affecting the nervous system associated with such relentless 
progression, involving so many areas of the brain, in the presence of a normal scan 
and basic CSF analysis. After some weeks or months the EEG has often evolved, or 
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14 -3 -3 protein may have been looked for, suggesting a diagnosis of CJD. The 
presentation of sporadic CJD is therefore of greater importance, both in establishing 
a diagnosis early, and in trying to differentiate the condition from other more 
treatable diseases. For this reason the onset of the disease was assessed in each case. 
In addition, for the reasons stated above, the first symptoms in the illness might be 
the most accurately reported and recorded in comparison to the development and 
timing of later features of the illness. 
Finally, it is possible the first symptoms might be of particular importance as they 
may be indicative of the site of the onset of pathological changes within the brain. 
This in turn might influence the progression of the disease other changes such as the 
duration of illness. If the disease process starts in the brainstem, it is possible that 
death will occur earlier as this site might be subject to more degeneration. 
If possible a decision was made if the onset of disease was "purely dementing ", 
"purely cerebellar ", as in the Brownell- Oppenheimer variant, or a "purely visual" 
onset leading to cortical blindness, suggesting the Heidenhain variant. The presence 
of other symptoms and signs at onset and during the course of the illness were 
recorded and these criteria have also been examined in the other studies of protein 
isotype, (possibly with less emphasis on the onset of illness). However, for the 
reasons listed above, many of the signs seemed to be present in most cases and more 
importantly, the absence of a particular sign cannot be taken to mean it was 
definitely absent. There may have been an omission in the recording of its presence 
or absence, or it may have appeared subsequent to the registrar visit. 
C: AMALGAMATION OF DATA FROM OTHER STUDIES 
The data from the Parchi studies were pooled from European and North American 
surveillance. Each country has its own methods of surveillance and not all countries 
visit the cases and examine the patients themselves, relying on information from case 
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notes. For this reason, it is possible the data from these studies may also have 
problems in the timing of symptoms and interpreting comments made in clinical 
notes. It is possible that the data in the UK study is more accurate as in the majority 
of cases the patient was interviewed and examined for the purposes of the ongoing 
study. In addition the EEG and MRI were reviewed personally in all the cases in 
which records and scan were available. Parchi et al. do not state whether they 
reviewed all records themselves but if not, this is another area for potential error. 
It was not possible to combine the data on age at onset and duration of illness, as it 
was not clear whether the values in the paper were a mean or median. In addition, 
the data from the smaller European studies were pooled from various countries, 
including the UK, and so some cases may have been included twice in the 
amalgamation of results in chapter 6. 
D: STATISTICAL ANALYSIS 
To further compound the analysis of data, there is one large group and 5 smaller 
groups. This makes any statistical analysis non -parametric and unreliable with large 
confidence intervals. This is particularly marked when comparing the MM -1 to VV- 
1 group; i.e. 54 cases and 3 cases respectively. Clearly, in a group of 3 cases, the 
presence or absence of any particular sign in all or any of the patients may well be 
due to chance. 
However, this may be the best we can do as the UK system, which has been set up to 
see all cases of sporadic (and latterly variant) CJD in the UK, had only 3 VV -1 cases 
in a 10 year time period. Surveillance would have to continue for possibly 20 -30 
years in order to obtain a statistically significant number of cases in each of the 
smaller groups. (Bearing in mind this is a new technique and it is hoped that more 
cases will be isotyped with time). Parchi et al encountered the same problems, with 
only 3 VV -1 cases in their 300 cases.399 
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E: ATYPICAL CASES 
It is likely that this study over represents atypical cases as there may be a bias 
towards protein isotyping of cases with unusual clinico- pathological phenotypes. 
These cases are likely to have been selected for further analysis because of unusual 
features of the disease, or indeed concerns over the type of CJD affecting the patient. 
In the young atypical cases there is often an underlying concern that the case is 
variant rather then sporadic CJD, again selecting them preferentially for protein 
isotyping. 
The cases that have been selected for PrP isotyping in this study will have been 
included because neuropathological material is available at the unit and permission 
has been given for autopsy by relatives. This may be a reflection of the degree of 
certainty of the diagnosis by the clinicians in charge of the patients care; i.e. atypical 
cases are less likely to be given a diagnosis of "probable CJD" during life and 
relatives and clinicians will be more inclined to proceed to autopsy to establish a 
cause of death. 
If a random selection of sporadic CJD cases were to undergo genotyping and protein 
isotyping, it is likely that a greater proportion than was seen in this study would be 
MM -1 cases and that the other groups have been overestimated. However, the case 
statistics were compared to the statistics of the NCJDSU data as a whole and were 
broadly similar in terms of age at onset and illness duration. 
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9.3: CLINICO- PATHOLOGICAL PHENOTYPE OF SPORADIC CJD 
A: CASE DATA 
99 cases of sporadic CJD were studied. 65% of the cases were Met homozygous, 
17% were heterozygous and 18% were Val homozygous. The percentage of 
heterozygotes and Val homozygotes is slightly higher than that seen in some studies 
and is probably a reflection of the selection of atypical cases for isotyping. There are 
12 cases included in whom there was no genetic sequencing to exclude hereditary 
CJD. There was no family history of dementia in any of the cases and the clinico- 
pathological phenotype was not suggestive of hereditary CJD, but an inherited form 
of the disease has not been definitively excluded. 
Nearly two thirds of the cases were isotype 1 and the remainder was type 2A. This is 
similar to the distribution seen in other studies. This implies that the case distribution 
in Parchi's and this study is similar and so the differences seen may be related to 
methodology. When the cases were further distributed according to genotype and 
isotype the distribution was again similar to that seen in previously published 
studies; the majority of cases fell into the MM -1 group (55%). As has been noted 
previously, very few of the type 1 cases are heterozygotes (5 %) or Val homozygotes 
(3 %), however, the type 2A group distributes fairly evenly between all 3 genotypes: 
10% were Met homozygotes, 12 % were heterozygotes and 15% were Val 
homozygotes. 
B: GENDER DISTRIBUTION 
The overall ratio of males to females was 0.8:1, similar to that seen in most 
epidemiological analyses of sporadic CJD. There was a slight excess of males in the 
Val homozygotes (1.25:1). The significance of this is uncertain, and did not achieve 
statistical significance. As there were only 3 VV -1 cases and 15 VV -2A cases it is 
likely to be due to chance. 
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C: AGE AT ONSET 
The age of onset has been related to genotype in various studies. Recent analysis of 
protein isotype with genotype has also suggested a relationship. There was a wide 
range of ages in each of the 6 groups, and so the data overlapped considerably. The 
MM -1, MV -2A and VV -2A groups had a median age of onset of 64, 64, and 66 
years respectively. This would fall within expected limits. However, both the VV -1 
and MM -2A groups had a younger median age of onset (41 years and 54 years 
respectively) and both these results achieved statistical significance. In contrast, the 
MV -1 cases had an older median age of onset of illness, 75 years. This figure is 
skewed somewhat by one very young case, whose age of onset was 15 years, the 
remaining cases developed the first signs of illness at 61, 75, 78 and 79 years. 
Although it was not clear if the data were mean or median values in Parchi's study,399 
they also showed a younger age of onset in the MM -2 group (58.3 years) and the 
VV -1 group (39.3 years), in whom it was statistically significant. However, the age 
of onset of MV -1 cases was 62.1 years, slightly younger than expected (in contrast to 
this study where the cases were older). 
When the Zerr 455 and Parchi399 studies are combined with the isolated case reports 
and the age at onset in this study, the majority of cases fall into the late 50s, early 
60s age group. Only the VV -1 cases stand out as being significantly younger than 
would be expected. (See Table 9.1) 
Because of the wide age range within each group, it seemed reasonable to look at 
how many young cases there were. A younger age of onset is often associated with 
an atypical phenotype of sporadic CJD; only 3 of the MM -1 cases were aged less 
than 50 years. There were also 3 of the MM -2A cases less than 50 years, 1 each of 
the MV -1, MV -2A and VV -2A groups and 2 of the VV -1 group. These cases will be 
discussed later in more detail. 
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Table 9.1: AGE AT ONSET OF CASES 
DISCUSSION 
Parchi et al N Zerr et al N Isolated 
cases 
N This study N 
MM -1 65.5 203 68 70 67 10 64 54 
MM -2A 58.3 12 63 3 54 10 
MV -1 62.1 8 63 8 66 1 75 5 
MV -2A 59.4 27 62 10 68 1 64 12 
VV -1 39.3 3 27 2 49 1 41 3 
VV -2A 61.3 47 62 15 65 3 66 15 
NB: Parchi data not clear if median or mean. All other data is a median value. 
D: DURATION OF ILLNESS 
One of the characteristic features of sporadic CJD is the relentless progression of 
disease and the short duration of illness. As with the age of onset, one of the most 
consistent findings in relation to genotype and, latterly, protein isotype, is that the 
more unusual genotype/ isotype cases have a longer duration of illness. (See Table 
9.2) 
In this study a shorter median duration of illness was seen in the MM -1 cases (3 
months) and the MV -1 cases and VV -2A cases (both 5 months). In contrast the MV- 
2A and VV -1 cases were of 11 months duration and the MM -2A cases were of 
median 14 months duration. Once again there was a large overlap when the range of 
values was analysed in each group, making the statistical significance of these 
findings difficult to quantify. 
This trend was also seen in the Parchi399 and Zerr4" studies, the MM -1, MV -1 and 
VV -2A cases seem to have a more characteristic short duration of illness. One 
isolated report of an MV -1 case had a rather longer than expected illness duration of 
12 months. It is interesting to note that the median duration of illness was generally 
considerably longer in other studies compared to that seen in this study. The reason 
for this is unclear. 
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Table 9.2: DURATION OF ILLNESS 
DISCUSSION 
Parchi et al N Zerr et al N Isolated 
cases 
N This study N 
MM -1 3.9 203 5.2 70 7 10 3 54 
MM -2A 15.7 12 14 3 14 10 
MV -1 4.9 8 3.4 8 12 1 5 5 
MV -2A 17.1 27 17.4 10 29 1 11 12 
VV -1 15.3 3 25.5 2 15 1 11 3 
VV -2A 6.5 47 7.5 15 9 3 5 15 
NB: Parchi data not clear if median or mean 
All other data is a median value. 
When the data were subdivided into the number of cases of duration of illness of less 
than 6 months this trend was reinforced. 60% of MV -1 cases, 80% of VV -2A cases 
and 87% of MM -1 cases had an illness of duration less than 6 months and almost all 
the cases in each group were of less than 1 year duration (80 %, 100% and 94% 
respectively). In contrast 50% of each of the MM -2A and MV -2A groups and 67% 
of the VV -1 groups were of duration greater than 1 year. Only 1 MV -2A case and no 
MM -2A or VV -I cases were of less than 6 months duration. 
This may reflect a true genotype/ isotype influence but the data are likely to be 
biased by a number of factors: It is possible that the cases of longer duration had 
naso- gastric (NG) or parenteral gastrostomy (PEG) feeding. Unfortunately 
information about NG or PEG feeding was unavailable in most cases. Recent 
questionnaires comment on the presence of an NG tube or PEG however, some cases 
are ambulant with an intact gag reflex when they are visited by a member of the 
NCJDSU. They may survive for many months after a visit and artificial feeding may 
have been introduced later in the illness. This information may not necessarily reach 
the NCJDSU. Of course, this does not exclude the possibility that PEG feeding 
might be commenced because the patient survives for longer 
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From personal observation, it seemed that some cases who had a longer duration of 
illness were fed artificially, but there was only information about 1 1 cases in this 
study. Only 55% of these were of illness duration greater than 6 months. Of these, 9 
were in the MM -1 group who had the shortest overall median duration of illness (3 
months). The median duration in the cases who were artificially fed was 5 months 
(range 2 -17 months). However, only 3 of the MM -1 cases were of greater than I 
years illness duration and 2 of these cases were NG fed. Similarly, the only MV -1 
case whose duration was greater than 1 year was also NG fed. In contrast, 3 of the 
VV -2A cases were of illness duration greater than 6 months (7, 11 and 11 months). 
None of these cases were NG fed as far as we know. One VV -2A case was NG fed, 
of duration 6 months. (The median duration of the group as a whole was 5 months.) 
It may also be that younger cases are more likely to be artificially fed for more 
emotive reasons. Families sometimes find it more difficult to let a younger relative 
die and may wish to keep them alive in the hope of a recovery or a cure. Sometimes 
relatives feel that an older person has had an opportunity to live their life, or may not 
wish to see them continue any longer in a state of akinetic mutism. However, of the 
11 cases in whom there is information about NG feeding, only 2 were less than 60 
years. One was 15 years old and one was 54 years. The median age of onset of all 
the 11 cases was 64 years. 
It is also possible that younger cases live for longer irrespective of supportive 
measures such as artificial feeding. They may have a greater capacity to fight 
infection, the terminal event in many cases of sporadic CJD. Or a decision may be 
made to treat infection in a younger person whereas in an older person treatment 
may be withheld for the same reasons given above. There is no information about 
whether infection was treated or not in the majority of cases. 
Another possibility is that younger patients may have a greater "brain reserve" so 
that they can survive a progressive neurodegenerative process for longer. Initial 
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analysis of the data had suggested a significant correlation between duration of 
illness and age of onset but only 6 cases were of duration greater than 2 years, 
making any interpretation of these data difficult. (Although all but one case was aged 
less than 60 years.) Overall, 70% of cases that had an illness of duration less than 2 
years, were over 60 years. When the MM -1 cases alone were analysed for an 
association between age at onset and illness duration, none was found. The other 
groups are too small to look for a trend. 
E: SYMPTOMS AND SIGNS 
i): Onset 
The symptoms at onset were felt to be very important in the analysis of clinical 
phenotype. Firstly, information about the onset of the illness was probably the most 
accurate in interviews with relatives. The timing of the development of pyramidal 
signs was very difficult in a patient who already had marked dementia and was bed - 
bound, but their first symptom, be it visual upset, cognitive impairment or anything 
else was often well remembered and clearly marked in case notes. 
Secondly, the onset of the illness might give some important information about 
where the pathological process began. This might be related to the strain of the agent 
or might be due to other factors, not yet known. The Brownell- Oppenheimer and 
Heidenhain variants are historically well recognised and should be recognizable 
from the case history. Establishing that each phenotype is related to a different 
protein isotype would support the working hypothesis of this study. 
Dementia, classically "rapidly progressive ", is one of the defining characteristics of 
sporadic CJD. 6 cases had a duration of illness of greater than 2 years and so were 
excluded as possible cases because of the strict diagnostic criteria. However, these 
cases still had a rapidly progressive dementia, deteriorating significantly in function 
in less than a 1 year period. 
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One of the MM -1 cases did not clearly have a dementing illness and so was 
classified "don't know ". 41 cases (41 %) presented with purely dementing symptoms, 
the majority of these were MM -1 cases (43% of this group). All of the VV -1 cases 
and 80% of the MM -2A cases presented with dementia as the only clinical feature. 
This latter result achieved statistical significance, although the group is small, 
casting doubt on the significance of this. 
A purely cerebellar onset was only seen in the MM -1, MV -2A and VV -2A groups, 
14 cases (14 %) in all. Again the figures are small but a third of the MV -2A group (4 
cases) presented with this onset and a fifth of the VV -2A group (3 cases) had purely 
cerebellar symptoms at onset. 13% (7 cases) in the MM -1 group presented with only 
cerebellar symptoms and signs. 
Perhaps more significant, a purely visual onset was seen in only 11 cases (11 %) and 
all of these apart from 1 case were MM -1 cases (19% of this group). One VV -2A 
case also presented with purely visual symptoms. They complained of diplopia from 
the onset, progressing to complaints of visual blurring. However, another VV -2A 
case complained of diplopia at onset. The second case did not complain of loss of or 
deterioration of vision however, although, like the first case they complained of 
dizziness and were seen to be poorly co- coordinated. Both developed cortical 
blindness. 
This illustrates the difficulties in classification. The first VV -2A case would be 
considered to be a Heidenhain variant. It is less clear in the second case: Patients 
sometimes describe a blurring of vision as double vision. Dizziness (not vertigo) and 
poor coordination can be seen if the vision is poor, but can also be seen in cerebellar 
problems. Therefore this case could not be definitely classified as a Heidenhain 
variant. This is unfortunate, as a second Heidenhain variant in the VV -2A group 
would make an association of this presentation with the MM -1 group less significant. 
211 
CHAPTER 9 DISCUSSION 
In the MM -1 cases it was difficult to establish if these cases presented with cortical 
blindness (i.e. classical Heidenhain variant). They usually presented with visual 
symptoms first and at least one case had cataract surgery before other dementing 
features became apparent and a diagnosis of sporadic CJD was made. All but 3 of 
these cases were noted to develop cortical blindness in the course of their illness. 
Once again, failure to note the presence of cortical blindness does not necessarily 
mean it was absent. 
One of the hypotheses relating to genotype and protein isotype, and the clinico- 
pathological phenotype of sporadic CJD, was that the well- described variants of the 
illness might relate to the different subgroups. However, a purely dementing onset 
was seen in some cases from each group. Similarly, the Brownell -Oppenheimer 
variant was seen in the MM -1, MV -2A and VV -2A groups. Finally, the Heidenhain 
variant was seen in only the MM -1 cases and 1 or possibly 2 VV -2A cases. This 
would require analysis of future cases to assess if this is a chance result. 
Parchi et al.399 also analysed the clinical signs at onset, although they did not analyse 
the strict definition of a sole presentation used in this study. They noted that 
cognitive impairment was invariably present in both VV -1 and MM -2 cortical cases, 
but was absent in most VV -2 cases. This study also identified dementing features at 
onset in 90% of the MM -2A cases and 100% of the VV -1 cases. However, 54% of 
the MM -1 cases, 20% of MV -1 cases and 50% of MV -2A cases all had dementing 
symptoms from the onset of the illness as well as 47% of the VV -2A cases. 
They also noted ataxia was common in the VV -2A and MV -2A cases, but lacking in 
the VV -1 and MM -2 cortical groups. We also found similar trends, although less 
marked; 60% of MV -2A cases and 33% of VV -2A cases had cerebellar signs as one 
of the symptoms at onset, in contrast to 81% and 100% of the Parchi cases. They 
noted visual signs only in 26% of MM -1 cases and 12% of MV -1 cases, in contrast 
to the findings of this study. 
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A stroke -like onset has been described in some cases of sporadic CJD. In this group 
it was seen in 3 cases, all MM -1. A prodrome was seen in less than one third of cases 
in each group except for the MV -1 cases in whom 3 cases (60 %) had a prodrome. 
Dizziness was seen in the MM -1 group (26 %) and the MV -1 group (20 %). However 
47% of the VV -2A group experienced dizziness. This may be a reflection of the 
preponderance of cerebellar symptoms in this group. All the cases who complained 
of dizziness developed cerebellar problems. A disturbance of hearing was unusual 
and occurred rarely in the MM -1, MV -2A and VV -2A groups. 
Alien limb was also looked for because it has been described as a presenting 
symptom of sporadic CJD, however this was not seen as a presenting symptom in 
any of the cases in this series. Indeed, it was only seen in 3 cases in total. 
ii): Clinical Symptoms and Signs During Evolution 
Dementia 
If each symptom is considered in turn, dementia appeared early on in the majority of 
cases but half of the MV -2A cases and 40% of the VV -2A cases did not develop 
dementia until some months into the illness. Unlike the Parchi study,399 dementia 
was a feature of the illness in all cases apart from one MM -1 case, in whom there 
was insufficient information to he sure. In addition it usually appeared early on in the 
illness. Parchi et aí.399 noted dementia was mild and late in the VV -2A group. This 
was not seen in this study. 
Cerebellar problems 
Cerebellar symptoms and signs were noted in nearly two thirds of cases. They 
occurred early on in 60% of the VV -2A cases and 83% of the MV -2A cases and 
41% of the MM -1 group. It is possible that the former 2 groups tend to present 
earlier with cerebellar signs. If the presence of cerebellar signs and symptoms alone 
is looked at, 92% of the MV -2A group and 79% of the VV -2A group had these 
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problems. They were also present in 63% of the MM -1 group and 60% of the MV -1 
group. However less than a third (30 %) of the MM -2A group and none of the VV -1 
group had cerebellar problems. The figures could easily be skewed by the large 
number of cases in which there was no note made of cerebellar problems (14 %) or in 
whom there was insufficient evidence to be sure whether problems with gait were 
due to disturbance of the cerebellar system (23 %). 
Parchi et aL399 also found that the VV -2A and MV -2A cases were the most 
frequently affected by cerebellar symptoms and signs. In addition, they noted the 
lower frequency in the VV -1 cases. They found that the MM -2 cortical cases rarely 
had cerebellar signs but the MM -2 thalamic cases did. As will be discussed later, the 
thalamic/ cortical distinction was less apparent in this study, however, cerebellar 
problems were present in only 30% of MM -2A cases. 
Visual problems 
There was a similar problem with lack of information about visual problems. 
Probably because the cases were often not seen until they were severely demented 
and bedbound, by which point it would not be possible to establish if cerebellar 
problems were present and it would be difficult for the patient to report visual 
problems. Cortical blindness may have developed following the visit, and may be 
difficult to assess in the later stages of the illness; and so there may be under- 
reporting of this sign. The presence of visual symptoms did not necessarily mean 
that cases went on to develop cortical blindness, although this may simply be an 
artifact of under -reporting of cortical blindness. In the majority of all cases (54 %) 
there is insufficient information to comment on the visual symptoms and indeed their 
presence was only noted in 46%. 
As stated earlier, a purely visual onset was seen in 19% of the MM -1 cases and in 
37% of this group visual symptoms appeared early on. In contrast a smaller number 
of other cases were noted to have visual problems, 40% of MM -2A, MV -1 and VV- 
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2A cases and 8% of MV -2A cases. These symptoms usually appeared early or 
midway into the illness. Visual symptoms were not noted in any of the VV -1 cases. 
Cortical blindness was only a feature of a small number of cases, from 8% of the 
MV -2A cases to 40% (i.e. 2 cases) of the MV -1 cases. This is likely to be due to 
under -reporting. 
Parchi et aí.399 did not comment on cortical blindness separately. They included 
visual loss, visual field defect, visual distortion, abnormal colour vision and cortical 
blindness in the one category. These symptoms were only noted in the MM -1 and 
MV -1 cases. 
Sensory Symptoms 
Sensory symptoms are of interest because of vCJD in which they are a prominent 
feature. It is possible that sensory symptoms are over represented in cases of 
sporadic CJD since the description of vCJD, because a member of the NCJDSU may 
ask more specifically about them. However many of the cases in this series occurred 
before vCJD was described in 1996, and so this is unlikely. In all, 14 cases 
complained of sensory symptoms. In 10 of these cases this was in the early stages of 
the disease. There was no particular preponderance of sensory symptoms in any of 
the groups, occurring in 13% of MM -1, 30% of MM -2A, 20% of MV -1, 8% of MV- 
2A and 14% of VV -2A cases. No VV -1 cases had a sensory complaint noted. 
The nature of the symptoms was similar to that seen in vCJD i.e. burning and 
tingling or coldness, perhaps suggestive of a thalamic origin. However it was not 
often clear from the records whether these symptoms were persistent or not. 
Hallucinations 
29% of all the sporadic cases had hallucinations. These were nearly always visual in 
nature. In the majority of cases they developed mid to late into the illness. 
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Hallucinations were not seen in the MV -1 and VV -1 cases. In contrast they were 
seen in 40% of the VV -2A and 58% of the MV -2A cases. 
Delusions 
Delusions were seen in a small number of cases, 8% of cases in total. Again no 
particular group was affected. The delusions tended to be persecutory and again did 
not appear until some months into the illness. 
Clinical signs 
It is more difficult to be definitive about clinical signs. As stated previously it is 
possible that patients developed certain signs after a member of the NCJDSU made a 
visit. In some cases many of the signs were classified "don't know" because there 
was insufficient information to be sure they were present, underestimating the 
incidence of each sign. For this reason it is impossible to make any statistical 
analysis of the results and it is possible to comment only on trends. 
Pyramidal signs were seen in over half of all cases. It is possible that there were 
fewer cases with pyramidal signs in the MV -2A group as only 17% had pyramidal 
signs. About a third of all cases had extrapyramidal signs. None of these were MV -1 
cases, and this may reflect a difference in this group. Lower motor signs are 
uncommon in sporadic CJD although historically they were believed to be present in 
an amyotrophic variant of the condition. In this series they were seen in only 5 cases 
(5 %). 
In general as any form of CJD progresses the disease tends to be associated with the 
development of hypertonia, (sometimes in the form of gegenhalten), hyper -reflexia 
and primitive reflexes, seen in this series in 73% of cases. These signs would not be 
particularly useful as discriminators between different forms of the disease or indeed 
between different subtypes of sporadic CJD. Nearly two thirds of cases went on to 
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develop akinetic mutism. Again this is probably under -estimated because cases may 
well have developed this sign after a member of the unit saw them. 
The type of movement disorder may also be helpful. Myoclonus is a feature of all 
forms of CJD and develops at some stage in the majority of cases. In this series it 
was seen in 87% of all the cases, usually in the late stages of the disease. Myoclonus 
was only seen early in the disease in a few cases, 1 of these was an MM -2A case and 
the remaining 6 (11%) were MM -1 cases. 
31% of this series experienced choreaform or dystonic movements. 43% of the MM- 
1 cases were affected but only 1 or 2 cases in the other groups apart from the VV -1 
group in which 2 cases (67 %) and the VV -2A group, in which 4 cases (27 %) were 
affected. There was often little information about the nature of the movement 
disorder in the case notes. 
Parchi et aí.399 noted that myoclonus was a prominent feature of the MM -1 and MV- 
1 cases but less so in the other groups. This was not noted in this study, in which 
over 75% of each group was noted to develop myoclonus. They also noted 
myoclonus appeared earlier in these 2 groups whereas in this study only a small 
proportion of the MM -1 and MM -2A cases developed myoclonus early on and in the 
other cases it tended to be noted later on in the illness. Like this series, pyramidal 
and extrapyramidal features were present in a percentage of each group and there 
were no remarkable trends. 
E: INVESTIGATIONS 
i): EEG 
A decision was made to include a highly suggestive or typical EEG in the criteria for 
"probable" sporadic CJD. This was for several reasons: From the perspective of 
clinical management, a highly suggestive EEG is often sufficient to support a 
diagnosis of sporadic CJD in the appropriate clinical setting. However, for the 
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purposes of epidemiological surveillance clearly strict criteria would have to be 
employed to ensure a diagnosis of "probable" CJD is as secure as possible. 
Secondly, the EEG classification differs from study to study in the literature, and is 
sometimes less strict than the criteria used for a "typical" EEG in this study. It 
therefore seems not unreasonable to include a "highly suggestive" EEG, as it would 
often be classified in the literature as sufficient to support a diagnosis of sporadic 
CJD. However, in all possible cases the EEG was reclassified personally and 
according to stated criteria, avoiding inter -individual variation. Retrospective 
analysis of the EEG in other studies has shown that the classification of the records 
was at times inaccurate. Since the advent of 14 -3 -3 protein it is conceivable that the 
EEG is studied more strictly as CSF analysis for brain specific proteins provides an 
alternative means of supporting a diagnosis. 
In this study a positive EEG was seen in 59% of MM -1 cases. 13 cases did not have 
an EEG result available, or I did not see it. If those cases are excluded, the EEG was 
positive in 78% of MM -1 cases. Only 1 other case had a highly suggestive EEG, an 
MV -1 case. No other group had a positive EEG. 
Parchi et al.399 found a positive EEG in 80% of MM -1 cases and 71.4% of MV -1 
cases. Zerr et al.455 had similar findings, with a positive EEG in 80% of MM -1 cases 
and 75% of MV -1 cases. They also identified 1 MM -2A case with a positive EEG. 
Neither study comments on the exact criteria used in the analysis of the EEG and 
both classify a positive test as showing positive sharp wave complexes on the EEG. 
One of the cases in the MV -1 group did not have an EEG result available. However, 
of the 3 other cases, 2 had a suggestive or non -specific EEG and one record was not 
seen by me but was reported as non -specific. It is unlikely that there has been under- 
reporting of the EEG result in this study. 
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One other consideration is the timing and repeating of EEGs. It is known that with 
serial recording of EEGs in sporadic CJD the record often becomes more typical 
with time. It is conceivable that in an atypical case of CJD the diagnosis would not 
be considered. If the first EEG was not suggestive then the test might not be 
repeated. Very few cases in this study had more than one EEG. To be sure that the 
"atypical groups" were not associated with a typical EEG, serial EEG recordings 
throughout the illness would have to be performed. 
ii): 14 -3 -3 PROTEIN 
14 -3 -3 protein has been used increasingly in recent years to support a diagnosis of 
sporadic CJD. Because the test has only been validated relatively recently, many of 
the cases in this study have not been analysed as they date back to before 14 -3 -3 
analysis was available. 
Less than a third of the cases were tested: The MM -1 cases were positive in 80% (15 
cases). The remaining 3 MM -1 cases that were tested had an equivocal result. 
Experience with 14 -3 -3 analysis of cases not included in this study, suggests that 
retesting cases later in the disease sometimes gives a positive result. The VV -2A 
cases were positive in 100% (7 cases tested). In the remaining groups there were 
only isolated results but only 1 MM -2A (25 %) and 1 MV -1 case (33 %) had a 
positive result. 
In contrast, Zerr et al. 455 found that all groups had a positive 14 -3 -3 analysis in 96 %- 
100% of cases, except the MV -2A group in whom 3/10 cases (30 %) were positive. 
They tested 107 cases, however like this study, the majority of cases tested were in 
the MM -1 and VV -2 groups. Parchi et aí.399 did not comment on the use of 14 -3 -3 
analysis. 
Analysis of S -100b showed that this protein was raised in all but 2 cases. The level 
of the protein was often raised despite a negative 14 -3 -3. Current opinion is that this 
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test is less specific however and a high S -100b level in the absence of a positive 14- 
3-3 result could not be taken to be supportive of a diagnosis of sporadic CJD. None 
of the other studies comment on the use of S -100b. Zerr et al.455 use NSE however 
we have also found this a less specific test at the NCJDSU, and no longer use it. 
iii): MRI 
Finally, high signal in the basal ganglia on MRI imaging has been reported in 79% 
of sporadic CJD cases.8 An MRI was available for review at the NCJDSU in 44 
cases (44 %). The scan was positive in 14 cases (32 %). Like 14 -3 -3 analysis, there 
are insufficient MRIs available in each group to make a useful statistical analysis. 
The scan was positive in 3 MV -2A cases (75 %) and 1 VV -1 case (50 %). Less than 
half of the cases in each of the other groups had a positive scan. 
Most of the scans were requested retrospectively. In many cases, several years after 
the imaging was performed, and several years before Finkenstaedt et al.8 published 
their findings on the use of MRI in sporadic CJD. Only 1 case was reported to have 
shown high signal in the basal ganglia by the hospital in which the patient was 
based. It is likely that there will be more positive reports now that MRI changes in 
sporadic CJD have been published and more modern scanning techniques are 
available, using different weightings. It is well recognised that different MRI 
machines can have vary in brightness in areas of the brain, and more modern 
machines may be more uniform. 
Zerr et al.455 reported the results of 43 scans (40% of the cases in their study). 70% 
of the scans were positive. Again many of the groups only had scans in 1 or 2 cases 
in each subgroup available for analysis. They were encouraged by the results 
because 2 MV -1 cases (100 %), 8 MV -2A cases (89 %) and 7 VV -2A cases (70 %) 
were positive. German surveillance has been in place since June 1993 and the timing 
of the MRI images is not clear; i.e. if most of the scans post -date Finkenstaedts' 
paper on the use of MRI in sporadic CJD.8 
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G: PATHOLOGY 
The pathological results for this study were extrapolated from pathological reports 
on each case. In the majority these were the reports issued by the NCJDSU, and each 
case had been examined by the NCJDSU, with 2 exceptions. However this was not a 
quantatative pathological study, unlike the Parchi study399 and the study by 
Macdonald et al.447 (who looked at genotype alone). The results are based only on 
comments about the distribution of spongiform change and other findings in a 
routine pathological report. 
Spongiform change was prominent in most cases. The occipital lobe was involved 
extensively in the MM -1 cases, although many of these cases did not have prominent 
occipital lobe symptoms such as cortical blindness. The frontal and occipital lobes 
seemed to be involved more in the MM -2A cases and the frontal, occipital and 
temporal lobes in the MV -1 cases. In the MV -2A cases and both VV groups the 
basal ganglia were the areas most affected by spongiform change. Only the 
heterozygotes had kuru -type plaques present prior to staining. 
There were exceptions however; In 2 MM -1 cases the changes in the basal ganglia 
were more marked than in the cortex. 1 of these cases had no extrapyramidal features 
but was noted to have dystonic movements of the mouth and limbs. The second case 
did not have evidence of any movement disorder although there was some 
gegenhalten on examination. The presentation in this case was of the Heidenhain 
variant. This case also had prominent changes in the thalamus, not seen in any of the 
other MM -1 cases. Sensory symptoms were not reported. 
There did not appear to be a relationship between the areas of more pronounced 
spongiform change and the presence of symptoms and signs: In the MV -2A group 
spongiform change was more marked in the basal ganglia than in the cortex in 9 
cases (75 %). Extrapyramidal signs were not more prominent in this group. In the 
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VV -2A cases spongiform change was again more marked in the basal ganglia and 
changes in the cerebellum were not prominent. However this group had prominent 
cerebellar features in many of the cases and again, extrapyramidal signs were not 
particularly prominent. 
Status spongiosis was seen in 7 cases, although other cases had areas of severe 
confluent spongiform change. This included 5 MM -1 cases, 1 MV -1 case and 1 VV- 
1 case. The duration of illness of these cases ranged from 1 -54 months. The MM -1 
cases were of 1, 4, 15, 17 and 17 month's duration. The VV -1 case was of 11 months 
duration and the MV -1 case was of 54 months duration. The median duration in the 
MM -1 cases with status spongiosis was 15 months, in comparison to an overall 
median duration in this group of 3 months. This suggests that status spongiosis is 
more likely to be seen in cases of long duration but can occur also in cases of short 
duration. An MRI was available for review in only 1 of these cases, in whom 
widespread severe atrophy was noted. 
Immunohistochemistry changes were attributable to the genotype and there was no 
real difference in the patterns seen between the 6 subgroups. The deposition pattern 
in each area of the brain seemed to reflect the degree of underlying spongiform 
change. The changes in the cortex and basal ganglia tended to be reticular and 
perivacuolar. In the cerebellum, the changes were reticular in the molecular layer 
and granular in the granular layer. The VV -2A cases had a more linear deposition 
pattern in the cortex. 
The MV cases seemed to be associated with the deposition of plaque -like material. 
In the MV -2A cases these seemed to be kuru -type plaques, whereas in the MV -1 
group the deposits weré more plaque -like. Plaque -like deposits were also seen in the 
VV -2A cases. Tissue was available in only two of the VV -1 cases, neither of whom 
had plaque -like deposits. 
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Rather surprisingly, a single MM -1 case had plaque -like deposits in the basal 
ganglia. They had a typical illness but did develop extrapyramidal rigidity and 
choreiform movements as the illness progressed. Three of the MM -2A cases also had 
some plaque -like deposits. These were deposited in the cerebellum in all cases. Two 
of these cases were not seen in life and CJD was considered unlikely, and there is not 
a great deal of clinical information available. All were unsteady during the illness 
and two were noted to have definite cerebellar signs. 
There were some cases with an unusual pathology. Three of the MM -2A cases were 
atypical: 1 case had pathological changes of the thalamic variant (see later). 1 case 
had unusual pathology in the occipital and temporal cortex. The clinical features of 
this case were a little unusual. The patient presented with confusion and demented 
over an illness of 17 months. Investigations were not supportive of a diagnosis of 
sporadic CJD. There were no thalamic features to the illness. She complained of 
visual upset after some months but was not noted to be cortically blind. 
Two cases had plaque -like PrP deposition suggestive of GSS, an MM -2A and an 
MV -2A case. Very little information is available on the MM -2A case but what is 
known suggests that the illness was predominantly of a progressive dementia. The 
patient had been treated with neuroleptic medication for many years. Dystonic 
movements were a prominent feature but it is not known if these movements were a 
side effect of medication. The MV -2A case had a prolonged illness, also with 
prominent dementia and few other signs noted. Investigations were not supportive of 
sporadic CJD. 
In addition one MM -1 case had the changes of the panencephalopathic variant 
reported initially although the changes were later reported to be of status spongiosis. 
(The duration of illness was 17 months.) Another was originally reported as 
Alzheimer's disease and sporadic CJD was not diagnosed until PrP 
immunohistochemistry was developed. In this case the clinical picture was 
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suggestive of sporadic CJD and the EEG was reviewed by myself and classified 
"typical ". The duration of illness was 5 months. 
Parchi et al.399 comment on the "thalamic variant" of sporadic CJD and state that 
these cases are a subgroup of the MM -2A cases. Half of their MM -2A cases fall into 
this category. One case was identified in the MM -2A group whose pathology was 
suggestive of the thalamic variant although the clinical picture was not entirely 
typical of this variant. In 4 of the MM -1 cases there was prominent gliosis and 
neuronal loss in the thalamus, in 2 of these this was the most prominent feature. 
f- lowever, spongiform change was seen in the cortex and so the pathology would not 
have been entirely consistent with SFI. The clinical picture was not suggestive of 
SFI in any of these cases. 
Overall, the changes identified by Parchi et al.399 are probably broadly similar in this 
study. However, they employed a quantitative approach. In contrast, the pathological 
findings in this study are observational only and so the two studies are not directly 
comparable. 
H: DIAGNOSTIC CRITERIA. 
i): Probable and Possible Cases 
The MM -1 cases are typical of sporadic CJD. This is reflected in the fact that 69% of 
this group would have been classified as probable cases of sporadic CJD during life. 
14 cases in this group were classified as possible cases. This means that clinically 
these cases were suggestive of sporadic CJD but diagnostic tests were not 
supportive. The EEG was not typical in any of the cases. Previous studies have 
shown that the EEG evolves during the illness and it is conceivable that the EEG 
may have become more typical if it had been repeated later in the disease, had it 
been available. Many of these cases were seen before 14 -3 -3 protein analysis was 
available. It is also possible that this result may have been positive. One case had an 
equivocal 14 -3 -3 result and subsequent experience suggests these cases become 
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positive when retested. Finally, one case had a positive MRI result, which may be of 
significance in the future. 
The other group to include a significant proportion of probable cases is the VV -2A 
group. Again, the clinical features of this group were suggestive of sporadic CJD but 
the EEG was unhelpful. Before the advent of 14 -3 -3 protein these cases would have 
achieved a classification of "possible" in life, however in all 7 cases tested, a 
positive 14 -3 -3 result elevated them to "probable cases ". Seven further cases were 
"possible" and so if 14 -3 -3 had been tested it is conceivable that they would also 
have been "probable cases ". (Zerr et al.455 also found this result was positive in 
100% (15 cases) tested.) 
ii): Possible cases 
Only 2 further cases were classified "probable" sporadic CJD, one MM -2A case and 
one MV -1 case. However, 70% of MM -2A cases, 60% of MV -1 cases and 75% of 
MV -2A cases were "possible ". This means that clinically all these cases were 
suggestive of sporadic CJD, despite the fact they were in the "atypical" groups. 
Clearly these cases would have been classified "probable" if the results of 
investigation had been supportive of a diagnosis. 
Of the 7 "possible" MM -2A cases all had an EEG performed but it was negative in 
each case. 3 had 14 -3 -3 protein assessed and all were negative, 4 had an MRI scan 
available for review and it was positive in 1 of these cases. This might suggest that 
even if all 3 investigations had been available in all 7 cases, the results may not have 
elevated the cases to a "probable" classification. 
In the MV -1 cases the EEG and MRI seemed to be generally unhelpful but 14 -3 -3 
was only analysed in one of the 3 possible cases. It showed a trace of positive 
protein; again with subsequent experience this may have been positive had it been 
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repeated. Hopefully, as 14 -3 -3 protein is used more widely, this may prove to be a 
helpful investigation in the MV -1 cases. 
In the MV -2A cases 9 were "possible" sporadic CJD. The EEG was unhelpful in all 
of these cases but 14 -3 -3 protein was not analysed in any of them and further 
information on the use of this investigation in the future may prove that it is of some 
use. In addition the MRI was positive in the 2 cases that were scanned and further 
analysis of the use of this investigation is indicated. 
Finally the VV -1 group consists of only 3 cases and although the NCJDSU registrar 
saw 2 of them in life, the clinical information available does not point to a particular 
pattern of illness. In the single "possible" case 14 -3 -3. protein and MRI were not 
performed and the EEG was not supportive. 
As suggested previously, it is likely atypical cases will have been particularly 
selected by the unit for analysis of the PrP isotype. This may reflect the relatively 
low number of "positive" investigations. These cases are less likely to have been 
considered "probable" sporadic CJD during life, prompting autopsy and PrP 
analysis. 
Parchi et al.399 suggested that the EEG was a useful investigation in the MM -1 and 
MV -1 groups. This study has only shown that it is helpful in the MM -1 group, 
although 1 MV -I case (20 %) also had a highly suggestive EEG. They do not 
comment on the use of 14 -3 -3 protein and MRI in sporadic CJD. 
However, Zerr et al.455 analysed the use of all 3 investigation in the various 
subgroups. They also found that the EEG was helpful in the MM -1 and MV -1 
groups. 14 -3 -3 protein was useful in all the groups except the MV -2 group. This 
study cannot support these findings in any of the groups except the MM -1 and VV- 
2A cases, in whom the majority had a positive result. However, 14 -3 -3 analysis is 
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more widely available now and subsequent analysis of future cases may support the 
findings of Zerr et al.455 If this is the case, then significantly more cases may achieve 
a "probable" diagnosis during life. 
Finally, Zerr et al.455 also suggested that a positive MRI scan might be a useful tool 
in cases that had a negative EEG or 14 -3 -3 result. To date, the experience of the 
NCJDSU has not shown the MRI to be such a useful diagnostic tool. The MRI was 
only positive in 43% of cases, fewer than the 79% reported by the German group.8 
However, as suggested previously, many of the cases in this study were seen many 
years ago. MRI has become more widely available over the past 15 years and 
different weighting techniques are now in use which may increase the sensitivity of 
the test. In addition, the brightness of different structures varies between machines. 
It is possible that this is the reason for the lower number of positive scans in this 
study and that now abnormalities have been described, the sensitivity of the test may 
increase. The specificity of the test has not been reported, and further prospective 
evaluation of the use of MRI in sporadic CJD would be necessary before it could be 
included in the diagnostic criteria. 
Were the MRI to be included how much further information would it provide? If, as 
it has been suggested in studies to date, the EEG is only a useful diagnostic tool in 
MM -1 and possibly MV -1 cases, then a significant proportion of cases would not be 
classifiable as anything more than a "possible" case prior to the use of 14 -3 -3 
protein. (40% of this study.) 
14 -3 -3 protein has been shown to be a useful diagnostic tool in sporadic CJD and it 
seems likely that it will support a diagnosis of sporadic CJD in many of the 
"atypical" subgroups that the EEG has proved unhelpful in. To date, 14 -3 -3 has been 
shown to be a highly sensitive and specific tool in the appropriate clinical setting. 
However, some of the cases in these other subgroups tend to be "atypical" and a 
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further investigation might lend more support to a diagnosis of sporadic CJD. This 
could prevent a patient proceeding to brain biopsy, a highly invasive investigation. 
Finally, Zerr et al.4" found 14 -3 -3 analysis was only positive in 30% of the 10 MV- 
2A cases tested. It was also negative in the 1 MV -2A case analysed in this study. 
However, they found the MRI was positive in 89% of the 9 cases they tested. In this 
study 75% of the 4 MRIs performed in the MV -2A were positive. This suggests that 
the MRI may yet prove to be the most helpful investigation in this subset. 
iii): CJD unlikely cases 
Surprisingly, very few of even the "atypical" groups had many cases that would not 
have fulfilled "possible" criteria: i.e. the clinical picture fitted with sporadic CJD but 
the results of investigation were not supportive. The clinical features of these cases 
are described in Chapter 8: Results. 
There are three cases within the MM -1 group who were classified as "CJD unlikely ". 
In two of the cases the clinical syndrome sounds suggestive of sporadic CJD but 
there is insufficient clinical information to be sure that enough symptoms and signs 
were definitely present; may of them were classified "don't know ". In one case the 
EEG was highly suggestive and so they would almost certainly have been a 
"probable" case, had there been more certainty about the clinical syndrome. In the 
second case the MRI was positive but the other investigations were not supportive. 
At most this case would have been "possible" unless further investigation was 
embarked upon. 
There is less information available on the final case. Because of lower motor signs a 
diagnosis of motor neurone disease was made during life. Lower motor signs have 
been reported in 6% of sporadic CJD cases.121 There were also cerebellar signs 
evident from the onset and double vision developed after several weeks of an illness 
of 2 months duration. Dementia was not remarked upon and sensory symptoms were 
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prominent, the patient complained of burning feet. There is no information about the 
terminal stages of the illness. Finally, the EEG was non -specific after 1 month of 
illness. 14 -3 -3 analysis and MRI examination were not performed. This case cannot 
be classified higher than "CJD unlikely ". 
One VV -2A case was classified "CJD unlikely ". Like most of the other cases in this 
group, she also had a cerebellar presentation, going on to develop dementia. There is 
insufficient clinical information about whether or not other signs developed to make 
a "possible" diagnosis and the results of investigations were not supportive of a 
diagnosis. 
Of the 8 other cases, 6 were classified as "unlikely" because the duration of illness 
was greater than 2 years. 4 of these would have other wise been considered 
"possible" cases if the duration of illness had been shorter. Another 2 cases were not 
seen by a member of the unit and there was insufficient information to be sure of the 
presence of the various signs to confirm a "possible" case (and over -riding the illness 
duration of greater than 2 years). 
Of the two cases of less than 2 years duration, there was insufficient information in 
one and in the other although they were seen during their illness, there is again 
insufficient information but from the clinical details they may also have been 
"possible ". 
This seems to illustrate that the diagnostic criteria are relatively sensitive and that the 
main exclusion criterion is that some of the cases are greater than 2 years duration. 
In the majority of the other cases there is simply insufficient information to be 
certain of the presence of various symptoms and signs. For those that were classified 
as "CJD unlikely" it is conceivable that a positive 14 -3 -3 protein or MRI result 
might make the diagnosis be considered despite a duration of greater than 2 years. 
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I: CLINICAL FEATURES OF EACH GROUP 
The study of protein isotype in sporadic CJD has evolved from some of the original 
transmission studies on scrapie, which suggested that different clinical syndromes 
were transmissible, attributable to different strains of the scrapie agent. Subsequent 
work in THE and the various TSEs has suggested that there are structural variations 
within the Prpres molecule and that these properties are transmissible, suggesting 
different strains of the agent. Western blotting techniques have identified two 
distinct protein isotypes in sporadic CJD. These isotypes are believed to be surrogate 
markers of strain. If this is the case are there clinically and pathologically 
discriminating features to each group? 
i): MM -1 
The MM -1 cases make up by far the largest group. The clinical and pathological 
phenotype is similar to well- described classical sporadic CJD. In general, the cases 
are of short duration and have a predominantly dementing illness. However 
Brownell- Oppenheimer cases are seen in this group (17 %). All but one of the cases 
presenting with visual symptoms were MM -1 and although there was insufficient 
information to call all of these cases the Heidenhain variant, there seemed to be a 
trend towards this phenotype. The EEG and 14 -3 -3 protein were helpful in the 
majority of cases. 
ii): MV -1 
The MV -1 cases also had a short duration of illness. The median age at onset was 
rather older than that seen in sporadic CJD at 75 years. A prodrome seemed to be 
more common in this group. Dementia was an early feature of all the cases. Sensory 
symptoms, hallucinations and delusions were not common and there were no 
unusual features on examination. The EEG was typical in many of the cases reported 
by Parchi et al and Zerr et al. This was not supported in this study. 14 -3 -3 analysis 
was helpful in many of the cases reported by both these groups. Pathological 
changes were typical of heterozygotes, with prominent kuru -type plaques. 
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iii): VV -2A 
The VV -2A cases also tended to be of shorter duration. The median age of onset was 
not significantly different from the MM -1 cases. Cerebellar symptoms were 
prominent in this group and these were present from the onset in 20% although they 
were also present from the onset in 13% (7 cases) of the MM -1 cases. (Brownell - 
Oppenheimer) There was also at least one case with a purely visual onset. Dizziness 
was seen in 40% of this group, possibly a reflection of the prominent cerebellar 
problems. In addition hallucinations were prominent, occurring in 40 %. The EEG 
was not typical but 14 -3 -3 was helpful in all the cases tested. Pathological changes 
were typical of Val homozygotes, with spongiform change being more typical in the 
basal ganglia and plaque -like deposits present on immunohistochemistry. 
iv): MM -2A 
The MM -2A cases had a younger median age of onset and longer median duration of 
illness. None of the cases were of duration less than 6 months; indeed half of them 
were of duration greater than 1 year. Dementia appeared in all cases and in 90% this 
was an early feature of the illness. Cerebellar signs were reported in only 30% but 
50% were classified "don't know" so it is not clear if cerebellar features are 
significantly underrepresented. Visual symptoms and cortical blindness were a 
feature of the group but none of the cases had a true Heidenhain or Brownel (- 
Oppenheimer presentation. Sensory symptoms however were present in 30 %. 
Investigation of the cases in this study did not show evidence that the EEG, 14 -3 -3 
analysis or the MRI is particularly helpful. (Although Zerr et al.455 have suggested 
otherwise.) Pathological changes were unusual in several of the cases, including one 
thalamic variant however there were no particular distinguishing features to the 
group. 
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Parchi et a1.391 divided the MM -2A group into two subsets, a cortical and thalamic 
variant. Zerr et al. did not note this distinction and it was not apparent in this study. 
The cortical variant is characterised by a prominent dementia. Visual and cerebellar 
signs are typically absent. The thalamic variant has previously been called fatal 
sporadic insomnia, characterised by progressive insomnia and psychomotor agitation 
at night. Neuropathology shows prominent thalamic atrophy. The thalamic variant 
made up 50% of the Parchi MM -2A group. 
v): MV -2A 
The MV -2A group also had a longer duration of illness and again 50% of cases were 
of duration greater than 1 year. Dementia presented early on in the majority of cases 
but 4 cases (33 %) had a Brownell- Oppenheimer presentation and cerebellar features 
were present in 92 %, greater than any other group. In this group hallucinations were 
common, present in over 50 %. There were no notable features on examination. 
EEG and 14 -3 -3 analysis were unhelpful but future evaluation of the MRI may show 
that this investigation is of diagnostic were 
more in keeping with changes related to genotype and there were no findings to 
distinguish the group particularly from the MV -1 cases. 
Parchi et al.399 report similar findings in their MV -2A cases and an isolated case 
report of an MV -2A case also noted prominent cerebellar symptoms. 
vi): VV -1 
Finally in the VV -1 group there were only 3 cases spanning a wide age range. The 
median age of onset was only 41 years and the group all had a long duration of 
illness (8 -29 months). All the cases presented with a purely dementing illness. There 
were no cerebellar or visual symptoms or signs noted in any of the cases but 2 of 
them (67 %) had a movement disorder. One case had a positive MRI (50 %) but 
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investigation was generally unhelpful. The pathological changes were again more 
related to genotype and there were no unusual features within the group. 
Parchi et aí.399 also noted similar features with prominent dementing symptoms and 
the lack of cerebellar signs. However, their cases did not have any form of 
dyskinesia other than myoclonus. They noted particularly severe pathology in the 
cortex and striatum. This was present in only 1 of the cases in this study but 
pathology was only present in 1 other case and so it is not possible to draw 
conclusions on the pathological changes. 
J: GENERAL COMMENTS 
These changes may suggest a trend towards distinct clinical phenotypes in each 
group. There do seem to be some consistencies in the findings of this study and those 
of Parchi and Zerr. The most consistent finding is the difference in duration of 
illness; most of the short duration cases are in the MM -1 group, but it is possible that 
the changes seen in this study are related to genotype alone. In particular, the 
pathological changes seemed to be only associated with genotype, other than certain 
atypical cases. (See later) 
At this stage, it would not be possible to assess the clinical characteristics and 
investigative results of a case of probable sporadic CJD and make a confident 
judgment of the genotype and protein isotype subgroup. In most cases the case 
would be typical of classically described sporadic CJD and would be considered an 
MM -1 case. Based on the proportion of cases that are in the MM -1 group, there is a 
high probability that this would be correct. However, each group contained some 
cases that were suggestive of typical sporadic CJD, which might easily have been 
suspected of belonging to the MM -1 group. This was particularly true in the VV -2A 
and MV -1 groups. 
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If a cerebellar onset was present or cerebellar signs were prominent, the case might 
be expected to be in the VV -2A or MV -1 group, but many of the MM -1 cases and 
indeed cases in all the other groups had prominent cerebellar signs. Again, there 
would be considerable uncertainty in trying to predict to which group the case 
belonged. 
At this stage, the most consistent finding is that atypical cases, usually of long 
duration, and often with unsupportive investigation results, would be in a group 
other than the MM -1 group. Even this statement must be qualified, as there are 
several "atypical" cases within the MM -1 group, who might easily have been 
suspected of being in an "atypical" group. 
It seems likely that Parchi et a1.399 looked at the 6 different groups and attempted to 
attribute distinct clinical features to each group. In this study, the case notes were 
examined once the genotype and protein isotype had been identified, although at that 
stage each clinical symptoms and sign was not specifically examined to see if they 
fitted with the study by Parchi et al.399 However, the data were then examined to try 
and attribute trends to the genotype and protein isotype subgroups. It would be 
important to try and allocate several cases to each subgroups, blinded to their 
genotype and isotype. 
Clinically, this is of little importance to the patient or their family. From their 
perspective they are usually predominantly interested in reaching as certain a 
diagnosis as possible of "probable" sporadic CJD in life. From the clinicians' point 
of view, they are keen to exclude other treatable causes of a rapidly progressive 
dementia. The atypical cases of sporadic CJD might present a cause for concern. 
These patients may proceed to invasive techniques such as brain biopsy if there is 
sufficient doubt about the diagnosis. 
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In fact, rather surprisingly, the majority of atypical cases in this study were 
considered at least "possible" CJD. In those that did not reach this classification, 
there was usually insufficient information to be sure of the presence or absence of 
the clinical signs. In those that were considered "possible" many of them were seen 
and diagnosed before the advent of 14 -3 -3 protein and the description of the MRI 
changes in a series of sporadic cases. 
It seems likely, based on the findings of Zerr et al.,455 that many of those cases might 
have had a positive 14 -3 -3 result, had the test been available. These cases would 
therefore have been classified "probable" sporadic CJD. This classification would be 
associated with a specificity of about 95 %. There are of course reports of false 
positive results with 14 -3 -3 analysis, but many of the conditions in which a false 
positive result was obtained, should be distinguishable clinically from even atypical 
sporadic CJD. 
It is possible that the MRI will yet be validated as a useful investigative tool, 
although the specificity of this test also needs to be ascertained. Assuming the EEG 
is usually not typical except in the MM -1 cases. A "positive" MRI in association 
with positive 14 -3 -3 analysis may give sufficient confidence of the diagnosis in an 
atypical case, without proceeding to brain biopsy. In the MV -2A cases the limited 
data to date suggests that the MRI might be the most useful investigation. 
K: INTERMEDIATE CASES. 
There were 3 intermediate sporadic cases. No other group has reported cases of 
intermediate mobility. It is difficult to know the significance of this. It is possible 
that the intermediate mobility was due to technical difficulties. In particular, copper 
binding can affect the mobility of the protein and there may have been technical 
problems in removing the copper from these cases. It has been shown that the protein 
molecule unfolds more if there is less copper present. In theory if the intermediate 
cases were run again after treatment with E.D.T.A., which would bind copper, they 
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would be of type 1 mobility. This theory does not hold if the cases proved to be of 
type 2 mobility. 
Other possibilities are that the underlying mechanism of disease is different in these 
cases. Alternatively, copper binding in different regions of the brain varies and it 
may relate to the area of brain sampled. Presumably there are also differences in 
copper binding between individuals. 
Group B classified the 2 Met homozygous intermediate cases as type 2 cases. All the 
group B MM type 2 cases that were also classified by Group A were MM -1 cases i.e. 
typical sporadic CJD cases. These 2 cases would have been fairly typical of the MM- 
1 group, although 1 case had sensory symptoms at onset. Both cases had cerebellar 
symptoms and went on to develop dementia. The duration of illness was 3 and 9 
months. The patient who survived for 9 months had a PEG tube sited from early in 
the illness. The EEG was highly suggestive in both MM cases, again suggesting that 
they were MM -1 cases. 
The Val homozygote case was part of the Oxford study. The onset at 76 years with 
cerebellar signs and 5 months duration of illness would suggest this was a VV -2A 
case. The EEG was reported as typical but was not available for review. There was 
no pathology report other than the original, when PrP immunohistochemistry 
techniques were not available. There is no comment on involvement of the basal 
ganglia. 
There are no odd features about any of the cases to suggest that they might belong to 
a different isotype group of 20kDa mobility (although this study has demonstrated a 
wide variety of clinical features within the cases in each group anyway). No other 
group has reported cases of intermediate mobility. 
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9.4: GENOTYPE AND ISOTYPE ONLY 
The sporadic cases were analysed with respect to genotype or isotype alone to look 
for trends in the clinical picture, investigations and pathology. 
A: GENOTYPE ONLY 
i): Case Data 
It is possible that the changes noted in this study are related to genotype only and 
protein isotype has no influence on the clinico- pathological picture. The excess of 
Met homozygotes amongst sporadic CJD cases and the atypical features of the Val 
homozygous and heterozygous cases are well documented. The NCJDSU 




The distribution of genotype in this study was slightly different, probably a reflection 
of a bias towards studying atypical cases in more detail. However, 65% were Met 
homozygous. This is still greater than the 42% seen in the population as a whole. 
There are rather more than expected of heterozygotes (17 %) and Val homozygotes 
(18%). 
ii): Gender Distribution 
There was a slight excess of male Val homozygotes. In contrast there was a slight 
excess of females in the Met homozygotes and heterozygotes. The reason for this is 
not clear and may simply be due to chance. 
iii): Age At Onset 
As with previous studies, the Val homozygotes tended to be younger (median age 60 
years) than the Met homozygotes (median age 63 years) but the heterozygotes 
237 
CHAPTER 9 DISCUSSION 
tended to be older (median age 65 years). However, there was a wide range of ages 
in each genotype, with considerable overlap and the median age of onset varied from 
60 years in the Val homozygotes to 65 in the heterozygotes. Exceptionally young 
cases were present in each group. 
iv): Duration Of Illness 
Similarly, the Val homozygotes tended towards a longer duration of illness (median 
6 months) and the heterozygotes had a significantly longer duration of illness (9 
months). There was a wide variation in illness duration in each group. All 3 groups 
had cases of duration greater than 2 years. They also had cases with a very short 
duration of illness, typical of sporadic CJD. 
v): Clinical Symptoms And Signs 
The presenting symptom in each group was analysed. Dementia as a pure 
presentation was present in all groups, with little difference in frequency. A pure 
cerebellar presentation was more common in the heterozygotes and Val 
homozygotes. However 10 Met homozygous cases (17 %) presented with a pure 
visual onset. 1 Val homozygous case also presented with the same onset (6 %). 
Greater numbers would be required before the significance of this result could be 
ascertained. There was no other significant difference in any of the other clinical 
symptoms and signs. 
vi): Investigations 
In this study 52% of the Met homozygous case had a typical or highly suggestive 
EEG. Only 1 further case had a highly suggestive EEG, a heterozygote. The EEG is 
strongly associated with the Met homozygous genotype. 
However, if 14 -3 -3 analysis is studied a larger proportion of the other genotypes 
have a positive result, aiding diagnosis. The numbers are of course smaller and need 
further prospective study but 68% of the Met homozygotes and 88% of the Val 
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homozygotes that were tested had a positive 14 -3 -3 result. Only one of 3 
heterozygote cases (33 %) had a positive result. This may be chance and with further 
evaluation the test may prove to be more helpful in the heterozygotes. Alternatively, 
this may in some way be a reflection of a slight difference in the disease process in 
the heterozygotes. 
The MRI was positive in 50% of heterozygotes that were tested however and if this 
test was validated it may prove to be the most helpful investigation in this genotype. 
Again, very few case had an MRI scan available for analysis but only 25% of the 
Met homozygotes and 38% of the Val homozygotes that were tested had a positive 
scan. 
vii): Pathology 
There have been several reports already on the genotypic influence on the pathology 
of sporadic CJD. Met homozygosity seems to predispose to more spongiform change 
in the cortex and heterozygosity or Val homozygosity seems to predispose to more 
change in the basal ganglia. Heterozygotes are the only group to have Kuru -type 
plaques in this study prior to PrP staining. However after PrP staining plaques and 
plaque -like deposits are seen in just under a third of the Val homozygotes and 5% of 
the Met homozygotes as well as 65% of the heterozygotes. 
vii): General Comments 
The results of this study generally agree with other published data. Met 
homozygosity predisposes to sporadic CJD and, in general, the Val homozygotes 
tend to present at a younger age. In addition both Val homozygotes and 
heterozygotes tend to have a longer duration of illness. The only symptom to show a 
difference related to genotype was the presence of a visual onset, which was more 
common in the Met homozygotes. The numbers were too few to achieve 
significance. 
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It is also recognized that Met homozygous cases tended to have a positive EEG but 
this investigation is less helpful in the other genotypes. This study bears this finding 
out. However, although the results are very small, 14 -3 -3 protein analysis and MRI 
may prove to be useful in all the genotypes. Pathological analysis shows that many 
of the changes seen are related to genotype. In particular, Kuru -plaques are seen only 
in heterozygotes in this study and case studies in the literature. 
B): ISOTYPE ONLY 
i): Case Data 
The data were also analysed to see if the protein isotype had a significant influence 
on the phenotype of the disease and pathology, irrespective of genotype. About 2/3 
of cases were type 1 and the rest were type 2A. As with so much of the rest of the 
data, there was considerable overlap between the 2 groups and so it is only possible 
to comment on the trends apparent. 
ii): Gender Distribution 
No difference was seen in the gender distribution 
ii): Age At Onset 
The type 2 cases were slightly younger (61 years compared to 64 years), but again, 
there was considerable overlap between the groups. 
iv): Illness Duration 
The type 2A case had a longer duration of illness, 8 months compared to 3 months 
but the type 1 group had a case of 51 months compared to a case of 54 months 
duration in the type 2A group, again demonstrating considerable overlap. 
v): Symptoms And Signs 
When the onset of illness was compared, there was no significant difference when a 
purely dementing or cerebellar onset was compared. 16% of the type 1 cases 
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presented with purely visual symptoms, in comparison to 3% of the type 2A cases. 
This result achieved only borderline significance. There was no significant 
difference between the two groups in the other variables analysed. 
If the clinical signs are compared all signs were in general less common in the group 
2A. This is likely to be a reflection of under -reporting in this group because it occurs 
across the board. Only 16% of the 2A group had movement disorders other than 
myoclonus in comparison to 40% of the type 1 group. This may be a reflection that 
these signs are less common in the type 2A group or this may simply be chance due 
to under- reporting. Again, all signs were present in many of each group so no 
discriminating clinical features stood out. 
vi): Investigations 
A typical EEG was strongly associated with the type 1 group. None of the type 2A 
group had a positive EEG. However, nearly three quarters of the type 1 group and 
half the type 2A had a positive 14 -3 -3 analysis and 35% and 39% of the type 1 and 
2A groups respectively had a positive MRI scan. This suggests once again that 14 -3- 
3 protein analysis is a useful tool in the absence of a typical EEG, and the MRI may 
be positive where other investigations are not supportive. 
vii): Pathology 
When the pathological changes were analysed there was a suggestion that type 2A 
cases were more likely to have more spongiform change within the basal ganglia. 
Kuru plaques and PrP plaques and plaque -like deposits were also more likely to be 
seen in the type 2A cases but could be seen in either. 
viii): General Comments 
Once again, there are apparent trends. The type 1 cases tend to be more typical of 
sporadic CJD but there are no discriminating features that are present in only one 
group. Younger cases or cases of longer duration may be more likely to be in the 
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type 2A group but this is not exclusively the case. An onset of illness with purely 
visual symptoms is most strongly associated with a type 1 isotype, but there is one 
type 2A case with such an onset. It is therefore not a discriminating symptom. The 
other symptoms and signs are seen in either group and are even less discriminating. 
As far as investigation is concerned, the EEG is strongly associated with the type 1 
group. However 14 -3 -3 protein or MRI may be positive in either group. 
Pathologically, protein isotype appears to have less influence on the pattern of 
spongiform change and immunohistochemical staining. 
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9.5: GROUP B CLASSIFICATION 
Group B have proposed a different classification system for CJD. They identified the 
same 2 isotype mobilities but proposed the presence of more glycosylation 
patterns.20 This results in a larger number of groups, but a smaller number of cases in 
each. To date, they have concentrated more on the issue of protein isotype being a 
marker of strain and have not commented much on the clinical features of each 
group. Because there are fewer cases to study it was only possible to look for trends 
in each of the groups and further evaluation with a larger number of cases is 
required. 
A: CASE DATA 
Group B classified 48 cases. All but 4 were also classified by the NCJDSU, allowing 
the data to be compared. They identified 5 different isotypes of sporadic CJD. In 
conjunction with codon 129 genotype. this meant there were 9 different groups with 
1 to 19 cases in each. (Type BI was only seen in Met homozygotes and the type B6 
and B7 cases were 2 isolated cases.) Because of the large number of groups of 
diverse size, statistical analysis could not be preformed. 
B: AGE AT ONSET 
The median age at onset was in the mid 60s in all the groups apart from the VV -B2 
group (53 years) and the VV -B3 group (58 years). The MM -B3 group had an older 
age of onset at 71 years. 
C: ILLNESS DURATION 
Median disease duration varied from 2-13 months, a longer duration of illness being 
seen in the MV -B3 group (8 months). the \IM -B3 group (7 months) and the MV -B7 
group (13 months). 
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D: SYMPTOMS AND SIGNS 
When the cases were examined for clinical trends no real differences were apparent. 
A percentage of each group had a cerebellar or dementing onset and a small 
percentage of the MM-B1 and MM -B2 cases had an onset with visual upset. It might 
have been expected that the MM -B6 and MV -B7 cases would be atypical, because 
they were lone cases in each group: The MM -B6 had a typical Heidenhain onset, 
choreaform movements developed midway into the illness but there were no other 
atypical features. The MV -B7 case had a typical course but for a rather long duration 
of illness. However the case had a cerebellar onset. This case would have been 
classified as MV -2A by group A and it is interesting to note that it is the only one in 
that group who had a cerebellar onset. 
E: INVESTIGATIONS 
68% and 65% of the MM-B1 and MM -B2 cases respectively had a typical or highly 
suggestive EEG. Unfortunately there are too few 14 -3 -3 and MRI results to come to 
a conclusion about the relevance of these investigations. 
G: PATHOLOGY 
The Pathological changes were of kuru -plaques in the heterozygotes and plaque -like 
deposits in the Val homozygotes. 
H: GENERAL COMMENTS 
There are insufficient data to draw conclusions on the Group B data. It is possible 
that there are more isotypes then Group A suggest but the cases in this study do not 
have obvious clinical and pathological features which divide them up into discrete 
sub- groups. More cases would need to be analysed. 
The changes seen in these cases could be related to genotype alone: In general the 
Val homozygotes had a younger age at onset and a longer duration of illness is seen 
in the heterozygotes. The clinical features of the group are not unusual and very few 
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of the cases were atypical, the MV -B7 case if of interest because it was an atypical 
case, but this could be due to the influence of genotype alone. The MM -B6 case is a 
very typical sporadic CJD case, but for the presence of choreaform movements, 
which were seen in 33% of sporadic cases in this study. 
When the distribution of cases is compared to the Group A cases, all the MM -B I, 
MM -B2 and MM -B6 cases would have been MM -1 in the NCJDSU classification. 
All the MM -B3 would have been MM -2A. The VV -B2 would have been either VV- 
1 or VV -2A in the Group A classification but the VV -B3 would all have been VV- 
2A. The same is true of the MV -B2 and MV -B3 cases, but for one MV -B7 case. 
There are 3 possible reasons for the differences seen: 
1. That there are more isotypes based on glycoform ratios that have not been 
identified by the Parchi and NCJDSU groups to date. There is insufficient 
evidence at this stage to confirm or discard this theory. If protein isotype is a 
marker of strain, and if different strains of CJD have different clinico- 
pathological phenotypes, at this stage the clinical correlates have not been 
truly identified. 
2. That the differences between the 2 groups are due to differences in laboratory 
technique and interpretation. The analysis of the glycoform ratio by Western 
blotting in this study has been qualitative. Differences in the preparation 
techniques used could influence the glycosylation of the PrP`e$ and the 
relative molecular mass, depending on the chelation of copper and other 
factors. Again, this needs further evaluation. 
3. As discussed previously it is not clear how much the glycosylation of PrPfes is 
influenced by the biochemical milieu within the brain or by agent strain and 
again the importance of the glycosylation ratio on protein isotyping in 
sporadic CJD is not clear. 
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9.6: VARIANT CJD 
A: CASE DATA 
43 cases of variant CJD were included in this study, although there are now 129 
definite or probable confirmed cases. Since the first description of vCJD in 1996, the 
clinical and pathological picture has changed little. All the cases have been Met 
homozygous and have had a distinct protein isotype: type 2B, i.e. of 19 kDa mobility 
and a predominantly diglycosylated pattern. This same pattern has been seen in BSE 
and the other TSEs that have been linked in aetiology to BSE, such as FSE and 
exotic ungulate encephalopathy.104 
B: SYMPTOMS AND SIGNS 
The clinical picture has been very consistent, and is broadly similar in all the cases in 
this study. The median age of onset was 26 years and the median duration of illness 
was 14 months. The presenting complaint in all cases but one was of psychiatric 
symptoms. These were non -specific, including depression, anxiety and disturbance 
in sleep pattern. Primary psychiatric symptoms were less common; hallucinations 
were present in 35% and delusions were present in 37 %. 
Sensory symptoms were common early in the illness or at onset. One case presented 
with sensory symptoms before progressing to depressive symptoms. 14% of cases 
had sensory symptoms from the onset and symptoms were present in 65% at some 
point in the illness. These were only included if they were persistent and some cases 
were classified "don't know" because there was only an isolated mention of sensory 
upset. The nature of the symptoms were varied and described as non -specific limb 
pain, dysaesthesia, burning or cold feelings. The symptoms were sometimes 
lateralised and the aetiology is believed to be of thalamic origin. 
Patients went on to develop dementia in all cases but cognitive problems were 
present from the outset in only 2 cases. All cases became unsteady on their feet and 
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in all but 2 cases cerebellar signs were noted. In most cases cerebellar signs did not 
develop until some months into the illness. As the illness progressed pyramidal 
signs, in particular rigidity with brisk reflexes and extensor plantar responses were 
common. Primitive reflexes were present in 58% of cases. Myoclonus was noted in 
77% and dystonia or chorea was prominent in 68% of cases. 42% of cases had a 
reduction of upgaze. Cortical blindness was noted in 2% and 28% of cases were 
noted to develop akinetic mutism. This may be an underestimate, as in general the 
vCJD cases were seen earlier in their illness and late signs may simply be under- 
reported. 
Although 44% were noted to have abnormal swallowing there is only a note of NG 
or PEG feeding in 21 %, again this may be an underestimate but does not seem to 
account for the longer duration of illness seen in the vCJD cases as a whole, as the 
median duration of illness of the cases who were not NG fed was 13 months. It is 
also noteworthy, but probably coincidental, that fewer of the "later" cases appear to 
have been PEG fed, possibly because by this time the illness was better known and 
recognized as incurable. 
The median duration of illness of cases who were NG or PEG fed was 18 months. In 
comparison, the cases in whom we have no information or who were not NG fed had 
a median duration of 13 months. It seems likely that the cases who were NG fed did 
live longer. Only 4 of the 34 cases in whom we have no information lived longer 
than 18 months, the median duration of the assisted feeding cases. 
C: INVESTIGATIONS 
Again, the results of investigations in vCJD are fairly distinct from sporadic CJD. 
The EEG was normal in 5% and non -specific in the majority (91 %). No cases had a 
highly suggestive or typical EEG. Routine CSF analysis was normal or non- 
specifically abnormal in all cases. In a small number of cases the protein was raised, 
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sometimes in association with a raised red cell count. No cases had an abnormally 
high white cell count in the CSF. 
14 -3 -3 protein was analysed in 33 cases. A positive result was obtained in 45% 
(some cases had an initial negative result). S -100b was high in 85% of cases and was 
usually higher in the cases with a positive 14 -3 -3 protein. However, this is a less 
specific test. In general, analysis of brain specific proteins so far, has proved less 
helpful in vCJD than in sporadic CJD. Whilst a positive 14 -3 -3 protein might 
support a diagnosis of variant CJD, there are insufficient data for it to transform a 
possible case to a probable case as occurs in sporadic disease. In addition, it does not 
help differentiate sporadic from variant CJD. 
However, the MRI has been shown to be a relatively specific and sensitive test in 
vCJD. 77% of the cases in this study had high signal in the pulvinar area of the 
thalamus. Four scans were not available for review. Two of these were reported to be 
normal but they were both reported prior to the publication of the MRI findings in 
vCJD. It is conceivable that in retrospect these cases may be positive. 
If only the cases where the MRI was reviewed by the NCJDSU are considered, 33 of 
39 cases were positive i.e. 85 %. This fits with the ongoing analysis of cases by the 
NCJDSU since the MRI paper was published. 92% of cases in whom the MRI is 
available for review have a positive scan. Although, similar changes have been seen 
on MRI imaging in other conditions, they do not in general mimic vCJD clinically. 
One of the difficulties of diagnosing probable vCJD in life is in cases who fit the 
clinical picture but in whom the MRI is negative. In two cases a second MRI was 
positive. Others went on to have tonsil biopsy performed. This is an invasive 
procedure and is probably unnecessary in the presence of a positive MRI scan. 
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D: PATHOLOGY 
The pathological changes in the variant cases have also been remarkably consistent 
and to date, distinct from the changes of sporadic CJD. Spongiform change was mild 
to moderate in most cases and most marked in the occipital lobe of the cortex. in 
nearly half of cases. (Despite the absence of cortical blindness in all but 1 case.) The 
basal ganglia were more severely involved in most cases, with marked gliosis and 
neuronal loss. However, the most striking abnormality in all the cases was the 
deposition of florid plaques throughout the cortex, deep gray matter and cerebellum. 
These plaques are similar to those seen in kuru, and have not been noted in any of 
the sporadic, familial or iatrogenic cases. 
E: COMPARING SPORADIC AND VARIANT CJD CASES 
An important distinction, particularly from the point of view of patients and their 
relatives, is whether or not a case of CJD is sporadic or variant. The cases have been 
very distinct pathologically but it is desirable to make a distinction during life. 
To date the clinical phenotype of variant CJD has been relatively distinct from 
sporadic CJD, supporting the theory that a different single strain of agent is involved. 
In particular, the age at onset is in general younger and the duration of illness is 
generally longer. The psychiatric prodrome and prominent persistent sensory 
features are uncommon in sporadic CJD and the progression of variant CJD, with the 
development of cerebellar symptoms and signs has been very distinctive. In addition 
the pulvinar changes on MRI have been a useful diagnostic tool. 
It is notable that vCJD has a relatively consistent clinical course in contrast to the 
sporadic cases, in whom each sub -group has been shown to have some rather 
atypical cases. However there are some concerns that some "atypical" variant cases 
may be missed and considered to be sporadic CJD. All vCJD cases to date have been 
Met homozygous. It is possible that cases of vCJD who are heterozygous or Val 
homozygous at codon 129 may have a distinct clinico- pathological phenotype. These 
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cases could be mistaken for an alternative diagnosis in life and if autopsy is not 
performed could have been missed altogether by the surveillance system. Look -back 
studies have suggested this is unlikely.125,126 
Conversely, it is conceivable that some of the young atypical sporadic CJD cases, 
who are often Val homozygous or heterozygous, are in fact atypical vCJD cases. The 
results of pathological examination and eventually transmission studies should 
discriminate between the 2 groups but it is preferable to make the correct diagnosis 
in life. There are several similarities and differences evident from this study: 
i): Age at onset 
Although vCJD cases are generally younger, the youngest sporadic case in the study 
was aged 17 years at onset. In this study the oldest vCJD case was 53 years, younger 
than the median age at onset of sporadic CJD. However, subsequent to this study a 
case of variant CJD has been seen in a 74- year -old man.220 Nevertheless the median 
age at onset of vCJD is 26 years, in comparison to 65 years in sporadic CJD and only 
3 of the sporadic cases in this study were younger than 40 years. 
ii): Duration of illness 
Again, although vCJD cases are generally of longer duration of illness (median 14 
months), 14 sporadic cases were of longer than 14 months duration in this study. 2 
cases were of over 50 months duration, longer than any variant case to date. (The 
longest vCJD case was of 39 months duration.) In addition 18 of the vCJD cases 
were of 12 months duration or less. Many of the atypical sporadic CJD cases have an 
illness duration of about a year. The relationship to NG or PEG feeding was analysed 
but, although there was a suggestion that the cases who had assisted feeding lived for 
longer, there were insufficient cases to be sure. 
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iii): Psychiatric symptoms 
The long psychiatric prodrome of variant CJD cases is very distinctive. A prodrome 
was seen in 28 sporadic CJD cases (28 %), but in no case did it have the nature of the 
prominent psychiatric symptoms seen in the vCJD cases, usually consisting of a few 
weeks of being "under the weather" or having a flu -like illness. 
Hallucinations and delusions are also prominent in vCJD, but 29% of all the sporadic 
cases had hallucinations in contrast to 35% of the vCJD cases. In both groups, these 
were nearly always visual in nature and usually developed mid to late into the 
illness. 
Delusions were seen in 8% of sporadic cases. They tended to be persecutory and did 
not appear until some months into the illness. In vCJD however, delusion were seen 
in 37 %. They were similar in nature and timing to the sporadic cases. 
iv): Sensory symptoms 
Sensory symptoms are a prominent feature of the vCJD cases, occurring in two 
thirds of cases and present in 14% from the onset. They were seen in only 14% of 
sporadic CJD cases. The nature of the sensory symptoms was often similar, I case 
complained of burning feet and another of a feeling of their "blood boiling ". 2 others 
complained of cold feet and 3 complained of pains in limbs. Often, these symptoms 
appeared early on in the illness. The remaining cases complained of numbness, 
tingling and pins and needles. One of the prominent features of the sensory 
symptoms in vCJD is the persistence of the sensory upset. In general the sporadic 
cases decline cognitively much more quickly than the variant cases. It was not clear 
if the sensory symptoms in the sporadic cases were persistent or not in any of the 
cases. 
It is possible that since the original description of vCJD, sensory symptoms are 
looked for in sporadic CJD by very directed questioning, in an attempt by the 
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interviewer to distinguish between sporadic and variant CJD. In this study, of the 14 
cases with a sensory upset, 57% were seen after vCJD was described, suggesting that 
their presence is not due to direct questioning following the description of vCJD. 
In young cases of possible CJD it is possible that the presence of sensory symptoms 
may make vCJD more likely. However, it would not be possible to discriminate from 
sporadic CJD by the nature of the sensory symptoms, as they are broadly similar in 
both groups. In addition, as might have been expected, the presence of sensory 
symptoms does not exclude sporadic CJD. The median age of the cases with sensory 
symptoms was 56 years, older than the oldest vCJD case in this study. 
NO: Other symptoms and signs 
When considering the clinical signs in sporadic and variant CJD, although cerebellar 
signs are almost always present in variant CJD, they are so common in sporadic CJD 
that this could not be used to discriminate between the 2 conditions. Similarly, 
pyramidal signs and extrapyramidal rigidity are common in both. 
Myoclonus seems to be slightly more common in sporadic CJD, occurring in 77% of 
variant cases, but 87% of sporadic cases. However chorea and dystonia were seen 
more commonly in the variant cases, seen in 68% of cases compared to 33% of the 
sporadic cases. This type of movement disorder is often very distinctive in the 
variant cases, whereas, even if present, is often not a prominent feature in sporadic 
disease. 
Another feature of the vCJD cases was the presence of abnormal eye movements, in 
particular, reduced up gaze, present in 42 %. Comments on the nature of eye 
movements were missing in about two thirds of sporadic cases. Reduced up -gaze or 
a paucity of eye movements was noted in 10 cases (10 %). Paresis of conjugate 
upgaze in 5% of cases of sporadic CJD has been described.121 
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The clinical progression of the vCJD cases was similar to sporadic CJD after signs 
such as cerebellar problems began to appear. Most cases deteriorated rapidly and 
akinetic mutism was present in many cases although cortical blindness was seen less 
in vCJD. 
vi): Investigations 
Whilst, there are obvious differences between the variant and sporadic cases, in 
particular the prominent psychiatric onset and persistent sensory symptoms, it is 
clear that there is also some overlap in the clinical features. The use of supportive 
investigation is helpful in discriminating between the two diagnoses. None of the 
vCJD cases have had a typical EEG. However, an atypical EEG is usually seen in 
atypical cases of sporadic CJD, in whom the distinction between variant and 
sporadic is more in question. 
Similarly, the presence of 14 -3 -3 protein may support the diagnosis of CJD but 
would not discriminate between the 2 types. A negative 14 -3 -3 protein would not 
rule out vCJD, although it would make sporadic CJD less likely. 
High signal in the pulvinar area of the thalamus is highly specific for vCJD and has 
not been seen in cases of sporadic disease. This test is therefore an important 
discriminator, however if the MRI is negative then more invasive investigation such 
as tonsil biopsy may be considered. In atypical cases of sporadic CJD, in whom the 
EEG and 14 -3 -3 is negative, basal ganglia changes on MRI may prove to be helpful 
but are yet to be validated. 
The final diagnosis rests on neuropathological changes. The distribution of 
spongiform change is fairly characteristic in vCJD and distinct from the changes of 
sporadic CJD. The most important finding is the presence of the florid plaque, which 
has been seen only in vCJD. 
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9.7: IS PROTEIN ISOTYPE A MARKER OF STRAIN? 
Transmission studies of scrapie, extending back to the 1960s suggested that there are 
different strains of scrapie. There is little information on the clinical features of the 
disease in sheep and goats but when the disease is transmitted to mice, distinct 
clinical features are seen; scratching and drowsy. 
Most of our understanding of TSE strain variation has come from experimental 
mouse models. Strains of scrapie with distinct clinical characteristics have been 
demonstrated. The characteristics are maintained through hosts of different PrP 
genotypes, or even through hosts of different species. The extent to which these 
models extend to human correlates is unclear. 
i): Molecular basis 
The molecular basis for this is poorly understood. However, Western blot analysis of 
THE identified 2 distinct mobilities of PrPreS that corresponded with distinct clinical 
phenotypes, drowsy and hyper, in transmission to a mouse host. These 2 protein 
isotypes of 19 and 21 kDA were identified in a number of different TSEs. 
At the same time, understanding of the structure of PrPc and PrPs, and some of the 
mechanisms involved in the pathological process in prion diseases was 
accumulating. A structural basis for the different isotypes was proposed, based on 
the site of cleavage at the amino terminal of the PrP molecule. This in turn was 
influenced by the amount of f3-sheet in PrP$e. It has been proposed that protein 
isotype is a marker of strain of the prion agent. 
In addition, it has been shown that the site of amino terminal cleavage is also 
affected by the codon 129 polymorphism, theoretically explaining the influence that 
codon 129 has on the disease phenotype. 
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Parchi et al. found some clinical and pathological correlates in each group, however, 
their data were amalgamated from different countries with varying surveillance 
systems. It is possible that many of the cases were not seen in life by a neurologist 
and data extracted from case notes can be less accurate. This study had the advantage 
of a dedicated surveillance system in which as many cases as possible were seen by a 
research fellow. In addition, I reviewed all the EEG and MRI records available 
myself. Whilst the overall ratio of groups was similar and there were some trends 
identified that were the same as Parchi, in general the results were less conclusive. 
At this stage the clinical correlates in sporadic CJD do not yet support the laboratory 
models of strain variation. Although there are some trends relating to the 6 genotype/ 
isotype groups of sporadic CJD, they do not neatly segregate into distinct clinic - 
pathological entities. In addition, many elements of the formation of PrPs` from PrPc 
are still not fully understood and all hypotheses on the structural variation related to 
prion strain remain theoretical. 
ii): Influence of the host 
It is possible that as yet there are simply insufficient data to prove the existence of 
strain. However, there are other factors to consider. The influence of the 
biochemistry and cell structure within the brain could affect the progression of 
disease and deposition of PrPs`. The structural differences seen in protein isotype 
may be related to the cellular environment, rather than a strain of PrP. Puoti et al 
have identified a case of sporadic CJD with different PrPres isotypes within the same 
brain.398 One iatrogenic case in this study also contained both type 1 and 2A 
isotypes. They suggested this finding might provide evidence of the mechanism of 
PrPres formation from PCP`, as it is conceivable that the influence of different areas of 
the brain might alter the conformation of PrPres 
Piccardo et al. demonstrated variations in glycoform ratio between different cases of 
GSS with the P102L mutation. They also demonstrated variation within the same 
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brain.397 Again, the degree to which the PrPs` molecule is glycosylated could depend 
on the biochemical milieu, as with many proteins. In addition age and factors such as 
the amount of corticosteroid in the body can influence the glycosylation of proteins. 
The sites of glycosylation are at Asn 181 -183 and 197 -199. It is interesting to note 
that many of the mutations associated with familial CJD and GSS occur around these 
sites, e.g. D178N and F198S. It has been suggested that a mutation at either site 
affects glycosylation, and hence the conformation of the protein.46I 
This might support the theory that sporadic CJD is a chance stochastic mutation 
within PRNP, and therefore can occur at several sites. The different protein isotypes 
produced may form into f3-sheet at different sites producing slightly different 
patterns of protein deposition within the brain and hence different clinical 
phenotypes. Type 1 is more common, and may be the preferred, more stable 
conformation, but certain cell types may predispose to the type 2 conformation. 
Formation of more of either isotype may then influence the course of the disease. 
One of the difficulties of a clinical, rather than an in vitro study is removing the 
influence of other diseases and factors in the host from the influence of the infective 
agent in the disease process. In human prion diseases codon 129 has a marked 
influence on the disease phenotype, irrespective of the agent strain. Polymorphisms 
in sheep also exist, influencing the susceptibility to disease.462 A possible structural 
basis for this has already been mentioned but the mechanisms involved are not fully 
understood. It is not clear why Met homozygosity should be so strongly associated 
with the type 1 isotype, but this may also be due to a structural alteration in PrPsc 
related to the site at codon 129. 
The influence of genotype on disease has been studied in other neurological 
conditions. Alzheimer's disease has a diverse clinical picture and is associated with 
the deposition of amyloid protein within the brain. In addition a point mutation 
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within the Presenilin -1 gene463 and a polymorphism on the dopamine receptor 
gene464 have both been associated with different disease phenotypes of Alzheimer's 
disease. In addition codon 129 of PRNP has also been shown to influence the disease 
phenotype in Alzheimer's disease.465 
There is however no evidence that Alzheimer's disease is an infectious disease and 
no transmissible agent has been identified. The majority of human diseases, whether 
infectious or not, have a diverse clinical course, determined by many factors such as 
the health of the individual prior to the illness, the treatment of concurrent infections 
etc, all of which determine the disease phenotype. 
There are other factors that could be affecting the disease phenotype, e.g. the 
presence of pre- existing disease such as Alzheimer's disease or stroke. Both are far 
more common in the elderly than sporadic CJD and could easily be co- occurring. 
It is possible that other unidentified polymorphisms may also affect the disease 
phenotype. In recent years the Japanese have identified a polymorphism at codon 
219 that they believe influences disease phenotype. They have also demonstrated 
that heterozygosity at this site may protect against sporadic CJD.449 
iii): Evidence from vCJD 
Does this mean that there is no good evidence for the existence of strain in human 
prion diseases? The vCJD cases form a distinct group with a relatively consistent 
clinical and pathological picture. Even allowing for the fact that all the cases to date 
have been Met homozygotes, they are a more consistent group than that seen in any 
of the genotype groups in sporadic, familial and iatrogenic cases. 
In addition, research in recent years has shown that vCJD is causally related to 
BSE,1oi, 
102.103 probably from the ingestion of contaminated meat products. 
Transmission studies have shown that the neuropathological lesion profile and 
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incubation period of vCJD is distinct from scrapie but remarkably similar to BSE.104 
This suggests that vCJD and BSE are a distinct prion strain. 
Western blot of vCJD cases by both the NCJDSU and Collinge et aí.20 has shown a 
distinct pattern. However, the difference is in glycosylation ratio rather than in 
protein isotype mobility. Collinge et al. have placed more weight on the importance 
of glycosylation, using this ratio to differentiate a larger number of isotypes than the 
Parchi group. However, Parchi et al. have found the only difference between the 
vCJD cases and the type 2 sporadic, iatrogenic and familial cases, and indeed Kuru, 
is in the glycosylation ratio.379 
These data would suggest that protein isotype is a marker of strain and that the 
glycosylation of PrP$0 is dependent on the strain of prion agent rather than the 
cellular makeup within the brain. An alternative explanation is that the differences 
are related to the route of infection. Further studies on kuru might support this as this 
disease is also likely to be passed on through oral ingestion. However, Parchi et al. 
identified type 2A in Kuru PrP`e5. 379 In addition, the neuropathology of vCJD and 
Kuru have been compared and were distinct.446 
Typing the protein isotype in vCJD has been used as evidence that cases of Val 
homozygous and heterozygous vCJD have not been missed. It seems likely, based on 
the study of sporadic, familial and iatrogenic cases, that a Val homozygous or 
heterozygous case of vCJD will have an atypical clinico- pathological phenotype. It 
is therefore conceivable that some of the sporadic cases of these genotypes are 
actually vCJD. The protein isotyping studies suggest this is unlikely, as they have 
consistently demonstrated the vCJD cases have a type 2 mobility with a distinct 
glycosylation pattern. This does not of course imply that a different strain is 
involved; it simply demonstrates the deposition of an alternative protein. 
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9.10: POSSIBLE RESEARCH IN THE FUTURE 
DISCUSSION 
There are still some methodological problems to resolve: Parchi et aí.379 and 
Collinge et al.396 have yet to agree on the exact number and typing of the different 
protein isotypes. Clearly, until this is resolved it is difficult to know how to classify 
the individual cases. In this study, neither classification could be definitely 
associated with a distinct clinico- pathological phenotype. The Parchi classification 
had more potential associations but there were fewer groups and more cases, making 
statistical analysis somewhat easier. 
Two groups have identified both isotypes in the same brain. Parchi et aí.399 noted 
both isotypes in 10 cases and a further case report by Puoti has noted the same 
changes. In addition Piccardo et aí.397 have identified different glycoform ratios 
within the same brain. This is clearly evidence against protein isotype being a 
marker of strain. This study only analysed one area of the brain in each case but 
further analysis of the regional variation within the brain of a case series is required 
in order to prove that protein isotype is not brain region -specific. 
In addition, 3 cases in this study were of intermediate mobility. These cases had no 
distinguishing features and it is not clear if the intermediate cases are a distinct 
protein isotype or related to methodological problems. The technique of isotyping is 
relatively new and these results may be due to early methodological difficulties. As 
familiarity with techniques improve, results may be more consistent. 
Prospective analysis of cases, looking for identified features may take away some of 
the uncertainties of the clinical features attributable to each isotype. However, as has 
already been shown, the UK surveillance system has been prospectively studying as 
many cases as possible, using a dedicated research fellow, for 10 years. Despite this 
data are still lacking due to the difficulties of monitoring such a rare disease. The 
differences seen between vCJD and sporadic CJD are more compelling andfurther 
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analysis of the differences in isotype between these two conditions might provide 
more information about the relationship between isotype and strain. 
Further in vitro work might allow a greater understanding of the pathological and 
structural processes involved in prion diseases and the molecular basis of strain 
variation. Currently, there is insufficient evidence to conclude that protein isotype is 
indeed a marker of strain, rather than a different conformation of PrPs` produced in 
different areas of the brain. 
Future research should first of all establish a unified classification of the protein 
isotypes seen in CJD and establish the significance of identifying both isotypes 
within the same individual. If this is done, prospective surveillance could look in 
more detail at the onset of the disease, as this seems to be the most accurate 
symptom to evaluate. In addition the significance of the duration of illness could be 
looked in relation to age, PEG feeding and the onset of the disease. (An onset in the 
brainstem would presumably be of shorter duration.) 
Further analysis of investigations in CJD will hopefully expand the diagnostic 
criteria, possibly to include MRI. 14 -3 -3 has already been shown to be of 
importance. The EEG does not appear to be of use in "atypical groups" but serial 
recordings in all groups would have to be performed to establish this. 
The diagnostic criteria have been shown to be helpful even in "atypical groups ". 
However, it may be possible in the future to subdivide the criteria for each subgoup 
if future analysis shows there are definite differences. 
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This study has illustrated the difficulties of a surveillance system for a rare disease. 
Even with a registrar dedicated to obtaining information on any case of CJD 
throughout the UK, there are limitations in the data obtained, both in the timing of 
symptoms and the analysis of whether symptoms or signs have definitely developed 
during the illness. Additionally, the division of cases into one large group and five 
small groups makes statistical analysis very difficult. 
Allowing for these difficulties, are there any trends that divide the cases into the six 
distinct groups? As has been illustrated, there is a suggestion that the MM -1 cases 
are of shorter duration and follow the more classical course of sporadic CJD and that 
the other groups tend to include the more atypical cases. However, some of the MM- 
1 cases would be considered atypical and the other groups all include cases that 
follow a typical course for sporadic CJD. 
The most discriminating sign was the presence of visual symptoms at the onset of 
the illness, but not even this symptom was a truly 100% discriminator as it occurred 
in at least 1 case other than an MM -1 case. The result did not achieve statistical 
significance because of the small numbers involved. 
As far as investigations are concerned, a typical EEG is almost always a marker of 
the MM -1 group, but there are exceptions and these factors again cannot be regarded 
as wholly specific to the MM -1 group. There were insufficient data on the results of 
14 -3 -3 protein analysis and MRI. 
The data were analysed to see if the changes could be due to either genotype or 
isotype alone. Again, a Heidenhain type onset of illness and a typical EEG were the 
most significant discriminators, both seemed to be associated with Met 
homozygosity and isotype. However the numbers are too small for this result to 
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achieve significance. Pathologically, the changes between the groups were more 
suggestive of differences due to genotype than isotype. 
Clinically and pathologically therefore there are some trends in the six groups that 
may suggest differences in the clinico- pathological phenotype, but there is 
insufficient evidence to confirm that the groups are distinct clinical entities. 
The differences between sporadic CJD and vCJD are more marked and provide the 
best evidence of strain of the CJD agent. However, there is insufficient evidence at 
this stage to conclude that protein isotype is a marker of strain, or that the molecular 
basis for this, proposed from in vitro studies of strain, is correct. Further analysis of 
the regional variation of protein isotype and the clinical and pathological correlates 
with isotype and genotype are required. 
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APPENDIX A: DESCRIPTION OF CLINICAL SYMPTOMS/ SIGNS 
The following descriptions were included as synonyms of a particular symptom or 
sign. This is not a definition of each category but a glossary of terms found in case 
notes which were felt to be sufficiently suggestive of each category: 
AGGRESSION: bad -tempered, angry, fighting, argumentative 
AKINETIC MUTE: Immobile and mute, immobile or mute alone classified as 
"don't know" 
ALIEN LIMB: limb moving out of control, posturing limb 
ANXIETY: panic attacks, tearful, fear, worried 
CEREBELLAR: gait/ truncal/ limb ataxia, broad -based gait, poor coordination, as if 
drunk, finger nose ataxia, heel shin ataxia. "unsteady" and nystagmus not 
included if no qualification 
CORTICAL BLINDNESS: loss of vision due to loss of cortical visual function in 
which anterior visual structures are intact, often described in notes as 
absent menace response 
DELUSIONS: persecutory, paranoid 
DEPRESSION: low mood, withdrawn, loss of interest, anhedonia 
DIZZY: giddy, vertigo, light- headed 
EYE MOVEMENT DISORDER: reduced upgaze, nystagmus, limited eye 
movement 
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EXTRAPYRAMIDAL: parkinsonism, gegenhalten, shuffling gait, cogwheeling 
HALLUCINATIONS: visual or auditory, seeing things, talking to someone not there 
HEARING PROBLEM: deaf, not hearing properly, buzzing in ears 
MOVEMENT DISORDER: athetoid, chorea, writhing movement, restless, tremor 
if distinct from extrapyramidal or cerebellar, grimacing, blepharospasm, 
dystonia 
MYOCLONUS: jerking, startle, jumpy 
PRIMITIVE REFLEXES: frontal release, grasp, rooting, palmomental, pout reflexes 
PRODROME: flu like illness, "not him/ herself", headache, tired, mood change, 
depressed, weight -loss, insomnia, personality change, memory 
problem, moody, irritable. Combination of above. 
PYRAMIDAL: rigidity if associated with brisk reflexes or extensor plantars, brisk 
reflexes, paratonic rigidity, hemiparesis. "upgoing plantars" or brisk 
jaw jerk alone not included. Classified "don't know" 
RAPIDLY PROGRESSIVE DEMENTIA: memory loss, confusion, disorientation, 
behavioural abnormality, progressive dysphasia, forgetful. Significant 
deterioration in cognitive function over a year or less. 
SENSORY: cold feelings, dysaesthesia, paraesthesia, pins and needles, limb pain, 
burning, tingling, numb, loss of sensation, coldness 
SWALLOWING: absent gag response, food pooling in mouth, unable to eat, 
nasogastric or PEG tube sited 
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VISUAL PROBLEM: diplopia, double vision, blurring of vision, problem with 
glasses, smearing of vision, script moving 
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APPENDIX B CLASSIFICATION OF EEG 
NON -SPECIFIC 
Non -specific deterioration in normal background rhythms 
Non -specific excessive slow wave activity 
Non -specific excessive fast wave activity 
SUGGESTIVE 
General deterioration in/ loss of normal background 
Intermittent bi/ tri -phasic discharges similar to those seen in classical CJD 
records 
BUT 
1. Occurring in bursts of only relatively short duration ( <15 seconds) 
AND either 2 or 3 or both 
2. Not being truly generalised and synchronous 
3. Without true periodicity 
HIGHLY SUGGESTIVE 
General deterioration in/ loss of normal background 
Intermittent bi/ tri phasic discharges similar to those seen in classical CJD 
records, being truly generalised and periodic at times 
BUT EITHER 1 or 2 
1. Occurring in bursts of only relatively short duration ( <15 seconds) and 
occupying less than a quarter of the record 
2. Not being truly generalised and synchronised in all portions of the record 
TYPICAL 
Generalised deterioration in/ loss of normal background 
Truly periodic generalised synchronous bi/ tri -phasic discharges 
Occurring throughout the whole record or at least one quarter of it and in 
relatively long segments (15 seconds at a minimum) 
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APPENDIX C: DIAGNOSTIC CRITERIA FOR SPORADIC CJD 
1. OXFORD CRITERIA. Used until 1993 
SPORADIC CJD 
I Rapidly Progressive Dementia 
II A Myoclonus 
B Cortical Blindness 
C Pyramidal /Extrapyramidal /Cerebellar Signs 
D Akinetic Mutism 
E Early Onset of Neurogenic Muscle Wasting 
III Typical EEG 
IV Neuropathology 
DEFINITE: IV 
PROBABLE: I + 2 of II and III 
POSSIBLE: I + 3 of II 
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2 ROME CRITERIA. Used 1993 -1998 
CLASSICAL SPORADIC CJD 
1. DEFINITE 
a) Neuropathologically (histologically) confirmed 
and /or 
b) Immunocytochemically confirmed PrP positive (or Western blot) 
and /or 




Typical periodic EEG findings 
and at least 2 out of the following 4 clinical features: 
a) Myoclonus 
b) Visual or Cerebellar problems 
c) Pyramidal or Extrapyramidal features 




2 out of the 4 above clinical features 
But no EEG or atypical EEG 
and 
Duration less than 2 years 
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3. ROTTERDAM CRITERIA. Agreed 1998. 
Used for reclassification purposes in this study. 
SPORADIC CJD 
I Rapidly Progressive Dementia 
II 'A Myoclonus 
B Visual or Cerebellar problems 
C Pyramidal or Extrapyramidal Features 
D Akinetic Mutism 
III Typical EEG 
DEFINITE: Neuropathological /immunocytochemically confirmed 
PROBABLE: I + 2 of II + III 
or 
Possible + positive 14 -3 -3 
POSSIBLE: I + 2 of II and duration < 2 years. 
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APPENDIX D: DIAGNOSTIC CRITERIA FOR VARIANT CJD 
I I 
A PROGRESSIVE NEUROPSYCHIATRIC DISORDER 
B DURATION OF ILLNESS > 6 MONTHS 
C ROUTINE INVESTIGATIONS DO NOT SUGGEST AN 
ALTERNATIVE DIAGNOSIS 
D NO HISTORY OF POTENTIAL IATROGENIC EXPOSURE 
A - EARLY PSYCHIATRIC SYMPTOMS* 
B - PERSISTENT PAINFUL SENSORY SYMPTOMS ** 
C - ATAXIA 
D - MYOCLONUS OR CHOREA OR DYSTONIA 
E - DEMENTIA 
III A. EEG DOES NOT SHOW THE TYPICAL APPEARANCE 
OF CLASSICAL CJD * ** 
(OR NO EEG PERFORMED) 
B. BILATERAL PULVINAR HIGH SIGNAL ON MRI SCAN 
IV A. POSITIVE TONSIL BIOPSY 
DEFINITE: IA (PROGRESSIVE NEUROPSYCHIATRIC DISORDER) 
and 
NEUROPATHOLOGICAL CONFIRMATION OF DIAGNOSIS 
OF NV CJD * * ** 
PROBABLE: I and 
4/5 OF II and 
III A and III B 
PROBABLE: I and IV A 
POSSIBLE: I and 4/5 II and III A 
depression, anxiety, apathy, withdrawal, delusions 
this includes both frank pain and/ or unpleasant dysaesthesia 
generalised triphasic complexes at approximately one per second 
spongiform change and extensive PrP deposition with florid plaques, 
throughout the cerebrum and cerebellum. 
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APPENDIX E: LABORATORY TECHNIQUES 
1): BRAIN- SPECIFIC PROTEINS 
i): 14 -3 -3 protein 
CSF 14 -3 -3 in the CSF was detected by Western blotting after SDS- PAGE.180 50 .iL 
of CSF sample was mixed with an equal volume sample buffer (0.125M tris -CL, 
containing 20% v/v glycerol, 0.2M dithiothreitol, 4% sodium dodecyl sulphate and a 
0.02% bromophenol blue, pH 6.8) and boiled for 4 minutes. Sample proteins were 
separated by sodium dodecyl sulphate -polyacrylamide gel electrophoresis (4% 
stacking gel and 10% resolving gel) for 3 hours at 100V. The proteins were 
transferred by electroblotting to nitrocellulose for 2 hours using a current of 0.8 
mA /cm2. The unbound protein binding sites on the nitrocellulose were blocked using 
2% non -fat milk powder in phosphate- buffered saline. 
Immunodetection was carried out by incubation with 1:1000 dilution of rabbit ant - 
14-3-3 gamma (Santa Cruz Biotechnology, Germany) followed by incubation with 
1:1000 horseradish peroxidase conjugated swine anti -rabbit Ig (DAKO, Denmark) 
and visualisation with ethylaminocarbazole. A positive control (CSF from 
histopathologically confirmed case of sporadic CJD), a negative control (CSF from a 
patient without histological evidence of CJD) and molecular weight markers were 
included on each run. The results obtained are qualitative. 
ii): S -100b 
CSF S -100b was measured using sandwich ELISA.459 Micro titre plates were 
prepared by coating overnight with monoclonal anti- S -100b (Sigma Chemical 
Company, Poole, UK) at a concentration of 9.3 µg/ ml in 0.05M carbonate buffer, 
pH9.5. The plate was washed with 0.1% bovine serum albumin in phosphate - 
buffered saline (PBS) containing 0.05% Tween 20 (wash solution), and the unbound 
ii sites were blocked with 1% bovine serum in PBS for 30 min. 
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50 µl of CSF sample were added in duplicate to the plate, and 50 µl of 0.06M 
barbitone buffer, pH 8.6 containing 1mM calcium lactate were then added to each 
well (incubation buffer). The plate was incubated at 37 °C for 3 h. After washing 
rabbit, anti -S -100 antibody conjugated with horseradish peroxidase diluted 1 /1000 
with incubation buffer was added. The microtitre plate was incubated for 1 hour at 
room temperature. The microtitre plate was washed with wash solution and 100 µl of 
enzyme substrate (1mg /m1 o- phenylenediamine in 0.05M acetate buffer containing 
0.01% hydrogen peroxide) was added. After incubating the plate in the dark for 30 
minutes, the reaction was stopped by adding 1M HCI. The absorbance was read at 
492nrn with 405nm as the reference wavelength, using an Anthos 2001 Plate reader 
(Denley Instruments, Sussex, UK). 
The upper limit of normal was taken to be 0.38 ng /mL. 
2): PATHOLOGY 
The tissues were prepared by a standard method. The brains were fixed by 
immersion in 15% formalin for a minimum of 3 weeks. Tissue blocks were taken 
from areas of the cortex, deep grey matter, cerebellum and brainstem. Blocks were 
decontaminated in 96% formic acid for 1 hour prior to routine processing into 
paraffin wax. From each block, 5 p.m serial sections were floated on Vectabond- 
coated slides and stained using haematoxylin and eosin (H &E). After counterstaining 
with haematoxylin, sections were dehydrated, cleared in xylene and mounted in 
Pertex. 
3): HISTOPATHOLOGY 
10% tissue extracts of samples of frozen frontal cortex were made by 
homogenisation of <100 mg brain in Tris buffered saline pH 7.6 containing 0.5% 
Nonidet P40 and 0.5% Sodium deoxycholate. Extracts were cleared by low speed 
centrifugation and subjected to limited proteolysis by digestion with Proteinase K 
(BDH, 50 pg /mL, I hr, 37 °C). 
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Electrophoresis was performed on a 12 %T Acrylamide SDS -PAGE mini -gel format 
(Bio -Rad Laboratories) and proteins transferred to Hybond ECL nitrocellulose or 
Hybond -P PVDF membranes (Amersham Pharmacia Biotech). The anti -PrP 
monoclonal antibody 3F4 (Senetek) was used at a 1:10,000 dilution followed by an 
HRP conjugated secondary antibody (SAPU) and enhanced chemiluminescence. 
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APPENDIX F: SPORADIC CJD; GROUP B DATA 
A: CASE DATA 
48 cases were available for classification by Group B. Four cases were classified by 
Group B only and there was no classification by Group A. These were; MM type 2, 
MM type 3, VV type 2 and VV type 3. Of the 44 remaining cases, both Group A and 
B classifications were available for comparison. (See Table F:1) 
Table F:1: SPORADIC CJD: CLASSIFICATION OF GROUP B CASES 
GROUP A 
Genotype Isotype N= 
GROUP B 
Genotype Isotype N= 
MM 1 27 MM 1 8 
MM 2 18 
MM 6 1 
MM 2A 1 MM 3 1 
VV 1 1 VV 2 1 
VV 2A 6 VV 2 2 
VV 3 4 
MV 1 3 MV 2 3 
MV 2A 6 MV 2 2 
MV 3 3 
MV 7 1 
The subgroups were already small and further subdivision made analysis difficult. 
Of the 48 cases, the registrar had examined the patient in 40 cases, the relatives were 
interviewed in 44 cases and the hospital notes were available in 29 cases. All the 
cases were from the current NCJDSU study. The clinical features of each group are 
set out in table F:2. 
i): Group B Type 1 (B1) 
All the group B type 1 cases would also have been Group A type 1 Met 
homozygotes. There were 8 cases in this group (MM-B1). 
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ii): Group B Type 2 (B2) 
There were a total of 28 type B2 cases. Of these 19 were Met homozygotes, 5 were 
heterozygotes and 4 were Val homozygotes. 
If compared to the Group A classification, 2 were classified only by Group B. (1 Met 
homozygote and 1 Val homozygote.) 22 cases were type 1 in the Group A criteria 
(18 MM, 1 VV, 3 MV) and 4 cases were type 2A (2 VV, 2 MV). 
iii): Group B Type 3 (B3) 
There were 10 type 3 cases. Two of these were classified only by Group B. (1 Met 
homozygote and 1 Val homozygote.) 
There were 2 Met homozygous cases (MM -B3). 1 case would have been MM -2A in 
the Group A classification. There were 3 heterozygotes (MV -B3). All would have 
been MV -2A in the Group A classification. There were 5 Val homozygotes (VV- 
B3). 4 would have been VV -2A in the Group A classification. 
iv): Group B type 6 (B6) 
There were 2 additional subgroups: 1 case classified MM -1 by Group A was 
classified type 6 by Group B (MM -B6). 
v): Group B typc 7 (B7) 
The second case was an MV -2A according to Group A analysis but was classified 
type 7 by Group B (MV -B7). The 48 cases were analysed in the same way as 
described for the NCJDSU analysis. The results are laid out in tables 8.40 and 8.41. 
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B: GENDER DISTRBUTION 
20 cases were male and 28 female (ratio 0.7:1). 
C: AGE AT ONSET 
Group N Median age of onset Range 
MM -B1 8 64 years 56 -79 
MM -B2 19 64 years 43 -78 
MV -B2 5 65 years 15 -79 
VV -B2 4 53 years 41 -79 
MM -B3 2 71 years 63 -79 
MV -B3 3 61 years 61 -77 
VV -B3 5 58 years 46 -65 
MM -B6 1 69 years 
MV -B7 1 65 years 
D: DISEASE DURATION 
Group N Median duration Range 
MM-B1 8 2 months 1 -5 
MM -B2 19 4 months 1 -17 
MV -B2 5 3 months 2 -54 
VV -B2 4 6 months 5 -11 
MM -B3 2 7 months 3 -12 
MV -B3 3 8 months 7 -14 
VV -B3 5 3 months 2 -11 
MM -B6 1 3 months 
MV -B7 1 13 months 
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E: SYMPTOMS AND SIGNS 
MM -Bl Onset Cerebellar 1 case (13 %) 
Dementia 1 case (13 %) 
Visual 3 cases (38 %) 
They all went on to develop a rapidly progressive dementia and followed a typical 
course for sporadic CJD. 
MM -B2 Onset Cerebellar 2 cases (11%) 
Dementia 8 cases (43 %) 
Visual 3 cases (16 %) 
Dementia was an early feature of the illness in all but 5 cases (26 %). All but 2 cases 
developed myoclonus. 1 case had some hemi- sensory neglect and numbness. In 
general there were no unusual features in any of the cases. 
MV -B2 
No case had a mono -symptomatic onset. All developed dementia early in the illness. 
One patient complained of paraesthesia from the onset. Cerebellar features presented 
early in the illness in 3 cases (60 %), but all cases developed cerebellar features at 
some time. The case who survived for 54 months was NG fed. All cases deteriorated 
to a dependent state within a relatively short period of time. 
VV -B2 Onset Dementia 3 cases (75 %) 
One case also developed dementia early in the course of the illness but cerebellar 
symptoms and signs were one of the first features of the illness. 2 other cases 
probably had cerebellar signs at some point (1 patient was documented to be 
unsteady but the reason for this was not stated). All the cases probably developed 
myoclonus. 2 cases (50 %) developed chorea. 
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MM -B3 Onset Dementia 1 case (50 %) 
Both patients presented with a dementia. In one case cerebellar symptoms were also 
present at onset. Both developed visual symptoms after some months. The other case 
developed cerebellar symptoms some way into the illness. 
MV -B3 Onset Cerebellar l case (33 %) 
All the cases probably had cerebellar symptoms and signs at the onset. l case had 
associated dementia from the onset. The other 2 went on to develop dementia. 2 
cases developed visual symptoms during the course of the illness. 
VV -B3 Onset Dementia 3 cases (60 %) 
Cerebellar 2 cases (40 %) 
3 cases had dementia from the onset and another case developed dementia early on. 
The final case developed dementia some months into the illness. 2 cases had 
cerebellar symptoms from the onset and another 2 cases developed cerebellar 
symptoms and signs early on in the illness. 1 case was noted to have generalised 
muscle wasting and another had fasciculations. 4 of the cases developed visual 
symptoms midway into the illness. 1 case had paraesthesia from the onset and 
another developed a painful arm some months into the illness. 
MM -B6 Onset Visual failure 
Dementia developed rapidly and the patient became unsteady although cerebellar 
signs were not documented. Occipital blindness was a feature early on. Choreaform 
movements developed midway into the illness and myoclonus developed late. 
MV -B7 Onset Cerebellar 
Dementia developed after some months and there was no visual upset. Myoclonus 
was not noted. 
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F: INVESTIGATIONS 
MM-B1 The EEG was typical or highly suggestive in 5 cases. (68 %) 
14 -3 -3 not done. 







The EEG was typical or highly suggestive in 11 cases. (65 %) 
14 -3 -3 was positive in the 2 cases tested. (100 %) 
2 of the 6 available MRIs (33 %) were positive. 
None of the 3 cases had a typical EEG. 
1 case had 14 -3 -3 tested - negative result. 
0/2 positive MRI. (0 %) 
The EEG was not typical in any of the cases. 
14 -3 -3 not done. 
MRI was negative in the 1 case in whom it was performed. 
The EEG was suggestive in 1 case and the other was reported as 
typical. (50 %) 
MRI and 14 -3 -3 protein were not performed. 
The EEG was negative in 3 cases (0 %). 
1 case had a negative 14 -3 -3 protein. 
1 case had a positive MRI scan. 
The EEG was non- specific or suggestive in all cases. (0 %) 
1/4 cases had a positive14 -3 -3 protein. 
1 case had an MRI available for analysis. This was strongly positive. 
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MM -B6 The EEG was classified suggestive. 
14 -3 -3 and MRI not performed. 
MV -B7 The EEG was reported as suggestive but was not seen by me 
MRI and 14 -3 -3 protein analysis was not done. 
G: PATHOLOGY 
The details of the pathological changes in each group are set out in table F:3. 
MM-B1 The pathological changes were of spongiform change, predominantly 
cortical. No additional features. 
MM -B2 The pathological features of spongiform change, predominantly 
cortical. No additional features. 
MV-B2 
VV-B2 
There were no distinguishing features on pathological examination, 
except that the case of 54 months duration had widespread changes of 
status spongiosis and many plaque -like deposits. 
Spongiform change was most marked in the basal ganglia in 3 of the 
cases (75 %). 2 of the cases (50 %) had plaque -like deposits on PrP 
staining. 





All the cases demonstrated spongiform change greatest in the basal 
ganglia. Kuru -type plaques throughout the cerebellum and to a lesser 
extent in the cortex. PrP staining predominantly reticular, throughout 
the brain with many plaques and plaque -like structures. 
Spongiform change was present throughout the cortex but was more 
marked in the basal ganglia. PrP staining revealed plaque -like 
structures in the cortex, basal ganglia, thalamus and cerebellum. 
MM -B6 The pathological features of spongiform change. predominantly 
cortical. No additional features. 
MV -B7 Pathological changes were of marked spongiform change in the basal 
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